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Abstract 
Malaria is a major public health problem, with an estimated 207 million cases and 627,000 
deaths each year as well as associated socio-economic costs. Considerable inroads have 
been made in the reduction of malaria-related deaths and illness through the widespread 
use of preventative measures, but an effective vaccine is likely to hold our greatest chance 
of effectively eliminating the risk of Plasmodium infection. However, the most advanced 
anti-malarial vaccine candidate, RTS,S, has an efficacy rate of approximately 30%, and, 
alternative novel vaccine delivery platforms are likely to be required. 
During my doctoral studies, I have evaluated chimeric virus-like particles (VLPs), chimeric 
capsomeres and bacterial minicells targeted to dendritic cells as novel vaccine delivery 
platforms, in a rodent model of malaria.  
Chimeric VLPs are formed when recombinant viral structural proteins with foreign 
antigenic epitopes assemble into a highly repetitive array which resembles the native form 
of the virus. These VLPs are self-adjuvanting and highly immunogenic with regard to 
inducing antibody responses. Capsomeres are pentamers of viral capsid proteins which 
have not formed into VLPs. These are also immunogenic but require co-administration 
with adjuvants to induce comparable antibody titres to VLPs. Chimeric VLPs and 
capsomeres with surface exposed Plasmodium yoelii circumsporozoite (PyCSP) CD8+ and 
CD4+ T cell and B cell epitopes were constructed using a recently established murine 
polyomavirus VP1 structural protein scaffold. These constructs were designed so that the 
platform could be evaluated for their ability to induce cell-mediated immunity as well as 
antibody responses sufficient to protect against a complex pathogen. Individual and pooled 
VLPs or pooled capsomere constructs with (pooled VLPs and capsomeres) or without 
(VLPs only) adjuvant were evaluated in mice for immunogenicity (T cell and antibody 
responses) and protective capacity in both homologous and heterologous (DNA prime/VLP 
boost) immunisation regimens. I established that homologous regimens of VLPs and 
capsomeres induced moderate CD8+ T cell immune responses, and these responses were 
significantly enhanced by the prime/boost regimen. Both platforms were inefficient at 
generating a robust CD4+ T cell response, however, capsomere induced responses were 
superior to those induced by VLPs. Furthermore, I found that both VLPs and to a lesser 
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extent capsomeres, induced robust antibody responses, and that induced antibodies 
recognised conformational epitopes on the surface of the sporozoite. Neither VLPs nor 
capsomeres were able to protect mice from sporozoite challenge, with data suggesting 
that the magnitude of the response was insufficient. 
Bacterial minicells are small anucleate cells which bud off from bacteria during binary 
fission as a result of premature septum formation. They have shown potential as a drug 
delivery platform but have not been well studied as a potential vaccine platform. Minicells 
produced by transformed E.coli DS410 bacteria containing recombinant protein and 
homologous mammalian expression plasmid DNA were purified using a novel purification 
method. Antigen-loaded minicells were then targeted to dendritic cells (DCs) via endocytic 
receptors DEC205 or Clec9a using bi-specific antibodies to enhance uptake and antigen 
presentation by dendritic cells and subsequent enhancement of immunogenicity. This 
platform was evaluated in an ovalbumin model as well as a murine malaria model to 
assess immunogenicity and protection capacity. In OTI and OTII ovalbumin models, 
ovalbumin packaged minicells induced ova-specific antibodies but failed to induce 
proliferation of adoptively transferred cells or kill ovalbumin CD8+ T cell epitope pulsed 
lymphocytes in an in vivo CTL assay. The amount of target protein in the ovalbumin 
packaged minicells was only 0.1 µg/dose, and subsequent studies indicated that this 
antigen load was insufficient for inducing the sought immune responses. In the malaria 
model, minicells containing P. yoelii apical membrane antigen-1 (PyAMA-1) protein and 
plasmid DNA for mammalian expression of PyAMA-1, with a protein antigen dose of 
approximately 1 µg, was evaluated. Blood cytokine and white blood cell activation marker 
assays, and antibody assays did not indicate any Plasmodium-specific responses, and 
mice were not protected from sporozoite challenge. In each minicell experiment, targeting 
DCs did not alter the immune responses, however, this was likely dose-related rather than 
a platform-specific issue. 
The potential and limitations of chimeric VLPs, capsomeres and bacterial minicell vaccine 
delivery platforms were identified which will be useful for future research. Importantly, it 
was established that chimeric VLPs and capsomeres induce moderate levels of cellular 
immune responses which complements their capabilities to induce robust antibody 
responses. 
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Chapter 1: Introduction 
1.1. Malaria 
It is estimated that a child under the age of 5 years will die from a malaria-related 
illness every minute1, and these figures may be a significant underestimation due to 
non-diagnosis or the non-reporting of deaths to any formal health system2. There 
now 97 countries with on-going malaria transmission with an estimated 207 million 
cases and 627 thousand deaths annually1. Of these reported deaths, 90% occurred 
in African countries and 77% occurred in children under 5 years. Since 2004, 
significant inroads have been made to decrease malaria related morbidity and 
deaths, which were then estimated at between 350 to 500 million cases and over 
one million deaths3. The impact of the disease extends beyond the human costs of 
mortality and morbidity to include the associated socio-economic load4. This financial 
burden is distributed primarily to developing countries and would be unsustainable 
which without international financial support4. The most cost-effective and efficient 
long-term solution to this debilitating disease is likely to come in the form of a 
vaccine. 
The recent reductions in malaria-related deaths and illness can be attributed to 
preventative measures including the widespread distribution of insecticide-treated 
mosquito nets (ITNs), residual spraying and preventative therapies, all of which 
require considerable and on-going financial investment1. The distribution of 
decreased mortality rates from 2000 to 2012 (Figure 1) correlates strongly with the 
distribution of ITNs or residual spraying. For example, some central African regional 
populations have less than 50% coverage whereas southern African populations 
have greater than 80% coverage1. This disparity will be reduced with the continued 
roll-out of ITNs. 
The high cost of current preventative measures including ITN distribution, residual 
spraying and chemoprophylaxis is highlighted by the annual investment of nearly $2 
billion (USD) reported by WHO1. Despite the apparent success of current efforts, it 
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will take more money to gain complete global coverage, and to maintain already 
distributed equipment. Moreover, these benefits will be negated as mosquitoes 
develop resistance to insecticides or net usage declines due to complacency or net 
deterioration. Another major issue is the improper use of ITNs with the proportion of 
children under 5 years sleeping under ITNs being considerably lower than the 
proportion of households which have ITNs5. 
 
Figure 1: Percentage change in malaria mortality rates from 2000 to 20121 
For several decades, the favoured anti-malarial drug was aminoquinoline 
chloroquine because it was effective and cheap6. However, parasite resistance to 
this drug has evolved and spread rapidly across several continents including Africa, 
making it obsolete as a first-line treatment in most endemic regions6,7. To reduce the 
potential impact of drug resistance combination therapies are recommended by the 
WHO with two drugs given in combination1. The current recommended treatment for 
Plasmodium infections is an artemisinin-based combination therapy1, however, there 
is evidence that parasites are now developing resistance to these drugs8-11. Given 
that artemisinin is the current primary therapeutic, a spread of the resistant parasite 
could be devastating. As such, new drugs are urgently needed. 
Moreover, to reduce the global burden caused by this complex parasite, a 
combination of strategies in addition to drug based therapeutics is required, including 
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the development of an effective vaccine. Despite decades of research such a 
vaccine remains elusive. 
1.2. The Plasmodium parasite 
Malaria is a disease caused by an Apicomplexan parasitic infection of the genus 
Plasmodium. There are five Plasmodium species known to be infectious to humans: 
P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi, a zoonotic parasite 
which was until recently only reported in old world monkeys12. P. falciparum has 
been a primary focus of vaccine and drug intervention research as it is the most life 
threatening species1. However, P. vivax has a wider geographical distribution and is 
responsible for 50% of infections outside of Africa1. With mounting drug resistance 
and increased disease severity, there is growing interest in this species11. P. vivax 
also has a hypnozoite dormant liver stage, a feature which it shares with P. ovale. 
These hypnozoites can remain dormant for months to years before undergoing 
development to merozoites which results in clinical relapses without the need for re-
infection13. 
1.2.1. Plasmodium lifecycle 
The Plasmodium parasite has a complex, multi-stage lifecycle requiring both a 
mosquito vector and human host (Figure 2). Whilst ingesting a blood meal, an 
infected female Anopheline mosquito delivers saliva containing approximately 10 to 
100 Plasmodium sporozoites14. The sporozoites can remain in the skin for between 1 
to 6 h before entering the blood or lymphatic systems15 where they migrate to the 
liver and invade hepatocytes. Sporozoites differentiate and proliferate by asexual 
replication for between 5.5 to 10 days (in human infections) depending upon the 
species16, producing up to 40,000 merozoites which then rupture the host cell 
releasing themselves into the blood circulation where they quickly invade 
erythrocytes13. This marks the commencement of the asexual erythrocytic stage, 
with rapid amplification of the parasite population and clinical manifestations of the 
disease. After 48 hours of further asexual replication, a single erythrocyte can now 
contain up to 36 merozoites. Erythrocytes then rupture releasing merozoites which 
invade uninfected erythrocytes, resulting in a cycle of exponential parasite growth. 
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Some merozoites can differentiate into male or female gametocytes which circulate 
in the blood and can be ingested by another mosquito in which sexual reproduction 
occurs, allowing the infection of another human host and continuation of 
transmission.  
 
Figure 2: An overview of the Plasmodium lifecycle. Sporozoites in the saliva are 
transmitted from the Plasmodium infected female Anopheline mosquito, resulting in liver and 
blood stage infections. Gametocytes are ingested by other mosquitoes and sexual 
reproduction results in new sporozoites for continuation of the cycle17. 
1.2.2. Pathogenesis 
Plasmodium infections may be asymptomatic in people with clinical immunity, but 
when clinical disease is manifested, cases are categorised as uncomplicated or 
severe. In uncomplicated malaria, common symptoms include fever, chills, sweats, 
nausea and vomiting, general malaise, headaches and body aches. These 
symptoms classically appear every second or third day depending on the infecting 
species. Severe malaria can be a result of severe anaemia due to erythrocyte 
destruction and reduced production, cerebral malaria due to microvascular 
obstructions in the brain, or metabolic acidosis due to reduced tissue perfusion 
(reviewed in18). Further complications can arise as a result of an accumulation of 
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parasite waste products, and infections during pregnancy can result in low birth 
weight or foetal loss due to placental infection18.  
1.2.3. Challenges for vaccine development 
The Plasmodium species parasite has co-evolved with human hosts for a long time, 
effectively evading innate and adaptive immune responses. With the maturation of 
the immune system and repeated infections, individuals living in malaria-endemic 
regions can develop protective responses resulting in clinical immunity to 
malaria16,19. It is reasonable therefore to suggest that a vaccine could offer at least 
the same degree of protection. Of course, sterile protection would be the ultimate 
aim of vaccine researchers, preventing severe disease or death in the infected 
individual, as well as preventing the subsequent transmission of parasites to others. 
Early research by Freund et al20,21 using non-human primates (NHPs) established 
that immunisations with killed parasites provided protection from challenge. The 
ability to protect humans was later shown using irradiated sporozoites delivered by 
the bite of infected mosquitoes22. Evidence of clinical immunity and these foundation 
studies provide the rationale that a vaccine to eliminate this parasite is achievable. 
More than 50 years since the efforts to develop a malaria vaccine began, a feasible 
and efficient vaccine providing long-lasting protection still eludes researchers. Some 
are pursuing whole parasite vaccines, whilst others have turned to a sub-unit 
approach, each with varied successes. The malaria vaccine technology roadmap 
has set a goal to develop a vaccine with at least 75% protection from clinical malaria 
by 203023. This goal was modified from the 2006 roadmap where the goal was 80% 
protection by 2025. This extension further highlights the challenges involved in 
defeating such a complex foe. 
1.3. Vaccines 
By exposing an individual to pathogen-specific antigenic material, vaccines stimulate 
an adaptive immune response which can result in antibody generation and T cell 
activation and memory which protects an individual from future infections by that or 
closely related pathogens. Records of vaccination date back to 1000 AD when the 
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Chinese stored scabs from individuals suffering from mild smallpox infections for one 
month, then ground up the scabs and inoculated non-infected people intra-nasally24. 
In the following centuries, this practice spread through India, Asia and North Africa 
before reaching England in the 18th century. This practice was not without serious 
risk with up to 2% of procedures resulting in the death of the person, and some 
subjects inadvertently spreading the virus25. Edward Jenner in 1796 tested the 
efficacy of immunisation with cowpox virus to protect from smallpox. The cowpox 
immunisation resulted in an attenuated infection as that virus was host-specific, but 
the cowpox virus was similar enough to provide cross-species protection against 
smallpox. This vaccine approach was widely accepted and nearly 200 years later 
smallpox was eradicated25. 
With the exception of water sanitisation, vaccines are the most efficient and cost-
effective method of protection from disease related morbidity and mortality, 
improving public health and saving more lives than any other intervention26. Recent 
estimates suggest that current licensed vaccines save in excess of three million lives 
per year27. Through the development of vaccines, we are now protected against 
various bacterial and viral pathogens which were either debilitating or fatal such as 
yellow fever, measles, mumps, rubella, typhoid, hepatitis A and B, poliovirus and 
human papillomavirus1,27-29. The traditional “first generation” approach has been to 
immunise with either inactivated or live attenuated pathogens based on the 
principles of Louis Pasteur30. As our knowledge of pathogens has increased through 
microscopic imaging, genomic sequencing coupled with proteomic and 
transcriptomic data, and advances in vaccinology and related technologies; our 
vaccine delivery platforms have also evolved to a more rational vaccine design30. 
Research into sub-unit vaccines, where selected non-infectious components of a 
pathogen are given as immunogens, have resulted in vaccines delivering toxoid, 
pathogen polysaccharide, recombinant protein and virus-like particles30,31. These 
platforms are considered safer than the traditional whole organism approach as 
there are no infectious agents and therefore the possibility of virulence reversion is 
removed31,32. However, our current vaccine platforms have been either ineffective or 
inefficient against some pathogens including parasites, viral and bacterial infections 
such as Plasmodium, human immunodeficiency virus and Mycobacterium 
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tuberculosis respectively27,32. These three pathogens cause an estimated 4.8 million 
deaths per year27. 
1.4. Vaccines against malaria 
The most cost-efficient and effective measure against Plasmodium infections to 
remove the associated global health problem is likely to be through the development 
of an effective vaccine. Over time, people living in malaria endemic regions develop 
clinical immunity to disease, this does not prevent infections, but does limit the 
clinical symptoms of the disease19. A vaccine therefore must provide a better 
immune response than natural infections.  
Vaccines for malaria can be broadly categorised as pre-erythrocytic (sporozoite or 
liver-stage), erythrocytic (asexual blood-stage), or transmission-blocking (sexual-
stage) vaccines, representing key stages of the parasite‟s life cycle. A pre-
erythrocytic vaccine would provide sterile protection by either preventing sporozoite 
invasion of hepatocytes, or the development of merozoites within infected 
hepatocytes thereby preventing the development of the blood-stage of the parasite 
lifecycle and associated clinical symptoms33,34. Erythrocytic stage vaccines are 
designed to reduce the blood-stage parasite burden and decrease associated 
morbidity and mortality33. Sexual stage vaccines are designed to prevent 
transmission by destroying gametocytes or interfering with their ability to fertilise 
within the mosquito vector33. A multi-gene vaccine targeting each stage of the life-
cycle with both antibody and cellular immune responses may be required due to the 
complexity and immune evasiveness of the Plasmodium species33,35. 
The most promising platforms include intravenous (i.v.) immunisations with radiation 
attenuated sporozoites36 and the sub-unit VLP RTS,S/AS01 which incorporates the 
P. falciparum circumsporozoite protein (CSP) and is currently in phase 3 clinical 
trials37. 
1.4.1. Whole organism vaccines 
Whole parasite immunisations with either live, attenuated or irradiated sporozoites or 
parasitised red blood cells have been successful in protecting animals from infection 
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(reviewed in38,39). Four key approaches for whole parasite vaccines include 1) 
radiation attenuated sporozoites36,40,41, 2) infectious sporozoites under chloroquine 
chemoprophylaxis42,43, 3) genetically attenuated parasites44,45 and 4) chemically 
attenuated blood-stage parasites46. 
Immunisations with radiation-attenuated whole organisms are considered the gold 
standard and have shown to stimulate sterile protection to P. falciparum in 
humans22,40. In this platform, viable sporozoites track to the liver and invade 
hepatocytes, however, their ability to replicate is halted due to the irradiation and 
they do not develop to the blood stage47. Sporozoites can be purified from the 
salivary glands of infected and irradiated mosquitoes, however, viability retention and 
limitations of mass production currently limit the feasibility of this platform. These 
factors are being addressed by Sanaria Inc. (Rockville, MD USA)41,48. Using P. 
falciparum sporozoites purified by this facility, Epstein et al.49 in a dose-escalation 
study using subcutaneous (s.c.) or intradermal (i.d.) administration routes reported 
sterile protection in two people from an 80 person trial. Subsequently they found that 
in NHPs that if the sporozoites were administered intravenously, the CD8+ and CD4+ 
T cell responses in the livers were consistently higher than following s.c. injections. 
The importance of these cellular responses from sporozoite immunisations has been 
well established34,50. In a follow-up study36, 100% protection was achieved in six 
people receiving five i.v. doses of 135,000 sporozoites when challenged 3 weeks 
after their final immunisation. Protection was dose-dependent as only 60% of people 
receiving four i.v. doses had sterile protection, and immunogenicity data showed that 
lower sporozoite doses of 7,500 and 30,000 after 4 or 6 immunisations had markedly 
reduced antibody and cellular immune responses36. Despite this recent success, the 
distribution of viable irradiated sporozoites requires storage under liquid nitrogen and 
administration of high doses delivered by at least five i.v. doses. The mean number 
of sporozoites reportedly in the salivary gland of mosquitoes is between 16,500 and 
83,87551,52, meaning that between 8 and 41 mosquitoes need to be dissected to 
immunise one individual. The practicality of this platform as a world-wide solution to 
the problem of malaria is therefore questionable. 
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1.4.2. Subunit vaccines 
Much effort has been invested in the identification of potential vaccine targets for 
sub-unit vaccines. In Plasmodium falciparum the publication of the genome53, 
proteome54 and transcriptome55,56 has lead to the discovery of many novel vaccine 
antigen targets57,58 where antibody and or T cell immune responses are sought.  
1.4.2.1. Circumsporozoite protein 
The CSP is expressed by sporozoites and liver stage schizonts59,60. In sporozoites 
the protein is secreted at the apex, adhering to the sporozoite surface and is then 
translocated to the posterior in a manner which drives gliding motility61. The CSP 
also provides key ligands to the heparin sulphate proteoglycans on the plasma 
membrane of hepatocytes allowing for target cell specificity62.  
The CSP on the surface of sporozoites provides a target for neutralising antibodies 
only for a short time as they travel from the site of mosquito bite to the liver63,64. 
Following hepatocyte invasion, sporozoites are no longer available for effective 
antibody targeting. Fortunately, the protein is also expressed by liver schizonts65,66 
and can be displayed by infected hepatocytes in the context of major 
histocompatibility complex (MHC) class I molecules for antigen-specific CD8+ T cell 
recognition and responses 67,68. A vaccine targeting the CSP must provide sterile 
protection at the liver-stage preventing the parasite‟s progression to blood-stage 
where CSP is no longer expressed. A vaccine effective against Plasmodium 
sporozoites is likely to required both cellular and antibody responses.  
The CSP is a dominant protective antigen in the whole sporozoite platform69, and 
monoclonal antibodies to CSP have been shown to prevent sporozoite infectivity63. 
Due to the limited exposure time of sporozoites from delivery to hepatocyte invasion, 
it is unlikely that a vaccine totally reliant on anti-CSP antibodies will be successful70. 
Fortunately, the CSP also presents opportunities for CD8+ and CD4+ T cell 
responses whilst within the host liver71-75. Early studies with plasmid DNA 
incorporating the PyCSP conferred sterile protection to mice against P. yoelii 
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sporozoite challenge76, providing the foundation for subsequent clinical trials of 
malaria DNA vaccines in humans77.  
The most clinically advanced malaria vaccine candidate is the RTS,S/AS01 subunit 
vaccine which incorporates a large part of the P. falciparum CSP. The RTS,S 
vaccine comprises a fusion of partial length P. falciparum CSP (containing B cell 
repeats as well as T cell epitopes) (designated RT) combined with the hepatitis B 
surface protein (designated S) and delivered with GSK proprietary adjuvant AS0170. 
The hepatitis B component enables spontaneous assembly into virus-like particles78 
which RTS,S does following expression in yeast70. The AS01 adjuvant comprises a 
liposome suspension with a lipopolysaccharide (LPS) derivative monophosphoryl 
lipid A (MPL) and Quillaja saponaria 21 (QS21). AS01 has been identified as the 
most promising of a number of adjuvant systems trialled with this vaccine 
candidate79. 
In a phase 2 study, adults living in malaria endemic regions immunised with RTS,S 
in either AS01 or AS02 or combined adjuvants only achieved between 29.5% and 
31.7% protection80. Nonetheless, this was followed by phase 3 pre-licence trials 
conducted in seven African countries with over 15,000 participants under 17 months 
old. With most deaths occurring in children under 5 years1, this group is perhaps the 
most important for vaccine protection. In the 14 months following the first 
immunisation in the 5 to 17 month age group, there was a 50.4% reduction in 
reported infections and severe malaria incidents were reduced by 45.1%81. In the 
younger group (6 to 12 weeks old), protection from infection and reduced incidents of 
severe malaria were lower at 30.1% and 26.0% respectively37. Despite the inability to 
provide complete protection, this vaccine would compliment current preventative 
measures namely chemoprophylaxis and ITNs, resulting in a major reduction in the 
malaria burden70.  
1.4.2.2. Apical membrane antigen-1 
AMA-1 is expressed in multiple stages of the Plasmodium life-cycle including 
sporozoites, liver stages and merozoites and is important for parasite invasion of 
hepatocytes82 and erythrocytes83-85. This integral membrane protein is located in the 
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apical rhoptry organelles of the developing and mature merozoite, and relocates to 
the surface of the merozoite86. Consequently it is both a pre-erythrocytic and 
erythrocytic stage vaccine antigen and a target for which vaccine-induced antibodies 
and T cell responses are sought. AMA-1 is one of the most studied blood-stage 
vaccine target antigens, with a large body of animal studies confirming that immune 
responses against AMA-1 can inhibit the development of the parasite87. Antibodies 
against AMA-1 in persons naturally exposed to Plasmodium parasites are higher 
than any other blood-stage vaccine candidate88.  
Antigen-specific antibodies against AMA-1 are effective at neutralising merozoites 
and protecting mice from P. chabaudi and P. yoelii infections89,90 and non-human 
primates from P. falciparum91 by preventing merozoite invasion of erythrocytes92,93. 
CD4+ T cell epitopes on PcAMA-1 are reported to be important contributors for 
antibody and cellular responses94,95. Recently sterile protection from a sporozoite 
challenge in a rodent model was achieved using plasmid DNA and recombinant 
PyAMA-1 protein96, indicating a role for cellular responses within the infected 
hepatocyte. 
A list of PfAMA-1 clinical trials is presented in the review by Remarque et al.97 
Clinical trials with P. falciparum AMA-1 recombinant protein with various adjuvants 
have shown vaccine induced antibody and cellular immune responses with some in 
vitro parasite growth inhibition and a Th1 cell-mediated response98,99. Despite these 
promising results, protection or a reduced parasite burden in human trials has not yet 
been reported. This may be due to PfAMA1 polymorphisms100, since protein 
variability reduces the parasites susceptibility to antibody neutralisation97.  
1.4.3. Pre-erythrocytic and blood-stage protective responses 
1.4.3.1. Sporozoite and liver-stage 
Antibodies directed to the surface of the sporozoite can neutralise and inhibit 
sporozoite invasion63,64,101-103. However, the number of sporozoites delivered by an 
infected mosquito bite is very low with a median of only 15104 and 98% of infected 
mosquitoes in the field delivering less that 25 sporozoites105. This coupled with the 
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short period of sporozoite exposure to the immune system before invading an 
hepatocyte15, which can be as fast as 2 minutes if sporozoites directly enter 
circulation106, means that large quantities of circulating antibodies are required for 
effective neutralisation. 
Infected hepatocytes can be cleared by antigen-specific effector cytotoxic CD8+ T 
cells67,68 or by immune mediators released by CD8+ and or CD4+ T cells107, following 
the recognition the foreign antigens displayed on major histocompatibility complexes. 
There is a delay of approximately 5.5 to 7 days for P. falciparum108 and much longer 
in the case of P. vivax and P. ovale hypnozoites, before merozoites packaged in 
merosomes bud off from the infected hepatocyte109 marking the commencement of 
the erythrocytic stage of infection. This bottle-neck in parasite development makes 
for an attractive vaccine targeting strategy. 
1.4.3.2. Asexual blood-stage 
The start of the blood-stage infection is marked by merozoite release from 
hepatocytes and invasion of erythrocytes. Multiple cycles of replication within 
successive erythrocytes lead to the clinical manifestations of the disease. In the 
asexual stage, protective immunity is thought to be antibody mediated with a 
requirement for high levels of quality antibodies against a breadth of targets110-112. 
The primary mechanism of action of asexual based vaccines is antibody mediated, 
with surface binding of merozoites resulting in agglutination, blocking erythrocyte 
invasion, facilitating phagocytosis and through antibody dependent cellular 
inhibition113. A number of antigens have been targeted in clinical trials (reviewed 
in113,114) with most effort focusing on AMA-1 and the merozoites surface protein 1 
(MSP-1). MSP-1 antigens are expressed during liver-stage infection115 and are 
located on the surface of merozoites, and antibodies against MSP-1 inhibit 
erythrocyte invasion116,117 
Most erythrocytic stage sub-unit vaccines have focused on single antigens, and 
despite effectiveness in animal models, these have not progressed beyond phase II 
clinical trials118.  
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Whole blood-stage parasite strategies have also been investigated with some 
success in mice46,119, and in humans120. One strategy with either sub-patent low-
dose infections of parasitised blood followed by a drug treatment cure119,120 relies on 
T cell-mediated immunity, but most other strategies are thought to rely on antibody 
responses. 
1.4.3.3. Multi-stage vaccines 
Many researchers anticipate that the ultimate vaccine will comprise of a combination 
of antigens from various stages of the parasites development33,97. Proof of concept 
for this was demonstrated in a murine vaccine study where the combination of two 
proteins provided synergistic or additive protection against challenge121. Multi-
antigen/multi-stage antigens have shown some promise in animal models121-123 
however, clinical trials have been disappointing with poor protective efficacy118. For 
example, NYVAC-Pf7 consisting of seven P. falciparum proteins (including CSP, 
AMA-1 and MSP-1) representing all stages of the parasites life-cycle resulted in poor 
antibody and moderate cellular responses, with only 1 of 35 individuals protected 
from challenge, but with a significant delay in the time to reach parasite patency124. 
Generally anti-malarial sub-unit vaccines have shown efficacy in animal models but 
have failed to be effective in humans118. Whilst this may be an antigen selection 
issue, it is likely to also be influenced by the choice and strength of the co-
administered adjuvant. This adjuvant effect was shown in the RTS,S vaccine trials, 
where the variation of adjuvant systems resulted in different outcomes37,70,79. Sub-
unit vaccine efficacy may be further enhanced with more potent adjuvants, or 
through a redesign of the vaccine delivery platforms. 
1.5. Virus like particles 
Virus–like particles (VLPs) are formed from one or more viral structural proteins 
which can assemble into a highly repetitive and dense array resembling the native 
virus structure. VLPs lack all other viral components including DNA or RNA thus they 
are unable to replicate and non-infectious125. The capsid retains natural immune-
stimulatory properties126 and can induce potent cellular and humoral immune 
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responses without a requirement for adjuvant127. The high density and tight antigen 
spacing on the surface of the VLP is both unique to microbial pathogens128 and 
critical for VLP induced antibody production128,129 thought to be a result from cross-
linking B cell receptors130,131. The ordered structure constitutes a pathogen- 
associated molecular pattern (PAMP) recognised by pattern-recognition receptors 
(PPRs) on host APCs132,133. PAMP recognition results in the stimulation of antigen 
uptake by innate immune cells, and causes the maturation of dendritic cells (DCs) 
which enhances presentation of antigens to the adaptive immune system134,135. The 
structural importance of VLPs was shown with heat-denatured VLPs resulting in 
substantially reduced humoral and cellular responses136. The intrinsic properties of 
VLPs provide an effective vaccine delivery platform, and because they are non-
infectious, they are safe and readily produced in physical containment 2 (PC2) 
conditions. Moreover, VLPs are a self-adjuvanting platform as a result of their highly 
repetitive structure array which mimics the native virus126,128.  
A recent review by Zeltins31 identifies that at least 110 VLPs have been constructed 
from 35 viral families including Hepadnaviridae (Hepatitis virus), Papillomaviridae 
(Papillomavirus) and Polyomaviridae (Polyomavirus). These numbers are markedly 
increased when examining the number of VLP related publications in a range of 
technologies including their use as vaccines. Vaccine studies of homologous and 
chimeric heterologous VLPs have been driven by the success of the hepatitis B virus 
(HBV) and human papilloma virus (HPV) vaccines31, and more recently the hepatitis 
E virus (HEV) VLP based licensed vaccine137. 
1.5.1. Licensed VLP based vaccines 
There are three human viral pathogens for which licensed VLP based vaccines are 
available, each of which is comprised of a single viral protein from their respective 
target pathogen. The first was developed against HBV, using sera from donors who 
were negative for HBV virions but positive for the hepatitis B surface antigen 
(HBsAg), and particles were purified by affinity chromatography and antibody-coated 
gels, then inactivated with formalin138,139. The publication of HBV genome140,141 was 
an important step in researchers understanding the viral structure, and the three co-
translated structural proteins139. Subsequently, advances in recombinant DNA and 
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protein technologies, bacteria, yeast, insect and mammalian cells have been used to 
generate effective VLP vaccines against HBV (reviewed in139). VLP vaccines are 
now available for HBV, HPV and most recently the HEV. Details of these vaccines 
are listed below (Table 1). There are many companies which manufacture HBV 
vaccines with an extensive list of VLP vaccines both licensed and in clinical 
development available in a recent review by Kushnir et al.125 
Table 1: Licensed VLP based vaccines 
Vaccine Virus VLP protein (dose) Adjuvant (dose) 
Dose 
regimen 
Production 
Recombivax 
Merck 
142
 
HBV HBsAg  
(10 µg) 
Aluminium 
hydroxyphosphate 
(500 µg) 
0, 1 and 
2 months 
Yeast 
Engerix-B GSK
143
 HBV HBsAg  
(20 µg) 
Aluminium 
hydroxide (250 µg) 
0, 1 and 
6 months 
Yeast 
Cervarix GSK
144
 HPV HPV 16 L1 (20 µg) 
HPV 18 L1 (20 µg) 
AS04 – Aluminium 
hydroxide (500 µg) 
and Monophoshoryl 
lipid A (MPL) (50 
µg) 
0, 1 and 
6 months 
Insect cells 
Gardasil Merck
145
 HPV HPV 6 L1 (20 µg) 
HPV 11 L1 (40 µg) 
HPV 16 L1 (40 µg) 
HPV 18 L1 (20 µg) 
Aluminium 
hydroxyphosphate 
sulphate (225 µg) 
0, 2 and 
6 months 
Yeast 
Hecolin Xiamen 
Innovax
137
 
HEV Hep E antigen (30 
µg) 
Aluminium 
hydroxide (800 µg) 
0, 1 and 
6 months 
E. coli 
All licensed VLP based vaccines are administered by intra-muscular injection and 
are administered with an aluminium based adjuvant (Table 1). The primary 
immunological protective mechanism induced by VLPs and responsible for 
protection against both HBV and HPV infections are neutralising antibodies139,146 . To 
prevent acute infection there is a requirement for CD4+ T cell activation to promote 
memory B cell responses and isotype switching139. There is also evidence of CD8+ T 
cell-mediated protection with established HPV infections147 as confirmed by genital 
wart regression148.  
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All licensed VLP based vaccines are assembled using a capsid protein of the 
targeted viral pathogen125,137. If the VLP platform was limited to homogenous viral 
capsids, then the usefulness of the platform would be restricted to only viral 
pathogens, and further restricted to those from which VLPs could be generated. 
Fortunately this is not the case with many laboratory and clinical trials showing the 
VLPs to be efficient carriers of foreign heterologous epitopes, or partial or full length 
proteins. By incorporating foreign antigens into the non-targeted capsid structural 
protein, this platform can theoretically target any organism (reviewed in125,127,149), 
greatly increasing the value and versatility of VLPs as a vaccine delivery platform.  
1.5.2. Chimeric VLPs 
Candidate vaccine target antigens against the Plasmodium parasite have been and 
continue to be identified as our understanding of the parasite and natural or vaccine 
induced immune responses accumulate150,151. These sub-unit antigens may result in 
an effective vaccine if incorporated into a delivery platform which is highly 
immunogenic. VLPs are a highly immunogenic vaccine platform for native 
(homologous) viral antigens, and chimeric VLPs presenting foreign (heterologous) 
antigens have similar immunological characteristics which have led to their 
progression to clinical studies125. One promising chimeric platform is the RTS,S 
vaccine incorporating the regions of the P. falciparum CSP into the HBsAg viral 
protein37 (section 1.4.2.1). 
Antigens can be coupled within VLPs by chemical conjugation or genetic fusion. At 
the genetic level, peptide or protein units are inserted into viral proteins using 
conventional recombinant DNA techniques. Using this strategy, a viral structural 
protein is expressed with foreign antigens positioned at internal or surface exposed 
protein sites152-154. The positioning may be important for the type of immune 
response sought152,155. Multiple antigen insertion sites both internal and external can 
be used in a single construct 79,152 allowing surface exposed antigens to cross-link B 
cell receptors130 and potentially better access to proteomic cleavage at terminal 
regions relevant for T cell epitopes. The disadvantage with genetic antigen insertion 
is the potential disruption in the expression of the chimeric structural protein as well 
as the successful formation of VLPs156,157, with single amino acid variations capable 
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of platform destabilisation158. The current unpredictability both of chimeric VLP 
formation, and the antigen-specific immunogenicity, means that a single 
methodology will not be sufficient for all chimeras127. To increase the likelihood of 
VLP stability and to control steric arrangements, flexible linkers are often used to 
flank antigens159-161. Limited studies have evaluated the immunological benefits of 
flexible linker sequences, with results suggesting minimal differences to non-flanked 
epitopes154. 
The alternative is chemical conjugation of antigens to pre-formed VLPs. Many 
conjugation methods have proven successful in VLPs with conjugated antigens 
ranging from peptides157,162 to full length proteins163. Perhaps the most commercially 
advanced system is the E. coli produced bacteriophage Qβ developed by Cytos 
Biotechnology in Switzerland. Clinical trials are currently evaluating effectiveness of 
Qβ VLPs against asthma, Alzheimer‟s disease, diabetes mellitus and other 
conditions125. This binding system introduces a lysine residue flanked by glycine (x2) 
linkers on a surface exposed loop which is then coupled to any antigen with a free 
cysteine group using a heterobifunctional cross linker156,164. Qβ VLPs, however, are 
poorly immunogenic and require the inclusion of adjuvants127. Other groups have 
linked VLPs to antigens using biotinylated VLPs and streptavidin labelled peptides128 
or used peptides with a free sulphydral group to maleimide activated biotinylated 
VLPs162. Electrostatic binding using VLPs with multiple polyanionic sites decorated 
with polycationic peptides with induced disulfide bode formation has successfully 
resulted in antigen induced cytotoxic T lymphocyte (CTL) activity157. Whilst these 
conjugation systems are appealing for rapid development and testing of antigenic 
suitability using the VLP platform, the requirements for carriers and antigens made 
separately with elaborate binding processes reduce their practicality with inherent 
increases in manufacturing costs. 
1.5.3. Chimeric capsomeres 
The viral capsid is comprised of intermediate subunits called capsomeres which can 
link together using terminal regions of the structural proteins. In the case of the 
murine polyomavirus, for example, five VP-1 proteins are linked into a pentameric 
capsomere165,166. The flexible C-terminal arms of VP-1 proteins link with 
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neighbouring capsomeres likened to a rope and clamp system167. Researchers have 
shown that truncating the terminal region of the viral structural protein results in a 
capsomere unit which is not able to form the capsid unit168-170. A vaccine made from 
this VLP sub-unit removes the need for VLP assembly processing and structural 
confirmation, making it cheaper and faster to produce. It avoids costly VLP 
disassembly and reassembly processing to remove contaminants171. Furthermore, 
capsomeres are reported to be more stable than VLPs172,173 and because there is no 
requirement for a stable VLP assembly, more and longer-sized antigens can be 
loaded into the structural protein170. Increasing the antigen to carrier ratio can benefit 
a vaccine platform by both increasing the immune responses to the antigen174,175 but 
also decreasing the antibody titres against the carrier176. 
Capsomeres do not possess the ordered array of VLPs and so would be expected to 
lose the benefits of the VLP platform. Some studies have shown that capsomeres 
retain some self-adjuvanting immunogenicity177,178 stimulating humoral and cellular 
responses which can be further enhanced with the inclusion of adjuvants170,179. 
However, other studies have shown that the inclusion of an adjuvant is essential to 
enhance capsomere induced immunogenicity, in particular antibody 
responses131,173,180. Few studies have directly compared the immunogenicity of 
capsomeres and VLPs, but there is a consistent trend indicating VLPs are superior 
to capsomeres without adjuvants, with respect to antibody titres173,179. Induced titres 
with as high as a 20-fold difference180, or the requirement to use 40-times higher 
capsomere dose to achieve equivalent titres have been reported131. In most cases, 
however, this disparity is reduced or eliminated with the inclusion of adjuvants. 
Differences in capsomere induction of cellular responses was less obvious131 and 
these lower responses could be recovered with the inclusion of adjuvants179. In one 
study, IFN- ELISpot data comparing various HPV VLP and capsomere constructs 
indicated that the inclusion of an aluminium hydroxide and MPL based adjuvant did 
not enhance VLPs but was essential for capsomeres which were otherwise 
inefficient inducers179. In another study, capsomeres were identified as potent 
inducers of CTL responses without the requirement of adjuvants, where antigen-
specific tumour regression was similar to VLPs169. 
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1.5.4. Murine polyomavirus 
The murine polyomavirus (MuPyV), as the name suggests, is a virus which infects 
mice and results in the induction of multiple tumours181. This virus is a member of the 
Polyomaviridae family and was first isolated by Ludwig Gross in 1953 whilst studying 
leukaemia development in mice182. Since then, polyomaviruses have been identified 
in a variety of avian and mammalian hosts including humans (JC and BK 
polyomaviruses), non-human primates (simian virus 40), and hamsters (hamster 
polyomavirus)183. The virus is a non-enveloped, double stranded circular DNA virus 
with the capsid having icosahedral symmetry184. 
The native structure of MuPyV is formed using three structural proteins including the 
major capsid protein VP1, and two minor core proteins VP2 and VP3. The capsid 
comprises of 72 VP1 pentameric capsomeres each linking with other capsomeres 
and to VP2 and VP3 proteins to form the icosahedral surface with a diameter of 
approximately 45 nm185. In vitro experiments have shown that under the correct 
physiochemical conditions, bacterial produced VP1 proteins can self-assemble into 
VLPs without the requirement of VP2 or VP3 interactions166. 
After expression of the MuPyV VP1 protein, five monomers self-assemble into a 
pentameric capsomere which can then assemble into a VLP comprising 72 
capsomeres in a T=7d icosahedral surface lattice165. The formation of VLPs is 
dependent upon capsomeres binding to each other using amino acids on the C-
terminal region of the VP1 protein. This requirement has been confirmed with the 
removal of 63 amino acids from the C-terminal resulting in capsomeres which are 
incapable of VLP formation168,170. MuPyV VLPs are protective against their native 
virus in the limitation of induced tumour development186, however, this platform has a 
much higher potential in its ability to induce immunological responses against 
heterologous pathogenic antigens. 
In the chimeric MuPyV platform developed by Middelberg and colleagues173, 
genomic epitope insertion sites have been created in HI loop (S4) surface exposed 
region of the VP1 protein (Figure 3). When expressed, the antigen epitopes are 
flanked by a flexible linker sequence of four glycines and a serine (GGGGS-epitope-
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SGGGG). The inclusion of the linker is designed to project the epitope from the VP1 
surface and to limit interference in the formation of the VLP. The VP1 chimeric 
monomers expressed in E. coli at gram per litre levels187 arrange into a pentameric 
capsomere166 each containing five antigen epitopes. Capsomeres are harvested 
from homogenised lysate and chemically induced in vitro to self-assemble into 
VLPs173,188,189 comprising of 72 capsomeres. Hence a total of 360 epitopes are 
presented in a structured array resembling the native MuPyV capsid.  
 
Figure 3: Structure of the chimeric MuPyV VLP. In each image the coloured portions 
represent the antigen epitope genomically inserted into MuPyV VP1 protein. The chimeric 
VP1 monomer (A) shows the S4 epitope insertion site on the surface exposed loop. (B) Five 
monomers combine to form a pentameric capsomere whilst within the E. coli. The c-terminal 
region of each VP1 links with neighbouring capsomeres. (C) The chimeric VLP comprises of 
72 capsomeres in a T=7 icosahedral lattice with a total of 360 surface exposed inserted 
antigens. Images were adapted with permission190. 
VP1 protein production can be achieved using various eukaryotic and prokaryotic 
organisms and VLP assembly in either in vivo or in vitro systems187,191. Some 
systems are more efficient protein producers, are simpler allowing rapid modification, 
and more cost-effective in large scale manufacturing. To date, the use of VLPs as a 
vaccine platform has been limited by ineffective scale-up processes and other 
related manufacturing problems including the removal of contaminants. Studies to 
optimise bacterial expression of VP1 proteins189 and the use of fed-batch cultivation 
in bioreactors187 have resulted in a feasible bacterial production platform. Recently, 
the direct use of MuPyV capsomeres as a vaccine platform is also being 
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investigated170,173. Removal of the requirement to form VLPs would reduce 
production costs by removing dialysis processing and VLP stability requirements.  
1.5.5. Dendritic cell activation by VLPs 
Dendritic cells are professional antigen presenting cells (APCs) which are potent 
stimulators of the adaptive immune response. These highly motile cells are present 
in every organ and tissue throughout the body acting as an interface between the 
innate and adaptive immune systems192. Immature DCs survey their environment by 
sampling and processing self and foreign proteins and displaying peptide fragments 
on MHC class I and class II molecules. Without DC maturation stimuli, this 
presentation can result in tolerance, however, antigens accompanied by danger 
signals result in the maturation of DCs193 which can result in immunity. Maturation 
results in the up-regulation of MHC:peptide complexes, and co-stimulatory CD80 and 
CD86 receptors, and the production of soluble mediators which can polarise the T 
cell responses194. Importantly, DCs activated in the periphery migrate to lymphoid 
rich regions to present peptides to naive T cells195. Antigens can be processed and 
displayed on MHC class II molecules for CD4+ T cell presentation, or by the process 
of cross-presentation displayed on MHC class I molecules for CD8+ T cell 
recognition195. 
Using ovalbumin-coated polystyrene microspheres with sizes ranging from 20 to 
2000 nm, the induction of antibody responses and the stimulation of T cells in mice 
was clearly shown to be influenced by particular size196. The optimal size for DC 
uptake and activation was shown to be between 40 to 50 nm196. An analysis of 
draining lymph nodes 48 h post i.d. injection determined that the percentage of 
uptake of the 40 nm beads was significantly higher, and 40 nm bead positive cells 
populations had the highest proportion of DEC205, CD40 and CD86 surface marker 
expression196. Data indicates that DCs preferentially take up these size particles and 
become activated, whereas larger particles are cleared by macrophages.  
In another size dependant antigen delivery experiment, small particles of between 20 
to 200 nm diameters were detected in lymph node resident APCs197. These 
nanoparticles and VLPs (30 nm) entered the lymphatic system and were conveyed 
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to the lymph nodes, then endocytosed by resident APCs197. This feature is important 
for vaccines seeking CD8+ T cell responses, because studies have shown that it is 
the CD8α+ lymph node-resident DCs which are central to prime naive CD8+ T 
cells198,199. Both CD8α+ and CD8α- DCs are efficient at VLP uptake and antigen 
presentation on MHC class II complexes200. The optimal particle size determined by 
both microsphere experiments196,197 suggests that VLP platforms with vaccine 
candidate particles sizing between 22 and 60 nm (HBV: 22 nm, Qβ: 29.4 nm, 
MuPyV: 51 nm and HPV16: 60 nm)201 are therefore advantageous at reaching the 
required innate immune cells.  
It is well established that VLPs are capable of inducing DC maturation, and 
subsequent cellular immunological responses without the requirement for 
adjuvants125,127,130. Several studies have directly evaluated DC maturation by VLPs. 
In vitro cultures of murine bone marrow-derived DCs (BMDDCs) pulsed with MuPyV 
VLPs showed an up-regulation of DC maturation receptors and interleukin 12p70 (IL-
12p70) cytokine production without adjuvant202. Bovine papillomavirus (BPV)157 and 
hamster polyomavirus (HaPyV)154 VLPs also up-regulated BMDC activation 
receptors and IL-12p40 cytokines. Importantly for human vaccine delivery, MuPyV 
and HaPyV VLPs were efficient at activating human DCs as determined by the up-
regulation of activation markers, IL-12 production and a reduction in endocytic 
capacity203.  
The functional determination of a naive CD4+ T cell is regulated by signal patterns 
encountered during their initial antigen confrontation204. Vaccines targeting 
intracellular pathogens aim to induce a Th1 responses with key cytokines including 
IFN- and IL-2, with the latter critical for CD8+ T cell memory formation204,205. 
Activated DCs producing large amounts of IL-12 which promotes natural killer (NK) 
cells to produce IFN- which through a number of pathways induces Th1 
differentiation206. 
VLPs are not, however, universally immunogenic. In one study, immature human 
DCs were only marginally activated by JC, BK and SV40 VLPs whereas MuPyV and 
HaPyV VLPs were potent inducers203. Whilst structurally similar, HPV16 and HPV18 
VLPs are capable of inducing acute maturation of murine BMDDCs whereas JC and 
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BK VLPs are efficiently internalised by DCs but fail to stimulate maturation207. Others 
have reported that JC VLPs injected into rabbits only induced immune responses 
when administered with Freund‟s complete and incomplete adjuvants208. It also 
appears that the formation of VLPs is a determinant of DC maturation as observed in 
multiple studies where capsomeres were inefficient at activation of DCs in contrast to 
the VLPs157,207.  
1.5.6. Cellular immune VLP induced immune responses 
As earlier mentioned, VLPs are potent inducers of antibody responses with licensed 
VLP based vaccines stimulating stable and long-lasting neutralising antibody titres 
capable of preventing disease127. Using the chimeric MuPyV VLP and capsomere 
platforms, antibodies have been raised against inserted epitopes to target a range of 
pathogens including influenza and group A streptococcus170,173,188,209. However, the 
cellular responses to VLP vaccines, especially CD4+ T cell responses, are not as 
well characterised.  
Whilst a single CD8+ T cell clone can induce protection from a Plasmodium 
challenge, a high number of these cells are required to achieve sterile protection210. 
A chimeric VLP incorporating a single epitope designed to induce proliferation of a 
single T cell clone must therefore be a very efficient immune-modulator.  
Surprisingly few studies have been done evaluating cellular immunogenicity of VLPs 
using an ovalbumin transgenic mouse model. In one study, ovalbumin peptide 
MuPyV VLP chimeras resulted in the in vitro proliferation of both OTI and OTII cells, 
indicating that APCs presented antigen peptides on both MHC class I and class II 
molecules202. Chemically conjugated OVA257-264 (OTI) or OVA232-339 (OTII) peptides 
on rabbit haemorrhagic disease virus VLPs have also resulted in the in vitro 
proliferation of transgenic OTI and OTII cells with OTI chimeras inducing target 
peptide-specific lysis and a delay in B16.OVA tumour development162,211. In another 
study, tumour protection and survival was conferred by immunisations of OVA257-264 
chimeric MuPyV VLPs and capsomeres with antigen-specific T cell proliferation 
determined using peptide-specific tetramers212. Using chimeric HBV VLPs with either 
single OTI epitopes or combined OTI and OTII epitopes, T cell receptor-specific 
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proliferation was observed and cytotoxic lysis of OVA257-264 coated cells in vivo was 
detected213. It should be noted that in this study, the inclusion of a T helper epitope 
did not enhance CTL activity in the lysis model213. 
In an early chimeric VLP experiment, Sedlik et al. inserted a single CD8+ T cell 
epitope from lymphocytic choriomeningitis virus (LCMV) into a parvovirus VLP, and 
following two doses of non-adjuvanted VLPs (10 µg/dose) showed a strong CTL 
response against peptide-labelled or virus-infected target cells214. In those 
experiments, there was persistent in vivo CTL activity for at least 9 months, and mice 
were completely protected when challenged with a lethal LCMV administered 7 d 
post-immunisation and were 80% protected when challenged 49 d post-
immunisation. By depleting either CD8+ or CD4+ T cells, they showed that protection 
was CD8+ T cell-mediated214. Subsequently, using an LCMV model but a different 
CD8+ T cell epitope inserted into a HaPyV VLP, antigen-specific CD8+ T cell 
proliferation and an effective memory response was induced after a single dose of 
non-adjuvanted VLPs (50 µg), providing 70% protection from infection215. The 
effectiveness of VLPs may be dependent on the carrier with the same epitope 
inserted into a HBV VLP only capable of inducing weak CTL activity and no 
protection unless co-administered with adjuvants216. 
To assess the effectiveness of VLPs at achieving clonal CD8+ T cell expansion to 
reach the proposed the 1% threshold required for protection against Plasmodium 
challenge210, one has to review studies which have quantified the proportion of 
epitope-specific CD8+ T cell induced by immunisation. Kawano et al. constructed a 
chimeric SV40 VLP with an influenza A virus CTL epitope and administered a single 
non-adjuvanted dose (50 µg), then restimulated splenocytes in an ELISpot readout 
and showed approximately 1.5% of CD8+ T cells produced IFN-161. Using HPV16 
capsomeres in a single dose (5 µg), restimulated splenocytes were less than 0.35% 
of the CD8+ T cells were positive for IFN-169. In that study, ELISpot data from 
splenocytes of VLPs (10 µg) and capsomeres (5 µg) immunised mice had a mean of 
580 and 850 IFN- spots/106 splenocytes respectively and data was highly variable 
within groups169. Combined these studies show the potential of VLPs to achieve 
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target responses for protection. It would be expected that the inclusion of additional 
boost immunisations would enhance immunogenicity as reported by others217,218.  
The VLP carrier is itself likely to have CD4+ T cell epitopes which will aid in vaccine-
induced antibody responses, but these primed CD4+ T cells will have no effect when 
encountering the pathogen unless it also has the same epitope152,219. An example of 
carrier-specific CD4+ T cell stimulation was reported using hepatitis C virus (HCV) 
VLPs with endogenous T helper epitopes220. In a malaria vaccine model (ICC-1132), 
HBV VLPs containing a CSP B cell repeat in an exposed loop and a T cell epitope at 
the C-terminal were shown to produce CSP-specific CD4+ T cell clones and high 
antibody titres significantly enhanced by the inclusion of Montanide ISA 720 
adjuvants219. The inclusion of a pathogen-specific T helper epitope does not, 
however, guarantee that it will be functional and result in CD4+ T cell priming as 
shown by Schodel et al.152. Studies into CD4+ T cell activation by chimeric VLPs with 
T helper epitopes are very limited. The Th1/Th2 profile has generally been reported 
only in relation to the skewing of IgG antibody isotypes221. It is known that the 
inclusion of adjuvants can alter the profile with aluminium hydroxide generating a 
Th2 profile, whilst CpG, MPL and polyIC induce a Th1 skewed result221.  
1.6. Bacterial derived particles as delivery platforms 
1.6.1. Bacterial minicells 
Bacterial minicells are small anucleate cells which are enzymatically active but are 
incapable of further cell division because they contain no chromosomal DNA222-224. In 
the 1930‟s, Gardiner reported a microscopic observation of small spherical non-
viable granules resulting from unequal cell division in a strain of Vibrio cholera225. In 
1966, whilst studying the mechanisms of cell division in E. coli, Adler and 
colleagues226 detected a mutant of the K-12 strain that produced cell-like structures 
about one-tenth the size of the regular strain and noted that these structures lacked 
chromosomal DNA. The mutant strain named P678-54 underwent normal binary 
fission and was therefore able to proliferate, but also produced „minicells‟ at the polar 
regions which were unable to grow or divide222. A number of minicell-producing 
bacteria have now been reported including Gram negative and Gram positive 
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species227. Predominantly E. coli, S. typhimurium and Bacillis subtilis mutants have 
been investigated228,229. Microbiologists studying the replication of bacteria have 
since confirmed that multiple proteins are responsible for the correct placement and 
subsequent septum formation during replication (reviewed in 229). The MinCDE 
system is an inhibitory system which prevents the formation of the septum at any 
region other than the mid-cell229. Mutations in the minB locus containing minC, mind 
and minE genes disrupting the minCDE system230, or over-expression of the FtsZ 
protein231,232, can result in incorrect septum placement resulting in minicell formation. 
Since minicells are enzymatically active222, can contain plasmid DNA and can 
produce encoded proteins223,224,233,234, they are a valuable tool for studying bacterial 
functions and the effects of recombinant proteins without interference of 
chromosomal DNA derived factors. Additionally, the use of minicells as a potential 
medical delivery vehicle has been reported by several groups227,235-239. 
A crude separation process involving centrifugation of minicells on a sucrose 
gradient removed most of the parent bacteria222 resulting in a semi-pure yield of 
minicells was described by Adler et al222 and later by Frazer and Curtiss225 with the 
inclusion of a differential centrifugation. This has been the primary purification 
protocol since that time, however, additional antibiotic incubations235, and filtration 
steps227 have enhanced the removal of viable parent bacteria, so as to be suitable 
for human use. 
1.6.1.1. Bacterial minicells for treatment of cancer 
During chemotherapy, patients are administered large systemic doses of toxic drugs 
which indiscriminately target rapidly dividing cells. To reduce the quantity of drugs 
and avoid the unwanted side-effects of chemotherapy, bacterial minicells packaged 
with chemotherapeutic drugs have been successfully targeted to cancer cells using 
bi-specific antibodies (BsAbs)227,238. In the development of this drug-targeting 
minicell platform, researchers have generated minicell-producing mutants from S. 
typhimurium and E. coli by deleting the minCDE gene sequences227. Minicell-
producing strains were cultured and purified for complete removal of contaminating 
viable parent bacteria leaving minicells with a diameter of 400 nm ± 20 nm. Using the 
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RAW 264.7 mouse macrophage cell line, minicells were observed to be internalised 
in intracellular vacuoles with up to 50 minicells per macrophage227. The minicells 
were then incubated with a range of drugs which were taken up by the minicells 
either by means of diffusion down a concentration gradient227, or through charge 
related interactions through the porin channels240. Depending on the drug and 
concentration, incubation solution and incubation time, each minicell was capable of 
containing up to 107 drug molecules. When mice received an i.v. administration of 
non-targeted drug-laden minicells, there was no effect on tumour development. 
However, when minicells were targeted to the epidermal growth factor receptor 
(EGFR) which is over-expressed on cancer cells241 using BsAbs, significant inhibition 
and regression was shown227. In those studies, mice received a drug dose which 
was a 8000-fold dose reduction as compared to a standard systemic treatment. The 
targeting of the EGFR receptor both delivered the minicell to the correct location, and 
triggered receptor-mediated endocytosis which was essential for the up-take of 
minicells by non-phagocytic human breast adenocarcinoma cells227. 
Following this success, the same researchers showed that minicells could be 
packaged with small interfering RNAs (siRNAs) and plasmid DNA for expression of 
short hairpin RNAs (shRNA)227 which down-regulated proteins involved in cancer cell 
proliferation242. In this system, bacteria transformed with plasmid DNA was cultured 
expressing shRNAs and then purified, whereas siRNA was absorbed into the purified 
minicells by co-incubation. Analysis showed that each minicell contained 
approximately 100 copies plasmid DNA, equating to between 3 and 5 µg per 1010 
minicells, and 12,000 siRNA molecules238. Sequential treatment with EGFR targeted 
delivery of minicells containing siRNA or cytotoxic drugs prevented tumour growth 
and was also effective against a multidrug-resistant tumour cell line238. In vitro 
studies showed that endocytosed minicells were degraded by endosome/lysosome 
fusion238 and the plasmid DNA translocated to the nucleus where shRNA expression 
occurred239. 
In both studies227,238, the targeting of tumour cells with BsAbs was essential for 
delivery to cancer-specific cells and receptor mediated endocytosis which ultimately 
resulted in tumour growth inhibition or regression. BsAbs were made by protein A/G 
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coupling of the Fc region of two monoclonal antibodies specific for the O-antigen on 
the surface of the minicell or against EGFR over-expressed on some tumour cells.  
1.6.1.2. Bacterial minicells as a potential vaccine platform 
Whilst bacterial minicells are devoid of chromosomal DNA, they can contain plasmid 
DNA and, because they are still enzymatically active, they can express encoded 
proteins post-separation from the parent bacteria 225,233,243,244. This feature has 
recently been exploited by two research groups for vaccine-related studies, where 
either plasmid DNA or recombinant proteins from heterologous pathogens were 
packaged within minicells235-237,245. The biotech company Vaxiion Inc (San Diego) 
explored the potential of minicell up-take and the subsequent transfer of plasmid 
DNA using the eukaryotic Cos-7 cell line. They showed expression of a GFP reporter 
protein in 25% of cultured cells co-incubated with minicells, but only when minicells 
expressed and displayed the Yersinia pseudotubeculosis invasin protein235. This 
invasin protein interacts with α1β5 integrins on the surface of otherwise non-
phagocytic cells resulting in receptor-mediated endocytosis of bacteria246,247.  
In a subsequent study, mice were immunised with minicells containing GFP protein 
or GFP encoded plasmid DNA for mammalian expression, or both. Following a three 
dose i.m. regimen, minicells containing either GFP or plasmid DNA elicited an anti-
GFP IgG antibody response and a synergistic effect was observed when minicells 
contained both protein and plasmid DNA236. Oral, intranasal and i.m. routes each 
induced significant IgG titres as compared to the naive control, however, i.m. 
immunisations induced a 4-fold higher response236. The mean titre, however, was 
less than 1250, and the ability of such low titre antibodies to protect from challenge 
would need to be assessed. In vitro experiments showed minicells could be taken up 
by phagocytic cell lines including J774A.1, RAW264.7 and bone marrow-derived 
macrophages (BMDMs) and BMDDCs236. Whilst the reported transfection efficiency 
was only between 0.02 and 0.2%, those studies did demonstrate that APCs could 
uptake and express plasmid DNA delivered in minicells236.  
Only one study has evaluated the capacity of minicells to induce CD8+ T cell 
responses and confer T cell-mediated protection. In that study, the effectiveness of 
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protein and plasmid DNA loaded minicells was assessed using a LCMV model with 
the LCMV nucleoprotein antigen237. The minicells were able to induce peptide-
specific CD8+ T cell IFN-+ responses and protection from LCMV challenge. 
Following a 3 dose i.m. regimen, almost 5% of CD8+ T cells produced IFN- in 
response to antigen-specific peptide restimulation, and this response was similar to a 
50 µg/dose regimen of naked plasmid DNA. To evaluate the dose requirements for 
efficient protection, mice received doses ranging from 107 to 1010 minicells in log 
increments. Protection was most effective in mice (8/9) at the highest dose and 
efficiency was lost as doses decreased (2/5, 1/5 and 0/5) 237. The effective antigen 
load in a 1010 minicell dose was 1.2 ± 0.2 µg of protein and 3.0 ± 0.7 µg of plasmid 
DNA.  
The priming of protective CD8+ T cell responses has also been reported in minicells 
produced by S. typhimurium using an ovalbumin model245. That study reported that 
heterologous antigen protein delivery to the cytosol of APCs required the up-
regulation of the type III secretion system (T3SS) coupled with chimeric proteins 
which include pathway specific homing signals248 to increase antigen presentation 
and transgenic OT I CD8+ T cell proliferation245. These secretion systems are also 
present in some species of E. coli249, however, the data from the LCMV study 
indicates either the absence of T3SS or at least the up-regulation requirements237. 
1.6.2. Outer membrane vesicles 
There are three components to the envelope of Gram negative bacteria, specifically 
the outer membrane (OM) composed mostly of LPS, the inner membrane (IM) 
composed of phospholipids, and the viscous fluid in the periplasmic space250. OMVs 
form when the OM bulges away from the IM and pinches off forming spherical 
vesicles of between 20 to 250 nm in diameter which are surrounded by the OM and 
contain proteins from within the periplasm250. OMVs are a naturally secreted product 
from a wide variety of Gram negative bacteria which reportedly serve multiple 
purposes including the mediation of the exchange of DNA, protein and signalling 
molecules250-252.  
30 
 
Bexsero is a multi-component Meningococcal B vaccine produced by Novartis, 
which in 2013 achieved licensure for human use253. The vaccine consists of three 
recombinant Neisseria meningitidis serogroup B proteins, and an outer membrane 
vesicle (OMV) from the New Zealand NZ98/254 strain each adsorbed on aluminium 
hydroxide. This is the first vaccine licensed using a bacterium-like particle. Other N. 
meningitidis OMV based clinical trials conducted between 1987 and 2008 have 
reported a vaccine effectiveness of between 47 to 83%254-259. 
Various methods have been used to purify OMVs from bacterial cultures. The 
technique used for recent clinical trials254,255,259 involves sodium deoxycholate 
detergent extraction and differential centrifugation. Due to the small size of the 
OMVs other researchers have used a slow speed centrifugation to remove the bulk 
of parent bacteria followed by sequential 0.45 µm and 0.22 µm filtration then high 
speed centrifugation260,261 some using ammonium sulphate precipitation after 
filtration to enrich OMVs262,263.  
Predictably, there are a range of proteins in both the OM as well as the lumen, and 
because the vesicles form only from the periplasm250 it would be unexpected to find 
cytoplasmic proteins. Analysis of Bexsero showed that whilst 90% of the total 
protein amounts were OM proteins, 5% were periplasmic proteins and 5% were 
proteins from within the cytosol264. The unexpected high amounts of cytoplasmic 
proteins are likely an effect of the detergent extraction process, with OMVs 
harvested with filtration contained only two cytoplasmic proteins and the amount of 
OM proteins was increased265. Using a mutated N. meningitidis which constitutively 
produces higher amounts of OMVs with increased OM and reduced cytosolic 
proteins, the capacity of OMVs to induce protective efficacy across a wider panel of 
MenB strains was increased265.  
The small spherical nature of OMVs result in a high surface area to volume ratio 
which explains the high ratio of OM proteins in OMV proteomic analysis264. With 
limited periplasm or cytoplasm proteins, it would be difficult for OMVs to deliver high 
amounts of heterologous antigens unless they were concentrated in the OM. In an 
evaluation of foreign antigens delivered to the periplasm, GFP fused with the twin 
arginine transporter (Tat) signal sequence was expressed in E. coli resulting in the 
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isolation of GFP to the periplasm and detectable but very low quantities of GFP in 
the OMVs266. Predictably, antigens directed to the OM showed greater 
success266,267. Chen and colleagues267 fused GFP to the bacterial hemolysin ClyA 
which localised to the OM and was comprised 5% of the total protein content of 
OMVs. Following two immunisations with OMVs with an effective dose of 2.5 µg 
GFP, significant anti-GFP IgG responses were detected, however, these were 
similar to GFP adsorbed to aluminium hydroxide and the Cly-GFP purified protein 
administered with blank OMVs267. Whilst some have detected the presence of DNA 
encoding virulence genes in OMVs261 delivery of plasmids to the periplasm and low 
lumen volumes make this platform seem unlikely to succeed. 
1.6.3. Bacterial ghosts 
Bacterial ghosts (BGs) are produced following the expression of gene E from 
bacteriophage X174, which results in the formation of a transmembrane tunnel 
through the IM and OM of Gram negative bacteria (reviewed in 268,269). Due to 
osmotic pressure differences between the cytoplasm and the medium, the cytoplasm 
is forced out of the bacteria leaving an intact IM and OM structure270. The size of the 
BG is dependent on the bacteria from which it has been derived, with the larger size 
increasing their antigen load capacity as compared to the minicell or OMV platforms. 
The larger size of ghosts and the non-requirement of particle size isolation as per 
minicells and OMVs simplifies the purification process to require only 
centrifugation271. The large size of BGs may, however, be detrimental when 
delivering antigens targeted to DCs which preferentially take up much smaller 
particles196. 
In a recent review, Muhammad et al.269 presented an overview of BG vaccine trials 
for both human and veterinary medicine. Trials included those using the empty cell 
envelope as homologous immunogens, as well as proteins and plasmid DNA for 
heterologous pathogens. The majority of studies reported antigen-specific antibody 
response, some Th-1 type responses, and others with significant cellular immune 
responses269. The stimulation of the immune system is likely enhanced by the 
retention of LPS and PAMPs on the BGs.  
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Chemotherapeutic drugs have been loaded by a simple 5 min co-incubation with 
BGs, and shown to stay within the lumen and not adhere to the membranes272. 
Despite the transmembrane tunnel remaining after loading the drugs, approximately 
80% of the free drugs in the lumen, were retained following dialysis for 10 h and at 
least 50% retention was maintained after 5 days272. Importantly, there was efficient 
uptake of the BGs by Caco-2 cancer cells, and subsequent drug release had a 
potent anti-proliferation effect272. To prevent leakage of drugs from BGs, a system 
was devised which seals the tunnels using lipid vesicles with a biotin-streptavidin 
coupling method273. BGs were efficiently taken up by macrophages and cancer cells 
and the carried drugs were released within the cell273.  
Genetically fused protein anchor sequences to antigen proteins enables transformed 
bacteria to express vaccine targets which are transported to the IM or OM prior to 
controlled tunnel lysis274. These proteins are retained as part of the BG and are 
capable of inducing moderate antibody responses.  
Concentrated plasmid DNA can be loaded into BGs by co-incubation271,275,276, with 
the negatively charged DNA binding by electrostatic interactions with the positively 
charged moieties of the IM275 with up to 6000 plasmid copies per BG275. Efficient up-
take and protein expression was observed using a variety of BGs, by RAW 264.7 
murine macrophages275, murine BMDDCs271 and human monocyte-derived DCs276. 
This platform is still in early stages of development and its ability to induce robust 
antibody and cellular responses is yet to be established. The ability of BGs to result 
in the maturation of APCs also requires further attention. Whilst there are reports of 
increased inflammatory cytokines and IL-12 in porcine DCs and RAW264.7 cells277 
human monocyte-derived DCs showed no up-regulation of CD11c, CD40 or CD86 
receptors, and a down-regulation of CD80 and CD83 receptors despite high uptake 
and expression276. 
1.7. Thesis outline, aims and hypothesis 
My thesis was designed to comprehensively evaluate novel vaccine delivery 
platforms for their ability to induce antibody and cellular immune responses, as well 
as their ability to provide protection from P. yoelii 17XNL sporozoite challenge. The 
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platforms included chimeric VLPs and chimeric capsomeres to deliver defined 
foreign epitope immunogens, and bacterial minicells targeted to DCs which harbour 
recombinant protein and plasmid DNA.  
Aim 1: Evaluate the immunogenicity and protective efficacy of chimeric MuPyV 
VLPs with exposed PyCSP CD8+ T cell, CD4+ T cell and B cell epitopes.  
Hypothesis: VLPs presenting defined Plasmodium epitopes will be highly 
immunogenic stimulating B and T cell responses to levels sufficient to confer 
protection against parasite challenge. 
Project summary: The VLP platform of choice uses bacterial produced recombinant 
MuPyV VP1 structural protein with a P. yoelii CSP epitope genetically inserted into 
the S4 surface exposed loop with flanking G4S linker sequences. VLPs are inducible 
in vitro under physiochemical conditions to self-assemble into structures which 
resemble the native virus, retaining viral self-adjuvanting properties. This platform 
developed by the Middelberg group has been shown to induce robust antigen-
specific antibody responses173,188, but the platform has not been previously assessed 
for its ability to induce cellular responses. Chimeric VLPs were constructed to include 
PyCSP epitopes: CD8+280-288 T cell
73; CD8+59-67 T cell
75; CD4+281-296 T cell
72; CD4+57-70 
T cell74; CD4+59-79 T cell
71; or a dimer of the B cell central repeat (QGPGAP)2
63. 
Constructs which were efficiently produced by bacteria and formed VLPs were used 
in a series of immunisation experiments. Immunogenicity and protection was 
evaluated using individual or pooled constructs, pooled constructs with and without 
polyIC adjuvant, and used also in conjunction with PyCSP plasmid DNA in a 
heterologous prime-boost regimen. For protective efficacy analysis, mice immunised 
with VLPs or capsomeres were challenged with P. yoelii 17XNL sporozoites. 
Aim 2: Evaluate the immunogenicity and protective efficacy of chimeric MuPyV 
capsomeres with exposed PyCSP CD8+ T cell, CD4+ T cell and B cell epitopes.  
Hypothesis: Capsomeres presenting defined Plasmodium epitopes will be highly 
immunogenic stimulating B and T cell responses to levels sufficient to confer 
protection against parasite challenge. 
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Project summary: The same epitopes were inserted into the chimeric capsomere 
platform also developed by the Middelberg group but in this platform each epitope 
was inserted into three locations within the truncated MuPyV VP1 protein170. In a 
VLP comparative study, pooled capsomeres co-administered with polyIC were used 
to immunise mice in a homologous regimen, or with PyCSP plasmid DNA in a prime 
boost regimen. For protective efficacy analysis, mice immunised with VLPs or 
capsomeres were challenged with P. yoelii 17XNL sporozoites. 
Aim 3: Evaluate vaccine efficacy of E. coli minicells containing ovalbumin or PyAMA-
1 plasmid DNA and recombinant protein, and targeted to DCs using BsAbs against 
the minicell surface and DC receptors DEC205 or Clec9A.  
Hypothesis: Targeting DCs with bacterial minicells containing plasmid DNA and 
recombinant proteins will induce effective antigen-specific T cell and antibody 
responses and confer protection from parasite challenge. 
Project summary: The bacterial minicell platform was selected over the OMV and 
BG platforms because they are able to package cytoplasmic proteins and plasmid 
DNA, and minicells are smaller than BGs making them more open to DC uptake196. 
Only two studies have evaluated minicell potential as a vaccine platform to deliver 
both recombinant protein and plasmid DNA236,237. Those studies showed minicells 
could induce antibody236 and cellular237 immune responses, but the transfection 
efficacy in APCs was low (0.2-0.002%)236. Bacterial minicells have not previously 
been targeted to APCs as a vaccine delivery platform. In an effort to enhance DC 
uptake of minicells, my studies have coupled minicells to BsAbs to target DEC205 or 
Clec9a DC surface receptors. Minicell producing E. coli DS410 was transformed with 
plasmid DNA for both bacterial and mammalian expression of antigens including 
chicken ovalbumin or P. yoelii AMA-1. Bacterial cultures were induced to express the 
antigen and then minicells were purified using a novel purification process removing 
all viable parent bacteria, whilst retaining a high minicell yield. Minicells with or 
without BsAbs were used to immunise mice to assess their antigen-specific 
immunogenicity and protective efficacy using a P. yoelii 17XNL sporozoite challenge. 
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Chapter 2: Materials and Methods 
2.1. Bacteria 
Table 2: E. coli strains  
Strain Antibiotic 
resistance 
Use Source 
P678-54 Streptomycin Minicell producing 
222
 Dr Judya Praszkier 
(University of Melbourne) 
DS410 Streptomycin Minicell producing 
278
 Dr Miguel Vicente (Spanish 
National Biotechnology 
Centre)  
VIP205 Kanamycin Minicell producing
232
 Dr Miguel Vicente (Spanish 
National Biotechnology 
Centre) 
Top 10 Streptomycin Cloning Invitrogen, CA, USA 
DH5α Nil Cloning Invitrogen, CA, USA 
Omnimax 2T1 Nil Cloning  Invitrogen, CA, USA 
Rosetta (DE3) pLysS Chloramphenicol VP1 protein production Novagen, CA, USA 
2.2. Vectors 
Table 3: Expression and cloning vectors 
Name Expression Antibiotic 
selection 
Tag Comments and source 
pVR1020 Mammalian Kanamycin Nil Empty vector Vical Inc. 
pVR2516 Mammalian Kanamycin Nil PyCSP gene in pVR1020, Vical Inc.  
modVR1020 Mammalian Kanamycin Nil Empty vector pVR1020 with additional 
restriction sites in MCS, Vical Inc. 
With modifications by Dr. Don 
Gardiner 
pIASO Mammalian Chloramphenicol V5 Mod VR1020 modified to be 
chloramphenicol resistant and 
includes a V5 epitope (section 
4.2.9.1) 
pVRV5 Mammalian Kanamycin V5 ModVR1020 modified to include a V5 
epitope (section 4.2.9.2) 
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pBAD/Myc-
His A 
Bacterial Ampicillin c-Myc 
+ His 
Protein expression induced by 
addition of L-arabinose, Invitrogen 
pTrcHis2A Bacterial Ampicillin c-Myc 
+ His 
Protein expression induced by 
addition of IPTG, Invitrogen 
pDual GC Bacterial and 
mammalian 
Kanamycin c-myc 
+ His 
Dual expression vector, bacterial 
expression induced by IPTG, 
Stratagene, La Jolla, CA, USA 
pIVEX-
His/Ha 
Bacterial Ampicillin HA + 
His 
Empty vector pIVEX 2.4d modified to 
include an N-terminal HIS tag and C-
terminal HA tag 
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pGEM-T Cloning Ampicillin Nil Cloning vector, Promega Corporation, 
WI, USA 
2.3. Mice 
All mice were female, aged between 5 and 10 weeks and were purchased and/or 
maintained under specific pathogen-free conditions at the QIMR Berghofer animal 
facility. All studies were approved by the QIMR Animal Ethics Committee and were 
conducted in accordance with the Australian Code of Practice for the Care and Use 
of Animals for Scientific Purposes (2004). Mice were euthanised using either CO2 
asphyxiation or cervical dislocation. 
Table 4: Experimental mouse species and source  
Strain Strain features Source 
BALB/c H2K
d
 haplotype, inbred ARC 
C57BL/6 H2K
b
 haplotype, inbred, expresses b allele of the CD45 
molecule (CD45.2) 
ARC 
CS-TCR BALB/c background, H2K
d
 haplotype, transgenic for 
restricted T cell receptor specific for P. yoelii 
circumsporozoite protein 280-288 (SYVPSAEQI) 
Bred at QIMR 
Berghofer animal 
facility 
OT-I C57BL/6 background, H2K
b
 haplotype, transgenic for 
restricted T cell receptor (Vα2/Vβ5) specific for chicken 
ovalbumin 257-264 (SIINFEKL) 
Bred at QIMR 
Berghofer animal 
facility 
OT-II C57BL/6 background, H2K
b
 haplotype, transgenic for the 
mouse αβ-T cell receptor that pairs with the CD4 co-
receptor and is specific for chicken ovalbumin 323-339 
(ISQAVHAAHAEINEAGR) 
Bred at QIMR 
Berghofer animal 
facility 
B6.SJL-Ptprc
a
 
(PTP) 
C57BL/6 background, H2K
b
 haplotype, genetically 
modified inbred, expresses a allele of the CD45 molecule 
(CD45.1) 
ARC 
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2.4. Sporozoites 
Experimental challenges utilised Plasmodium yoelii 17XNL cryopreserved 
sporozoites obtained from Dr. Stephen Hoffman (Sanaria Inc., Rockville, MD, USA). 
Vials were thawed in a 37°C water bath then diluted to 5 x 103 sporozoites / ml in 
PBS with 2 % naive mouse serum and maintained at room temperature (RT) until 
administered in a 200 µl i.v. dose.  
2.5. Immunisations 
Intra-muscular injections (i.m.): mice were injected i.m. with 50 µg of plasmid DNA 
diluted to 50 µl in PBS into each tibialis anterior muscle using an insulin syringe with 
a 29 gauge needle (BD Biosciences) fitted with a plastic collar to limit needle 
penetration. 
Subcutaneous (s.c.) and Intraperitoneal injections (i.p.): Mice were injected with 
VLP‟s, capsomeres, peptides or recombinant proteins in adjuvant or minicells 
delivered s.c. at the base of the tail, or i.p. in a dose not exceeding 100 µl using an 
insulin syringe with a 27 gauge needle (Terumo, Somerset, NJ, USA) delivered as a 
single bolus. 
Intravenous injections (i.v.): Mice were pre-warmed under a heat lamp then 
injections given into lateral tail veins in a dose of 200 µl using an insulin syringe with 
a 27 gauge needle (Terumo, USA). 
Specific details of experimental immunisations are mentioned in the experimental 
design at the beginning of each research chapter. 
2.6. Molecular biology 
2.6.1. Competent bacteria 
Glycerol stocks of various E. coli strains were streaked onto LB agar plates with 
appropriate antibiotics and incubated overnight at 37°C. A single colony was 
selected and transferred into 10 ml tubes with 3 ml LB and appropriate antibiotics 
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then incubated overnight at 37°C and 225 RPM. A 100 ml culture was then 
inoculated with 100 µl of the starter culture and incubated at 37°C and 225 RPM until 
the OD600 was 0.5. Cultures were then cooled on ice for 10 min then centrifuged 
(3000 x g, 10 min, 4°C). The bacterial pellet was then resuspended in 100 ml of cold 
CaCl2 [0.1 M] and incubated on ice for 1 h. Bacteria were again centrifuged (3000 x 
g, 10 min, 4°C) then the pellet resuspended in 7 ml of cold CaCl2 [0.1 M] with 10% 
glycerol. Aliquots of 100 µl were transferred to 1.5 ml eppendorf tubes and snap 
frozen in an ethanol bath on dry ice and then stored at -70°C. Transformation 
efficiency was assessed by transforming bacteria with plasmid and incubating 
spread plates overnight. 
2.6.2. Target gene amplification 
2.6.2.1. PCR amplification of genes 
All gene amplification was done by polymerase chain reactions (PCR) using either 
Pfu turbo DNA polymerase (Agilent Technologies, CA, USA) or KOD Hot Start DNA 
polymerase (Novagen, CA, USA) each with proof-reading activity. PCR reagent 
concentrations and DNA polymerase, as well as reaction conditions including 
annealing and extension times and temperatures, were optimised for each gene. All 
PCR reactions were in 50 µl reaction volumes each with 0.2 mM dNTPs, 0.3 mM of 
forward and reverse primers, 1U of polymerase, between 5 to 50 ng of template DNA 
and either MgCl and MgSO4 with concentrations varied between 1.5 to 4.0 mM and 
1.5 to 2.5 mM respectively. 
A standard PCR protocol used a denaturation of 95°C for 2 min; 5 cycles of 95°C for 
20 s, 50°C for 20 s and 68°C for 1 min/kb of DNA; 30 cycles of 92°C for 20 s, 55°C 
for 15 s and 68°C for 1 min/kb of DNA; and a final extension at 68°C for 5 min. For 
non-Plasmodium genes, extension temperatures were increased to 72°C. 
Amplification was assessed visualising band intensity after agarose gel 
electrophoresis (section 2.6.3.1). 
PyCSP and PyAMA-1 genes were PCR amplified from the pVR2516 plasmid (Table 
3), or genomic DNA recovered from Plasmodium yoelii 17XNL sporozoites (section 
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2.4) respectively. Primers used for PCR amplification are detailed in (Appendix D) 
and protein sequences are listed in (Appendix E). 
The plasmids pBlueRIP/Ova and pBlueRIP/Tfr-ova were a gift from Professor 
Francis Carbone (University of Melbourne, Victoria, Australia). These plasmids 
include cDNA for chicken ovalbumin (OVA) and a fusion protein with a region from 
the human transferrin receptor and chicken ovalbumin280 (Tfr-Ova) respectively. 
These plasmids were used to PCR amplify both Ova and Tfr-Ova genes. Primers 
used for PCR amplification are detailed in (Appendix D). 
Plasmids containing a green fluorescent protein (GFP) and red fluorescent protein 
(RFP) were obtained from Dr. Don Gardiner (QIMR Berghofer, Herston, Qld, 
Australia). These were used to PCR amplify fluorescent genes. Primers used for 
PCR amplification are detailed in (Appendix D). 
2.6.3. Digestion, ligation and clonal selection 
2.6.3.1. Electrophoresis and gel extraction 
For electrophoresis, 0.8% agarose gels were made with either ethidium bromide or 
SYBR safe DNA gel stain (Invitrogen, CA, USA). Gels were run using a tris-borate 
buffer (TBE) (Appendix A) in a Mini-Sub cell GT tank (Bio-Rad Laboratories, CA, 
USA) with a Power-Pac 300 (Bio-Rad) power supply. Samples were pre-mixed with 
a New England Biolabs (NEB) gel loading dye (New England Biolabs Inc., MA, USA) 
then gels were run for 90 min with power set at 90 V and 400 mA. For size 
determination, a 1 Kb DNA ladder (NEB) was run in parallel. 
Agarose gels were viewed under UV light and where necessarily bands were 
excised. DNA was extracted from gel slices using a QIAquick gel extraction kit 
(Qiagen Pty Ltd, Hilden, Germany) according to the manufacturer‟s protocol with all 
elution steps done with water. 
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2.6.3.2. Restriction enzyme digestion 
All restriction enzymes were purchased from NEB (New England Biolabs Inc., MA, 
USA) and reaction reagent buffers and volumes were in accordance to the 
manufacturer‟s protocol. Reagents mixed in PCR tubes were incubated at either 
25°C (ApaI digestions only) or 37°C for between 1 h to 6 h depending on the 
efficiency of the enzyme. Products were separated by gel electrophoresis and 
appropriate size bands were excised and DNA extracted (section 2.6.3.1). 
2.6.3.3. Ligation 
All DNA ligations used T4 ligase (NEB) using recommended reaction conditions. 
Ligation reactions used 50 ng of vector in a vector:insert ratio of between 1:3 and 
1:50. The amount of insert was calculated using the following formula. 
                                       
                        
                      
Ligation reactions were incubated overnight at 16°C followed by heat inactivation 
using a 10 min incubation at 65°C.  
2.6.3.4. Transformations 
Tubes of competent bacteria were thawed on ice then 10 µl ligation mix or 
approximately 500 ng of purified plasmid was added, flicked to mix, then incubated 
on ice for 30 min. Tubes were then immersed in a 42°C water bath for 1 min then 
recovered on ice for 5 min. Then 800 µl of SOC media (Appendix A) was added to 
tubes which were then shaken in an incubator at 225 RPM and 37°C for 1 h. A 
spread plate was made using 100 µl of the mixture onto LB agar with appropriate 
selective antibiotics. Once the plate had dried, they were inverted and incubated at 
37°C overnight. 
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2.6.3.5. Colony PCR 
Following the overnight incubation of transformation plates, colony isolates were 
selected and mixed into 20 µl of sterile water in PCR tubes, and then 5 µl was 
removed and stored. The remaining 15 µl was heated to 94°C for 4 min then 
vortexed and centrifuged for 1 min to pellet bacteria, and then 5 µl of the supernatant 
was used as the PCR template.  
Each 20 µl PCR reaction comprised of 2 µl PCR buffer (10x), 1.2 µl MgCl2 [50 mM], 
0.4 µl dNTP [20 mM], 0.4 µl of forward and reverse primers [10 nM], 0.1 µl of 
platinum taq DNA polymerase (Invitrogen), 10.5 µl of water and 5 µl of PCR 
template. The PCR protocol was: 94°C for 3 min; then 30 cycles of 92°C for 15 s, 
45°C for 20 sec and 72°C for 1 min per kilobase of product; followed by 72°C for 5 
min. Electrophoresis was then conducted with the PCR product using 0.8% agarose 
gels with band size estimated using a 1 kb DNA ladder (NEB, MA, USA). Positive 
colonies were streaked onto transfer plates with appropriate selection antibiotics and 
incubated overnight at 37°C 
2.6.3.6. Plasmid purification and bacteria storage 
Bacterial colonies were selected from transfer plates and incubated overnight in a 50 
ml falcon tube with 7 ml LB with appropriate selection antibiotics. For colony storage, 
300 µl of the culture was combined with 300 µl of sterile glycerol which was vortexed 
and frozen in ethanol and dry ice then stored at -70°C. The remaining culture was 
used for plasmid extraction using a Qiagen miniprep kit (Qiagen Pty Ltd, Germany) 
following the manufacturer‟s protocol. Plasmid elution was done using 50 µl of water 
and quantified on a nanodrop 2000 (Thermo Fisher Scientific, MA, USA). 
2.6.3.7. Sequencing 
Sequencing was done using the BigDye Terminator v3.1 (Invitrogen) using ¼ 
reactions following the manufacturer‟s protocol. Analysis was conducted by QIMR 
Berghofer core facilities. Sequence confirmation was checked using either the 
National Centre for Biotechnology Information (NCBI) nucleotide Basic Local 
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Alignment Search Tool (Blastn) or Vector NTI (Invitrogen) sequence alignment 
software. 
All sequencing for the VLP and capsomere platforms (section 3.2.1) was done by the 
Australian Genome Research Facility (AGRF, Brisbane, Australia). 
2.7. Molecular biology for minicell platform 
2.7.1. Vector construction pIASO and pVRV5 
The pIASO vector was constructed from modVR1020 (Table 3) by replacing the 
kanamycin resistance gene with the chloramphenicol resistance gene, and inserting 
a V5 epitope tag at the C-terminal region of the multiple cloning site.  
The pVRV5 vector was also constructed from modVR1020 by inserting a V5 epitope 
tag at the C-terminal region of the multiple cloning site.  
Details of each vector construction are provided in (section 4.2.9). 
2.8. SDS-PAGE and Western Blot 
Proteins were analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) coupled with either coomassie blue staining or western 
blot. Samples were diluted in a mix of lysis buffer (Appendix A) load dye and NuPage 
reducing agent (Novex, CA, USA) to a maximum volume of 15 µl in 1.5 ml Eppendorf 
tubes. Tubes were heated at 95°C for 12 min, vortexed and allowed to cool, then 
spun momentarily. Samples were loaded onto self poured 10% acrylamide/bis-
acrylamide (Biorad, CA, USA) SDS-PAGE gels and run at 150 V for 60 min in 
running buffer (Appendix A). Each gel contained a lane with a Novex Sharp pre-
stained protein standard (Novex, USA). To determine protein quantity, a protein with 
a known concentration was run on the gel in a serial dilution. 
For western blot analysis, an Immobilon membrane (Millipore, MA, USA) was pre-
wet with methanol, then equilibrated in transfer buffer (Appendix A), and then 
sandwiched beside the SDS-PAGE gel. Transfer was done in a mini trans-blot cell 
(Biorad, CA, USA) transfer tank at 100 V for 2 h in transfer buffer. The membrane 
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was then blocked overnight at 4°C in Odyssey blocking buffer (Li-cor, Nebraska, 
USA), washed and stained using α-His peroxidase antibodies (Roche Diagnostics, 
Germany) diluted to 1:5000 in PBS + 0.1% Tween20. Following 2 h at RT on a 
rocker, the membrane was washed and developed using Amersham ECL Prime 
western blot detection reagent (GE Healthcare, UK) then imaged on an ImageQuant 
LAS 5000 (GE healthcare Biosciences, Uppsala, Sweden).  
When gels were analysed using the Li-cor Odyssey Classic (Li-cor, USA), after the 
overnight blocking, membranes were stained with rabbit α-c-Myc epitope (Thermo 
Pierce, IL, USA) diluted to 1:2500 and incubated for 1 h at RT, then donkey α-rabbit 
IR dye 800 (Li-cor, USA) diluted 1:15000 and incubated for 1h at RT, both dilutions 
were done in blocking buffer + 0.1% Tween20. The membrane was then washed in 
PBS + 0.1% Tween20 and rinsed with PBS then milliQ water before being imaged. 
2.9. Experimental cell preparation and restimulation 
2.9.1. Harvesting lymphocytes 
Single cell suspensions were made by physical disruption of spleen or lymph nodes 
passing them through a 100 µm nylon mesh (Biologix Plastics Co.Ltd, Jiangsu, 
China) with 5 ml Dulbecco‟s media with 2% FCS (Dulbecco‟s 2%)(Appendix A). Cells 
were centrifuged (600 x g, 4 min, 4°C) and supernatant removed. Removal of red 
blood cells (RBCs) was achieved by either buffer disruption or density gradient cell 
centrifugation.  
In the buffer disruption method, cells were incubated for 5 min at 37°C in 5 ml of pre-
warmed red cell removal buffer (Appendix A) then washed in Dulbecco‟s 2% and 
resuspended in KD-MEM with 10% FCS (Appendix A). Alternatively, single cell 
suspensions in 10 ml of Dulbecco‟s 2% were under laid with 5 ml of Ficoll-Paque 
Plus (GE Healthcare Biosciences, Uppsala, Sweden) and centrifuged (800 x g, 10 
min, 4°C) with a slow brake. Lymphocytes were harvested from the interface and 
washed in Dulbecco‟s 2% then resuspended in KD-MEM with 10% FCS. All wash 
steps used the same centrifuge conditions (600 x g, 4 min, 4°C). 
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Cells were counted microscopically using trypan blue (HyClone Laboratories Inc., 
UT, USA) staining and a haemocytometer then diluted as required prior to 
distribution for assays. 
2.9.2. CD8+ and CD4+ T cell purification and CFSE labelling 
Single cell suspensions were prepared (section 2.9.1) from both spleens and lymph 
nodes from naive OTI, OTII or CS-TCR mice (Table 4). CD8+ and CD4+ T cells were 
enriched by positive selection using mouse CD8a (Ly-2) or CD4 (L3T4) microbeads 
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the 
manufacturer‟s protocol using a magnetic column. 
For in vitro proliferation assays, cells were then washed in Dulbecco‟s with 0.1% 
FCS then resuspended at 107 cells/ml in pre-warmed (37°C) Dulbecco‟s 0.1% with 5 
µM carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, 
Victoria, Australia). The cells were incubated at 37°C for 10 min then washed three 
times in Dulbecco‟s 2% and then resuspended in KD-MEM with 10% FCS. 
Selective cell purification and CFSE staining was assessed by flow cytometry. Cells 
were surface stained for CD8 or CD4 markers as well as Vα2 (OTI and OTII cells) or 
Thy1.1 (CS-TCR) markers (Appendix C) with analysis performed on a BD 
LSRFortessa (BD Biosciences, CA, USA).  
2.9.3. Restimulation for cellular immunogenicity assays 
2.9.3.1. A20 cell line 
The A20 cell line (mouse B cell lymphoma, ATCC # TIB208) was used for antigen 
presentation during in vitro immunogenicity assays. This suspension cell was 
cultured in KD-MEM media with 5% FCS (Appendix A) at 37°C and 5% CO2. 
Following peptide stimulation or transfection (below) cells were irradiated with 
approximately 16666 cGy in a Cs 137 irradiator. 
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2.9.3.2. Positive controls 
For ELISpot and cytometric bead arrays (sections 2.10.1.8 and 2.10.1.9) positive 
control wells concanavalin A (ConA; Sigma Aldrich, NSW, Australia) was added 
post-irradiation at 5 µg/ml of total well volume. For intracellular cytokine staining 
(section 2.10.1.10) cells were incubated with phobol 12-myristate 13-acetate (PMA) 
and ionomycin (both from Sigma Aldrich) at 5 ng/ml and 500 ng/ml respectively of 
total well volume. This stimulant was added post-irradiation and at the same time 
that GolgiPlug (BD Biosciences, CA, USA) was added giving a total of 6 h 
stimulation.  
2.9.3.3. Peptide stimulation 
All peptides were synthesised by Mimotopes Pty Ltd (Victoria, Australia) and 
resuspended in 100% dimethyl sulfoxide (DMSO; Sigma Aldrich, MO, USA) and 
stored at -70°C. Prior to irradiation, A20 cells were pulsed with either PyCSP CD8280-
288 (SYVPSAEQI) or CD459-79 (YNRNIVNRLLGDALNGKPEEK) individual peptides or 
pooled PyCSP CD8280-288, CD459-79 and B cell (QGPGAPQGPGAP) peptides. Each 
peptide was added so that the final post-distribution well concentration was 10 µg/ml.  
2.9.3.4. Transfections 
A20 cells were maintained in culture between 1-2 x 106 cells/ml prior to transfections. 
Transfections were done using an AMAXA Nucleofactor system kit V (Lonza Group, 
Basel, Switzerland) following the manufacturer‟s protocol. Each reaction used 5 x 
106 A20 cells and 5 µg of pVR2516 (PyCSP) or pVR1020 (transfection control) both 
from Vical Inc., using Program L-13 or C-25 on an AMAXA Nucleofector I device 
(Lonza Group). 
2.9.3.5. Culture conditions 
All cell cultures were done in humidified incubations at 37°C and 5% CO2. 
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2.10. Immunology assays 
2.10.1. Cellular assays 
2.10.1.1. Dendritic cell migration to draining lymph nodes following 
minicell injections  
To assess the migration profile of dendritic cells (MHCIIhigh CD11chigh), C57BL/6 mice 
(n=1/condition) received s.c. injections of either 1010 ovalbumin loaded minicells with 
and without BsAbs to target DEC205 (section 4.2.12), empty minicells or ovalbumin 
protein (100 µg) with cholera toxin (CT; 1 µg). Injections were given at 6 h intervals 
from 48 to 24 h before draining lymph nodes were harvested. Single cell suspension 
from DLNs of each mouse were transferred into 96-well V-bottom plates and 
centrifuged (600 x g, 4 min, 4°C) then resuspended in 2.4G hybridoma supernatant 
(to block Fc receptors) for 10 min. Cells were washed and stained for MHCII and 
CD11c cell surface markers (Appendix C) for 20 min, then washed and resuspended 
in MACS buffer with propidium iodide (Pi). Cells were analysed on an LSR Fortessa 
(BD Biosciences, NSW, Australia). Post-acquisition analysis was done using FlowJo 
software version 9.4 (Treestar, Ashland, OR, USA) to determine the frequency of 
MHCII and CD11c high cells.  
2.10.1.2. Ovalbumin minicell induced proliferation of OTI and OTII cells 
by migrating dendritic cells 
C57BL/6 mice (n=5/group) received s.c. injections of ovalbumin loaded or empty 
minicells (1010 minicells/dose) with and without BsAbs to target DEC205 or a non-
specific receptor LTF2 (section 4.2.12). Control groups received either PBS or 
ovalbumin (100 µg) both with 1 µg of CT. Draining lymph nodes were harvested after 
24 h, pooled within groups and made into single cell suspensions (section 2.9.1). Fc 
receptors were blocked for 10 min in 2.4G hybridoma supernatant, and then stained 
with antibodies against MHCII, CD11c and CD103 (Appendix C) for 20 min on ice. 
Cells were then washed and resuspended in MACS buffer with Pi then sorted on a 
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FACSAria (BD Biosciences, USA) into dual MHCIIhigh and CD11chigh populations, 
with these cells further sorted into CD103high or CD103low populations. 
The sorted cells were then washed and resuspended in KD-MEM media (Appendix 
A) with 10% FCS then transferred into 96-well U-bottom plates at 104 cells per well in 
triplicates. Wells then received 5 x 104 of either OTI or OTII purified and CFSE 
stained cells (section 2.9.2). Cells were incubated at 37°C and 5% CO2 for 3 d then 
transferred to a 96-well V-bottom plate and centrifuged (600 x g, 4 min, 4°C). Cells 
were resuspended in 2.4G hybridoma supernatant to block Fc receptors for 10 min, 
and then washed and stained for Vα2, CD8 and CD4 cell markers (Appendix C). 
Cells were washed and resuspended in MACS buffer with Pi then analysed on an 
LSR Fortessa (BD Biosciences). Post-acquisition analysis was done using FlowJo 
software version 9.4 (Treestar, USA) to determine the median fluorescence intensity 
(MFI) of CFSE in both OTI and OTII cells. 
In a separate experiment, C57BL/6 mice (n=1/condition) were injected s.c. in the 
flank with ovalbumin packaged minicells (1010) with and without BsAbs to DEC205, 
empty minicells (1010), PBS or ovalbumin protein (100 µg) with CT (1 µg). Injections 
were given at 6 h intervals from 48 to 24 h before draining lymph nodes were 
harvested and single cell suspensions made in KD-MEM with 10% FCS (section 
2.9.1). These cells were then irradiated for 30 min, and then 5 x 105 cells were 
transferred into 96-well U-bottomed plates. Each well then received 5 x 104 of either 
OTI or OTII purified and CFSE stained cells (section 2.9.2) and cultures incubated 
for 3 to 5 days. After incubation, cells were washed, stained and analysed as 
described above. Cells were analysed on an LSR Fortessa (BD Biosciences) with 
CFSE detected with the 530/30 detector on the 488 nm laser. Post-acquisition 
analysis was done using FlowJo software version 9.4 (Treestar, USA) to determine 
the MFI of CFSE in both OTI and OTII cells. 
2.10.1.3. In vitro stimulation of CS-TCR transgenic cells 
Purified and CFSE stained CS-TCR CD8+ T cells (section 2.9.2) resuspended at 1 x 
106 cells/ml in KD-MEM + 10% FCS were distributed adding 100 µl/well into 96-well 
U-bottom plates. Cells were then combined with 5 x 106 lymphocytes isolated 
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(section 2.9.1) from five naive BALB/c mice. Each well then received either 
PyCSP280-288 peptide, CD8 VLPs, CD8 capsomeres, wild type VLPs or wild-type 
capsomeres all at a final concentration of 10 µg/ml. Cells were cultured at 37°C and 
5% CO2 and analysed after 2, 3, 4 and 5 days by flow cytometry.  
Cells were transferred to 96-well V-bottom plates and centrifuged (600 x g, 4 min, 
4°C) then resuspended in 20 µl of 2.4G hybridoma supernatant for 10 min to block 
Fc receptors. Cells were washed and stained for Thy1.1 and CD8 cell surface 
markers (Appendix C) for 20 min, then washed and resuspended in MACS buffer 
with Pi. Cells were analysed on an LSR Fortessa (BD Biosciences) with CFSE 
detected with the 530/30 detector on the 488 nm laser. The median CFSE 
fluorescence intensity of Thy1.1+ CD8+ T cells was calculated using FlowJo software 
version 9.4 (Treestar, USA). 
2.10.1.4. Adoptive transfer proliferation 
CD8+ and CD4+ T cells were purified from OTI and OTII mice respectively using 
previously described methods (section 2.9.2). Cells were adoptively transferred by 
i.v. injection (section 2.5) into PTP mice (Table 4). After each immunisation, blood 
was analysed to determine the frequency of transferred cells. Ten microlitres of 
blood was centrifuged (600 x g, 4 min, 4°C) then resuspended in antibodies directed 
against CD45.2, Vα2, CD8 and CD4 receptors (Appendix C) with an incubation at 
4°C for 20 min. Cells were washed then resuspended immediately in FCAB fix/lyse 
buffer (Appendix A) and incubated at 37°C for 10 min. Cells were washed and 
resuspended in MACS buffer then analysed on an LSR Fortessa (BD Biosciences).  
Following the final immunisation mice received a further i.v. cell transfer for CTL 
assay (section 2.10.1.5) then were sacrificed after 16 h. Single cell suspensions of 
spleen and draining lymph nodes (section 2.9.1) were obtained using the red cell 
removal buffer protocol, and blood was also collected. Cells were stained (as above) 
however, the spleen and lymph node samples were not lysed, and were instead 
resuspended in MACS buffer with Pi for analysis. 
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For all samples, post-acquisition analysis was done using FlowJo software version 
9.4 (Treestar, USA). The frequency of double positive CD45.2 and CD8 or CD4 cells 
as to the lymphocyte population gated on FSC and SSC plots was calculated. 
2.10.1.5. In vivo cytolytic assay 
Single cell suspensions were made using spleen and lymph nodes from naive PTP 
mice (Table 4) and lymphocytes purified using a ficol density centrifugation (section 
2.9.1). The cells were incubated with or without ovalbumin257-264 (SIINFEKL) peptide 
at 10 µg/ml for 1 h at 37°C, then washed in Dulbecco‟s + 0.1% FCS. SIINFEKL 
coated and uncoated cells were then stained with 2.5 µM and 0.5 µM BD Horizon 
violet cell proliferation dye 450 (VPD450; BD Biosciences, USA) respectively at 37°C 
for 10 min with frequent mixing. Cells were washed three times in Dulbecco‟s + 2% 
FCS then resuspended in PBS. Differential staining was confirmed by flow 
cytometry. Cells were counted and combined in a 1:1 ratio. 
Following the final immunisation in the ovalbumin model experiments mice received 
an i.v. transfer of 9 x 106 of the combined VPD450 stained cells. Sixteen hours later 
mice were euthanised and single cell suspensions of spleen and draining lymph 
nodes (section 2.9.1) were obtained using the red cell removal buffer protocol, and 
blood was also collected. Cells were stained with antibodies against CD45.1 (PTP 
mice) and CD45.2 (OTI and OTII mice) receptors (Appendix C) with an incubation at 
4°C for 20 min. Blood samples were resuspended in FCAB fix/lyse buffer (Appendix 
A) and incubated at 37°C for 10 min, then washed and resuspended in MACS buffer. 
Spleen and lymph node samples were resuspended in MACS with Pi. All samples 
were analysed on an LSR Fortessa (BD Biosciences, Australia) with post-acquisition 
analysis using FlowJo software version 7.6 (Treestar, USA).  
In the spleen and lymph node samples, viable lymphocytes were gated on forward 
and side scatter then Pi. Blood samples which had been fixed, were gated only on 
forward and side scatter parameters. Then CD45.1 cells were gated and VPD450 
high and low populations were quantified. The specific lysis was calculated using the 
following formula- 
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2.10.1.6. WBC staining for activation markers 
In the PyAMA-1 minicell experiment, following their final immunisation mice were 
challenged 1000 P. yoelii 17XNL sporozoites. Blood samples were collected pre-
challenge then daily from days 2 to 10 and then every second or third day until day 
22 post-challenge. Samples were obtained by a tail snip with 12 µl of blood collected 
and diluted in 12 µl of FCAB buffer containing double the amount of EDTA [4 mM] (to 
prevent clotting) in a 96-well V-bottom plate. Approximately 1.7 µl of blood was used 
for the analysis of white blood cells (WBCs). Cells were resuspended in a pool of 
antibodies against CD4, CD8, CD11a, CD19, CD49d, CD69, CD86, PD-L1 (CD274), 
PD-1(CD279) and Gr-1 (Ly-6G/C) (Appendix C) and incubated at 4°C for 20 min. 
Cells were washed and resuspended in FCAB fix/lyse buffer (Appendix A) and 
incubated at 37°C for 10 min, then washed and resuspended in MACS buffer. 
Pooled samples from each immunisation group were stained with isotype controls. 
All samples were analysed on an LSR Fortessa (BD Biosciences, Australia) with 
post-acquisition analysis using FlowJo software version 9.4 (Treestar, USA).  
The medium florescence intensity (MFI) of activation markers, and cell counts were 
compared during the time-course of infection. Comparisons were made between 
groups and within groups where groups contained protected mice. 
2.10.1.7. Assessment of serum cytokines 
In the PyAMA-1 minicell experiment, blood was collected immediately before 
challenge and daily from day 2 to day 10. Here 12 µl of blood collected from the tail 
tip was diluted in 12 µl of FCAB buffer containing double the amount of EDTA [4 mM] 
in a 96-well V-bottom plate. The plate was centrifuged (600 x g, 4 min, RT), then 6 µl 
of supernatant was transferred to a new V-bottomed plate and snap frozen (-80°C) 
for later analysis. A pool of supernatant each group was also collected (6 µl total 
volume) and similarly stored for analysis. 
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Samples were processed according to the manufacturer‟s protocol using the 
cytometric bead array (CBA) kit with selected mouse cytokines using flex sets (BD 
Biosciences). For pooled samples, bead and detector flex sets for interleukins IL-1b, 
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70 and IL-13, as well as IFN- and TNF. Individual 
samples were analysed only for IL-6, IFN- and TNF cytokines with samples taken 
from days 7 and 8 post-challenge. Analysis was performed on an LSR Fortessa (BD 
Biosciences, NSW, Australia) using a high-throughput sampler (HTS). Post-
acquisition data analysis was performed using FCAP Array 3.0 software (Soft Flow 
Inc., Pecs, Hungary). 
2.10.1.8. IFN-γ ELISpot 
Following the final immunisation in the VLP and capsomere experiments, 
splenocytes were harvested as previously described (section 2.9.1) using red cell 
removal buffer, and then cells were counted. MSIPS4510 multiscreen ELISpot plates 
(Merck Millipore, Darmstadt, Germany) were pre-coated overnight at RT with 100 µl 
of sterile PBS containing 100 µg/ml anti-mouse IFN- (BD Biosciences, San Jose, 
CA, USA). Wells were then blocked with KD-MEM + 10% FCS for 3 h at 37°C, 
before adding combined splenocyte (5 x 105)/A20 (1.5 x 105) treated cultures 
(section 2.9.3) in quadruplicates. Treatments included transfected A20 cells, 
peptides individually or pooled, or A20 cells with ConA or without stimuli. 
Plates were incubated at 37°C and 5% CO2 for 40 h then washed with PBS with 
0.05% Tween20 (PBST). Then 75 µl of PBS containing 0.5% BSA (PBS-BSA) and 2 
µg/ml biotinylated anti-mouse IFN- (BD Biosciences, USA) was added to each well 
and incubated at 37°C for 3 h before being washed in PBST. Then 75 µl of PBS-BSA 
with 1 µg/ml streptavidin-horseradish peroxidase (BD Biosciences, USA) was added 
to each well and incubated for 1 h at RT, before being washed with PBST and finally 
PBS. Plates were developed using 50 µl/well of AEC substrate (BD Biosciences, 
USA) for 5 min before being flooded with water and dried. Spots were counted using 
the AID ELISpot reader system (Autoimmun Diagnostika GmbH, Strassberg, 
Germany). For analysis, background responses detected in A20 only wells were 
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subtracted from spots detected in A20 plus peptide wells. Likewise, pVR1020 
transfected A20 spots were subtracted from pVR2516 stimulated wells. 
2.10.1.9. Cytometric bead array 
Following the final immunisation in the VLP and capsomere experiments, 
splenocytes were harvested as previously described (section 2.9.1). Using 96-well 
round-bottom plates, 5 x 105 splenocytes and 1.5 x 105 irradiated A20 cells were 
combined and mixed with PyCSP peptides alone or pooled or with A20 cells with 
conA or without stimuli as described above (section 2.9.3). Cultures were incubated 
at 37°C and 5% CO2 for 72 h, and then culture supernatant was collected and stored 
at -70°C for subsequent analysis. Pooled supernatant was analysed for interleukins 
IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70 and IL-13, as well as IFN- and TNF 
using the mouse cytometric bead array flex kit (BD Biosciences, USA) following the 
manufacturer‟s protocol. Individual samples were analysed only for selected 
cytokines which was determined after running pooled samples. Samples were 
analysed using a FACSArray instrument (BD Biosciences, USA) and analysed using 
the FCAP array software (BD Biosciences, USA). 
2.10.1.10. Intracellular cytokine staining 
Following the final immunisation in the VLP and capsomere experiments, 
splenocytes were harvested as previously described (section 2.9.1). Using 96-well 
U-bottom plates, 5 x 105 splenocytes and 1.5 x 105 irradiated A20 cells were 
combined and mixed with PyCSP peptides alone or pooled or with A20 cells with 
PMA/Ionomycin or without stimuli as described above (section 2.9.3). GolgiPlug (BD 
Biosciences, CA, USA) was added to each well to 0.1%, then cultures were 
incubated for 4 h at 37°C and 5% CO2. Cells were then centrifuged (600 x g, 4 min) 
then washed in MACS buffer. CD8 and CD4 surface-markers were stained with 
fluorochrome-conjugated antibodies (Appendix C) for 30 min at 4°C. Cells were 
washed in MACS buffer then fixed with 1% paraformaldehyde for 15 min at RT, then 
washed and stained for intracellular cytokines IFN-, IL-2 and TNF with antibodies 
(Appendix C) diluted in Cytofix/Cytoperm (BD Biosciences) and incubated overnight 
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at 4°C. The cells were then washed and resuspended in MACS buffer, and then flow 
cytometric analysis was performed on a Fortessa LSR flow cytometer (BD 
Biosciences, CA, USA). Post-acquisition data analysis was performed using FlowJo 
software version 9.4 (Treestar, Ashland, OR, USA). Pooled samples from each 
immunisation group, under each restimulation condition, were stained with antibody 
isotype controls and analysed as described above. 
2.10.2. Antibody assays 
2.10.2.1. ELISA 
Various capture antigens were used in different experiments each specific for the 
antigen immunisation component. For the VLP experiments the capture antigen was 
either 5 µg/ml of PyCSP B cell repeat epitope peptide (QGPGAPx3) with an 
incorporated polystyrene binding tag with glycine linker (RIIIRRIRGGGG)281,282 
(Mimotopes, Vic, Australia) or 1 µg/ml of PyCSP protein (Naval Medical Research 
Center, US Navy, MD, USA). Ovalbumin minicell experiments use chicken 
ovalbumin protein (Sigma-Aldrich) diluted to 5 µg/ml. PyAMA-1 minicell experiments 
used PyAMA-1 purified protein diluted to 1.5 µg/ml, which had been generated using 
RTS reactions and purified using Talon beads (section 4.2.6).  
Nunc maxisorp 96-well flat bottom plates (Thermo Fisher Scientific, MA, USA) were 
coated with 100 µl of capture antigen diluted in a carbonate buffer (Appendix A), and 
incubated overnight at 4°C. Plates were washed twice with PBS then blocked with 
230 µl of PBS with either 2% bovine serum antigen (BSA, Sigma Aldrich, MO, USA) 
or 5% skim milk powder (SMP) at 37°C for 2 h. Plates were washed twice with PBS 
then 100 µl of sera diluted in PBS with 0.1% BSA or SMP was added to triplicate 
wells. When assessing end-point antibody titres, the serum was then diluted 2-fold 
down the plate. In some cases sera was added at a fixed dilution only. Plates were 
incubated at 37°C for 2 h then washed three times in PBS with 0.02% tween20 
(PBST). For IgG responses, plates were then incubated in biotinylated donkey α-
mouse IgG (Jackson ImmunoResearch Laboratories Inc. PA, USA) diluted 1:20000 
in PBS-BSA or SMP 0.1% at 37°C for 1 h, washed , then further incubated in 
streptavidin-HRP (BD Biosciences, USA) diluted 1:1000 in PBS-BSA or SMP 0.1% 
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and 0.2% tween20 at 37°C for 1 h. For IgG isotype responses, plates were incubated 
in HRP conjugated goat α-mouse IgG1, rabbit α-mouse IgG2a, goat α-mouse IgG2b, 
or goat α-mouse IgG3 (Invitrogen, CA, USA) all diluted 1:3000 in PBS-BSA or SMP 
(0.1%) and tween20 (0.2%) and incubated at 37°C for 1 h. Plates were washed 5 
times in PBST (0.05%) then twice in PBS. Plates were developed by adding 50 
µl/well of tetramethylbenzidine liquid substrate (TMB T4444, Sigma Aldrich, MO, 
USA) and left for 10 min at RT in the dark before stopping the reaction with 50 µl/well 
of TMB stop reagent (S5814, Sigma Aldrich, USA). Plates were then read on a 
VersaMax micro plate reader (Molecular Devices, CA, USA) at 450 nm.  
For analysis, the OD450 mean plus three standard deviations of triplicate blank wells 
(no sera) was subtracted from the OD450 of each well, and then the mean of sample 
triplicates were determined. Samples were deemed antibody positive when post-
subtraction values were positive. When a single sera dilution was used, blank-
subtracted OD450 triplicate means were reported. When reporting antibody titrations 
equal to 1, a logarithmic equal based on four serial dilutions was determined using 
Microsoft Office Excel 2007 (Microsoft Corporation, WA, USA), which was used to 
calculate the titre where at OD450=1.0. 
2.10.2.2. Flow cytometry based IFAT 
Anti-parasite antibody levels prior to, and during the course of infection were 
assessed using a flow cytometric procedure as previously described283. Briefly, blood 
samples collected for the serum cytokine (section 2.10.1.7) or FCAB (section 
2.10.3.1) assays were centrifuged (600 x g, 4 min) then supernatant was removed 
either 6 µl or 1 µl respectively. The 1 µl samples were diluted in 167 µl of FCAB 
buffer then 6 µl was added to 6 µl of P. yoelii 17XNL blood-stage parasite extract in a 
96-well V-bottom plate and incubated for 30 min at RT. Samples were washed and 
resuspended in anti-mouse IgG-FITC (Biolegend, USA) for 30 min at 4°C. Samples 
were washed and resuspended in 35 µl of FCAB buffer (Appendix A), then analysed 
on an LSR Fortessa (BD Biosciences, NSW, Australia) using a high-throughput 
sampler (HTS). Post-acquisition data analysis was performed with FlowJo software 
version 9.4 (Treestar Inc., Ashland, OR, USA). The parasite extract was gated on 
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forward and side scatter then the median fluorescence intensity of FITC was 
determined and reported for individual mice. 
2.10.2.3. IFAT slides 
Antibody affinity to the surface of P. yoelii 17NXL sporozoites was assessed using a 
previously described protocol284 with some modifications. Sporozoites were 
centrifuged (10000 x g, 5 min) then resuspended to 103 sporozoites per 10 µl of 
Medium 199 (Life Technologies, NY, USA). Then 10 µl was added to pre-drawn 
(Barrier Pap pen) wells on a microscope slide and air dried at RT before being stored 
at -70°C. Prior to use, slides were returned to RT in a desiccation cabinet. Pooled 
sera from each immunisation group, collected 7 days after the final immunisation, 
was diluted 1:400 in filtered PBS with 2% BSA, then 10 µl was added to each well 
and incubated at 37°C in a humid box. Wells were gently washed with PBS then 
stained with 10 µl of FITC conjugated anti-mouse IgG (BD Biosciences, USA), 
diluted 1:30 in filtered PBS containing 0.005% Evans blue. Slides were incubated for 
30 min in a humid chamber then washed gently with PBS. A cover slide was 
mounted over PBS with 10% glycerol and slides viewed on an EVOS fluorescence 
microscope (x400) (Advanced Microscopy Group, Washington, USA). Samples were 
treated as positive when fluorescence was detected on the sporozoite surface. 
2.10.3. Protection efficacy assays 
2.10.3.1. Flow cytometry assessment of blood (FCAB) 
Parasitemia quantification was done using a flow cytometric assessment of blood 
(FCAB) assay as previously described285. Blood samples were collected immediately 
before challenge then daily from day 2 to day 10, and then every 2nd or 3rd day until 
the infection was resolved. Briefly, 2 µl of blood was collected from the tail tip of mice 
and immediately diluted into 200 µl of FCAB buffer (Appendix A). Six microlitres of 
diluted blood was transferred into a 96-well V-bottomed plate and stained with 15 µl 
of anti-CD71-PE (Biolegend, San Diego, USA). Cells were washed and resuspended 
in 30 µl of FCAB fixation and lysis buffer (Appendix A) and incubated for 10 min at 
37°C. The cells were then washed and resuspended in FCAB buffer containing 
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bisbenzimide Hoechst 33342 (Sigma-Aldrich, USA) at 0.5 µg/ml and incubated for 20 
min at 4°C. Flow cytometric analysis was performed on an LSR Fortessa (BD 
Biosciences, NSW, Australia) using a high-throughput sampler (HTS). Post-
acquisition data analysis was performed with FlowJo software version 9.4 (Treestar 
Inc., Ashland, OR, USA). The gating strategy as previously described285 removed 
lymphocytes and platelets, with parasitised RBCs quantified by nucleic acid content 
stained with hoechst. A naive/non-infected control group was included in the analysis 
with detected background responses subtracted from infection groups. The area 
under the curve (AUC) of blood-stage parasitemia over time was calculated using 
GraphPad Prism software version 6.0 (Graph-Pad, CA, USA).  
2.10.3.2. Quantitative reverse transcription PCR 
Parasite burden in livers of challenged mice was assessed by qRT-PCR as 
previously described286,287 with some modifications. Livers were harvested from mice 
42 h post challenge and homogenised in 5 ml of RLT lysis buffer (Qiagen Pty Ltd, 
Vic, Australia) with 1% β-2-mercaptoethanol (Sigma-Aldrich) using a TissueRuptor 
hand-held homogeniser (Qiagen, Hilden, Germany) with disposable tips. Using a 
medium speed setting to avoid frothing, livers were homogenised for 1 min. A 200 µl 
sample was then used for RNA extraction using an RNeasy mini kit (Qiagen) 
following the manufacturer‟s protocol. RNA was eluted in 60 µl of water then 
quantified using a Nanodrop Spectrophotometer (Thermo Fischer Scientific). Using 
2.5 µg of RNA per reaction, cDNA was synthesised using a SuperScript VILO cDNA 
synthesis kit (Invitrogen) in 10 µl reaction volumes following the manufacturer‟s 
protocol. Reactions were incubated for 10 min at RT, then for 2 h at 37°C, and then 
the reactions were terminated by heating to 85°C for 5 min.  
The cDNA was then diluted to 50 µl in water and used as a template for qRT-PCR 
reactions. For Py18S cDNA quantification, a Taqman Fast Advanced master mix 
(Applied Biosystems, Australia) with a custom made Taqman probe [250 nm] (6FAM-
CTGGCCCTTTGAGAGCCCACTGATT-BHQ-1) and primers [1 um] (5‟- 
CTTGGCTCCGCCTCGATAT and 3‟- TCAAAGTAACGAGAGCCCAATG) (Applied 
Biosystems) were mixed with 2 µl of cDNA in 15 µl reactions. Samples were loaded 
into 0.1 ml strip tubes (Qiagen) and run on a Rotor-gene 3000 or 6000 PCR machine 
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(Corbett Research, Mortlake, NSW). The running protocol was hold at 50°C for 2 
min, hold at 95°C for 2 min then 50 cycles of 95°C for 5 s and 60°C for 30 s. 
Between cycles acquisition was taken from the FAM channel. cDNA samples were 
also used to quantify the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
housekeeping gene. Here a GAPDH kit (Applied Biosystems) combined with 
platinum Taq polymerase, PCR buffers and MgCl2 (Invitrogen), dNTPs (Promega) 
and 2 µl of cDNA were combined in a 15 µl reaction volume. The running protocol 
was hold at 95°C for 2 min then 45 cycles of 95°C for 5 s and 60°C for 30 s with 
acquisition on the FAM channel.  
In each reaction a standard curve was generated by running a 10-fold titration of 
either Py18S or GAPDH cloned cDNA. Data was analysed using Rotor-gene 6000 
series software version 1.7 (Corbett Research) and presented as a ratio of copies of 
Py18S per 105 copies of GAPDH. 
2.11. Statistical analysis 
All statistical analysis was done using GraphPad Prism Version 6.00 (GraphPad 
Software Inc., CA, USA). Unless otherwise stated, where multiple comparisons were 
made, data was first log transformed, and then analysed using one-way ANOVA 
followed by Bonferroni‟s post-hoc test. Results were considered statistically 
significant when p<0.05. Statistical significance is graphically represented as p< 0.05 
*, p<0.01**, p<0.001*** and p<0.0001****. 
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Chapter 3: Evaluation of the capacity of chimeric VLPs 
and capsomeres to induce antigen-specific 
immune responses and protective efficacy 
3.1. Introduction 
VLPs are formed when recombinant viral structural proteins assemble into a highly 
repetitive array which resembles the native form of the virus. Foreign antigen 
sequences can be incorporated within the VLP protein sequences, allowing for the 
development of chimeric VLPs capable of targeting pathogens with antigens of 
interest125,127,149. These units do not contain genomic material, so are incapable of 
replication, yet they highly immunogenic and very good inducers of antibody 
responses125,127,130.  
The MuPyV VLP platform has been developed by the Middelberg laboratory173, such 
that foreign epitopes flanked by flexible linker sequences can be displayed on 
surface exposed regions of VLPs173. The modified MuPyV VP1-S4-G4S173 has an 
epitope insertion site flanked by a flexible linker amino acid sequence (GGGGS-
epitope-SGGGG) on the S4 surface exposed loop of the VP1 structural protein. 
Bacterial expression of the MuPyV VP1 protein results in the formation of pentameric 
capsomere units which can be subsequently be harvested166,288. Expression and 
purification processes have been developed and optimised such that high yields of 
chimeric proteins can be obtained173,187,189,289. These purified capsomeres can then 
be chemically induced in vitro to self-assemble into VLPs166,288,289.  
In order to reduce production costs and time involved in VLP formation, direct use of 
chimeric MuPyV VP1 capsomeres as a vaccine platform has also been investigated 
by the Middelberg laboratory170,173. By removing the first 28 and last 63 amino acids 
from the VP1 protein, the capsomeres are unable to form VLPs because those 
residues are essential for forming links with surrounding capsomeres170. Without the 
requirement for stable VLP formation, a greater number of epitopes can be 
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incorporated into the capsomeres170. Furthermore, increasing the antigen to vector 
ratio can result in increased target-specific immune responses174,175, and decrease 
anti-carrier antibody titres170,176. The capsomeres are produced and purified in the 
same manner as the VLPs, however, the chemical VLP induction step is not 
required, hence the reduced production costs and time170.  
Whilst antibody responses generated by immunisation with chimeric VLPs are well 
documented (reviewed in125), little research has been done to evaluate their efficacy 
at generating cellular responses, or conferring protection from complex pathogens. 
In vitro studies have shown that chimeric polyomavirus VLPs with CD8+ T cell 
epitopes can activate epitope-specific CD8+ T cells154,161. Furthermore, VLP 
immunisations reportedly induce in vivo clonal proliferation of adoptively transferred 
epitope-specific CD8+ T cells, tumour growth inhibition, and protection from 
lymphocytic choriomeningitis virus has been described215. In comparison to VLPs, 
capsomeres are reportedly less efficient at generating IgG antibody responses and 
require co-administration with adjuvants131,173. In contrast, in two HPV16 L1 model 
studies, capsomeres reportedly induced cellular responses which were similar to 
VLP induced responses131,169, and induced tumour regression in the absence of 
adjuvants169.  
Whilst VLPs are self-adjuvanting127,290, capsomeres require the inclusion of 
adjuvants to initiate antibody responses170,173, and adjuvants also enhance cell-
mediated IFN- responses131,179. In the Middelberg laboratory, with the aim of 
increasing antibody responses alone, the adjuvant of choice has been aluminium 
hydroxide170,173. In this study, however, an adjuvant efficient at inducing cellular 
immune responses was required. The selected adjuvant was polyIC which is a 
synthetic analogue of double stranded RNA acting on TLR3291. This adjuvant is 
effective at inducing a IL-12 and type I interferon response and DC maturation with 
increased MHC II expression and antigen cross-presentation (reviewed in292,293). As 
a result polyIC stimulates antibody and CD4+ T cell responses294,295 and enhances 
CD8+ T cell primary and memory responses293,296,297. PolyIC administered with HIV-1 
VLPs has been shown to improve antigen immunogenicity, eliciting higher IgG titres 
and eliciting a Th1 biased IgG subclass (IgG2a and IgG3) response
221. In another 
study it was reported that influenza VLPs co-administered with polyIC enhanced DC 
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maturation, increased endpoint antibody titres and induced CD8+ T cell clonal 
proliferation298. 
The Plasmodium species circumsporozoite protein is the most studied antigen for 
anti- malaria sub-unit vaccines in mice and humans. It is the antigenic component in 
the virus-like particle RTS,S which is the most advanced human vaccine against 
Plasmodium falciparum37. It is therefore logical to include this protein in the 
evaluation of novel vaccine delivery platforms. Liver-stage protection from sporozoite 
challenge can be achieved by either CD8+ T cell72,73,299 or antibody responses63,300 
thus we evaluated both cellular and antibody responses using chimeric VLPs and 
capsomeres as a vaccine delivery platform. An effective pre-erythrocytic vaccine is 
likely to require high amplitude immune responses73,210,301. 
The selected CD8, CD4 and B cell epitopes for insertion into the chimeras are all 
from the P. yoelii CSP and have each been identified as relevant for vaccine 
development. The PyCSP CD8+280-288 dominant epitope was identified on a CD8
+ T 
cell following immunisations with P. yoelii sporozoites73. A clone of this cell 
adoptively transferred into naive mice was able to protect against subsequent 
challenge with both P. yoelii and P. berghei sporozoites73. The PyCSP subdominant 
CD8+58-67 T cell epitope has been reported to eliminate infected hepatocytes in vitro 
and induce CD8+ T cell proliferation and peptide-specific CTL responses75. Whilst 
protection can be afforded by CD8 T cells alone, the inclusion of CD4+ T helper 
epitopes have been shown to enhance CD8+ T cell responses302. Also, the passive 
transfer of an IgG3 monoclonal antibody against the PyCSP central repeat region 
(QGPGAP) can provide complete protection from sporozoite challenge63. A separate 
chimera was constructed incorporating either the CD8 dominant, CD8 subdominant, 
or a dimer of QGPGAP for VLPs and capsomeres. To examine whether the inclusion 
of T helper epitopes would enhance responses in the VLP or capsomere platforms, 
the PyCSP dominant CD4+280-295 T cell epitope
72 , or CD4+57-70 T cell epitope
74, or 
subdominant CD4+59-79 T cell epitope
71 hereafter referred to as CD4 dominant 1 or 2 
or subdominant respectively, were individually used to construct chimeric VLP and 
capsomere constructs.  
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This study involved a comprehensive comparison of antibody and CD8+ and CD4+ T 
cell responses as well as protection from Plasmodium yoelii 17XNL sporozoite 
challenge. Chimeric MuPyV capsomere and VLP constructs incorporating defined 
PyCSP CD8+280-288 T cell epitope 
73
, or CD4
+
59-79 T cell epitope
 71,or B cell repeat 
epitopes (QGPGAP)2
63 were evaluated as these constructs has high expression of 
soluble protein and formed VLPs. Capsomeres and in some cases VLPs were co-
administered with polyIC as an adjuvant, and a heterologous DNA prime-boost 
regimen was included.  
3.2. Methods 
3.2.1. Genomic construction of chimeric proteins 
3.2.1.1. Target selection and E. coli optimisation  
Complementary oligonucleotides for the PyCSP dominant CD8+280-288T cell 
(SYVPSAEQI)73, sub-dominant CD8+58-67T cell (IYNRNIVNRL)
75, dominant CD4+280-
295 T cell (SYVPSAEQILEFVKQI)
72, dominant CD4+57-70T cell (KIYNRNIVNRLLGD)
74, 
sub-dominant CD4+59-79T cell (YNRNIVNRLLGDALNGKPEEK)
71, and B cell repeat 
(QGPGAPQGPGAP)63 epitopes were codon-optimised for E. coli expression 
(Appendix B) and then synthesized and HPLC purified by GeneWorks (Adelaide, 
Australia).  
3.2.1.2. Genomic construction of chimeric VP1 proteins for VLPs  
The plasmid pGEX-VP1 comprising the pGEX-4T-1 (GE Healthcare Biosciences, 
Chalfont St.Giles, UK) expression vector and the murine polyomavirus VP1 genomic 
sequence (M34958) inserted between the BamHI and XhoI restriction enzyme sites 
was a gift from Professor Robert Garcea (University of Colorado, Colorado, USA). 
This plasmid was further modified inserting an AfeI restriction enzyme site at position 
293, then flanking the site with GGGGS (G4S) linker sequences to generate pGEX-
VP1-S4-G4S173. The protein sequence is listed in (Appendix E). 
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The pGEX-VP1-S4-G4S (1 µg) was linearised by AfeI restriction enzyme (NEB, MA, 
USA) digestion in a 50 µl reaction at 37°C for 4 h. To limit self-ligation, 5‟ phosphate 
groups were removed by adding 1 µl of alkaline phosphatase (10 units, NEB, MA, 
USA) and continuing 37°C incubation for 1 h. The mixture was then loaded into a 
0.8% agarose gel and separated by electrophoresis. Bands at the expected size 
(6145 bp) were excised and purified using a PureLink quick gel extraction kit 
(Invitrogen, CA, USA) following the manufacturer‟s protocol with DNA eluted in 
water. 
Epitope-specific complimentary oligonucleotides (100 µM stock) were annealed by 
mixing 8 µl of each complementary oligonucleotide with 84 µl of annealing buffer 
(Appendix A). In a thermocycler, tubes were heated to 95°C for 5 min then the 
temperature was reduced to match the oligonucleotide melting temperature (Tm; 
Appendix B) for 30 min, followed by a further temperature decrease of 0.1°C/s until 
reaching 25°C. Annealed oligonucleotides (2 µl) were then phosphorylated by adding 
0.5 µl of T4 ligation buffer, 1 µl of T4 polynucleotide kinase (10 units, NEB, MA, 
USA) and 1.5 µl water and heating to 37°C for 1 h, then heat inactivating at 70°C for 
20 min to inactivate the kinase, then diluting with 95 µl of water.  
The digested vector and phosphorylated annealed oligonucleotides were ligated in a 
1:50 ratio using T4 DNA ligase (NEB) in a 20 µl reaction for 3 h at RT. Then 
chemically competent E. coli Omnimax 2 T1 or DH5α (Invitrogen, CA, USA) were 
transformed (section 2.6.3.4) using 5 µl of the ligation mix, and cultured overnight on 
LB agar plates with 100 µg/ml ampicillin. Colony isolates were screened by colony 
PCR (section 2.6.3.5), then cultured in LB media with 100 µg/ml ampicillin and used 
for plasmid purification using PureLink quick plasmid miniprep kit (Invitrogen, CA, 
USA) following the manufacturer‟s protocol and eluting in water. 
Chimeric plasmids were designated CD8 dominant, CD8 sub-dominant, CD4 
dominant 1, CD4 dominant 2, CD4 sub-dominant and B Cell and all were confirmed 
by DNA sequencing (AGRF, Brisbane, Australia). 
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3.2.1.3. Genomic construction of chimeric VP1 proteins for capsomeres  
The pGEX-VP1 plasmid DNA was previously modified to truncate the VP1 gene 
removing the first 28 N-terminal and the last 63 C-terminal amino acids. Then 
restriction enzyme sites PmlI, NaeI, AfeI and SnaBI were inserted into positions 28, 
85, 293, and 380 respectively according to the original VP1 position. This vector was 
designated VP1ΔNΔC170 and was used as the starting plasmid for all capsomere 
constructs. The protein sequence is listed in (Appendix E). 
Oligonucleotides as described in VLP construction (section 3.2.1.1), were cloned into 
the VP1ΔNΔC170 by staff at the Protein Expression Facility (University of 
Queensland, St. Lucia, Australia). Each oligonucleotide was inserted into positions 
28, 293 and 380 and confirmed by genomic sequencing (AGRF, Brisbane, Australia). 
3.2.2. Protein expression 
VP1 protein expression was done according to previously described methods189. 
Briefly, chemically competent E. coli Rosetta (DE3) pLysS bacteria (Novagen, CA, 
USA) were transformed with either pGEX-VP1 (wild-type VP1) or each of the 
chimeric plasmids and grown overnight on LB agar. Colony isolates were transferred 
into 5 ml TB media (Appendix A) and incubated overnight at 30°C and 180 RPM. 
This starter culture was used to inoculate either 400 or 800 ml of TB media in baffled 
flasks with 400 or 800 µl respectively. Cultures were incubated at 37°C and 180 
RPM until the OD600 reached 0.4 – 0.5. The culture was then cooled under slightly 
chilled tap water for 10 or 20 min (for 400 or 800 ml cultures respectively) with 
frequent mixing to distribute heat, before inducing protein expression with 0.2 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG). Cultures were then incubated at 26°C 
and 180 RPM overnight, and then harvested by centrifugation (6000 x g, 4°C, 20 
min). The pellet was then stored at -80°C. Protein expression and solubility was 
assessed by coomassie stained SDS-PAGE gels. The molecular weights of 
constructs are listed in (Appendix F). All media was supplemented with ampicillin (50 
µg/ml) and chloramphenicol (34 µg/ml). 
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3.2.3. Protein purification process 
3.2.3.1. VLP and capsomere purification process 
The MuPyV VP1 proteins were expressed with a glutathionine-s-transferase (GST) 
tag on the N-terminus for purification using affinity purification as previously 
described189. Bacterial pellets were thawed and resuspended in 30 ml lysis buffer303 
(Appendix A) per 800 ml of culture generated pellet then sonicated (Branson 
Ultrasonics Corporation, Connecticut, USA) at output 30 for 4 cycles of 40 s each. 
Samples were rested on ice for 10 min between cycles. The lysate was centrifuged 
(18 000 RPM, 4°C, 20 min) then the supernatant was filtered through a 0.45 um 
syringe driven filter. 
The filtered lysate was passed through a 5 ml GSTrap HP affinity column (GE 
Healthcare, UK) pre-equilibrated with of L buffer. Unbound protein was washed out 
with L buffer, and then the GST-tagged VP1 proteins were eluted using an elution 
buffer (Appendix A). 
The GST tag was cleaved using 40 units of thrombin (GE Healthcare, UK) per ml of 
protein with a 2 h incubation at RT. Insoluble aggregates were isolated by 
centrifugation (15000 x g, 4°C, 5 min). The supernatant was collected and passed 
through a Superdex 200 10/300 GL column (GE Healthcare, UK) pre-equilibrated 
with L buffer, which separated capsomeres separated from aggregates and GST by 
size exclusion chromatography. 
3.2.3.2. Endotoxin removal 
Endotoxin was removed from the capsomere fractions using Vivapure Q maxi H ion 
exchange columns (Sartorius Stedim, Gottingen, Germany). Columns were 
equilibrated with 4 ml of L buffer (with NaCl increased to 300 mM), and centrifuged 
(500 x g, 4°C, 5 min). Capsomere fractions were combined and NaCl concentration 
increased to 300 mM by adding 20 µl of 5 M NaCl per 250 µl of capsomeres. These 
were loaded onto columns and centrifuged (500 x g, 4°C, 5 min) then the flow 
through was returned to column and the process was repeated three times.  
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Samples were then analysed by an LAL-based assay using an Endosafe PTS reader 
(Charles River Laboratory, MA, USA) following the manufacturer‟s protocol and 
considered suitable for use if results were less than 5 EU/ml.  
3.2.3.3. VLP assembly 
To cause the assembly of VLPs, purified VP1 capsomeres were dialysed in slide-a-
lyzer dialysis cassettes (10K MWCO, Thermo Scientific, Illinois, USA) against 
assembly buffer 1 (Appendix A) at 50 ml of buffer per 100 µl of capsomeres, for 15 h 
at RT with stirring. The cassettes were then transferred into the same volume of PBS 
and dialysed for 24 h at 4°C as previously described189,304.  
For the capsomere platform, protein expression and purification was done using the 
same protocols as the VLPs, however, because capsomeres were unable to form 
VLPs, they were dialysed only against PBS for 24 h at 4°C with stirring.  
3.2.3.4. Protein quantification 
The theoretical molecular weight and extinction co-efficient for each construct was 
estimated using ProtParam305. Protein concentration was calculated using Beer-
Lambert‟s Law: A =εx b x C, where A is the UV absorbance at 280 nm, εis the 
extinction coefficient, b is the path length of the sample (1 cm using cuvette), and C 
is the concentration of the sample (M). 
3.2.4. Confirmation of VLP formation 
3.2.4.1. AF4-MALS 
VLP formation was analysed using Asymmetrical Flow Field-Flow Fractionation with 
multi-angle light scattering (AFFFF-MALS) using an Eclipse 2 AFFFF system 
coupled with a Dawn EOS MALS system (Wyatt Technology Corporation, Santa 
Barbara, USA) as previous described13. Approximately 18 µg of each construct was 
injected into the system in a total volume of 30 µl with VLPs diluted in PBS. 
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3.2.4.2. TEM 
Wild-type and chimeric VLPs were applied to 200-mesh copper grids coated with 
Formvar film (Proscitech, QLD, Australia) for 2 min then washed with water. Grids 
were then stained with 1% (w/v) uranyl acetate for 1 min, dried and visualized with a 
JEOL 1010 (JEOL Ltd., Tokyo, Japan) microscope at 100 kV. Electron micrographs 
were recorded digitally using a side-mounted Morada camera (Olympus-Soft 
Imaging System GmbH, Muenster, Germany) with iTEM Software version 3.2 (Soft 
Imaging System GmbH). All images were obtained by Alice Lei Yu (AIBN, University 
of Queensland). 
3.3. Experimental design 
In initial studies to confirm that chimeric CD8280-288 VLPs and capsomeres could 
induce antigen-specific recognition of the PyCSP CD8280-288 epitope, an in vitro 
model was established using purified CD8+ T cells from transgenic CS-TCR mice 
(Table 4) stained with CFSE (section 2.10.1.3). In CS-TCR mice, all CD8+ T cell 
receptors are specific for the PyCSP280-288 epitope. These CD8
+ T cell epitope-
specific cells were co-cultured with splenocytes from naive BALB/c mice and 
stimulated with either wild-type or CD8 chimeric VLPs or capsomeres, or a synthetic 
peptide representing the defined PyCSP CD8+280-288 T cell epitope. The cells were 
analysed on days 2, 3 and 4, to assess epitope recognition by proliferation of CS-
TCR cells as identified by the decrease in CFSE intensity within cells following 
division. 
In the subsequent series of VLP and capsomere studies, BALB/c mice were 
immunised three times at 3 week intervals by with VLPs, capsomeres, peptides or 
PyCSP plasmid DNA in either homologous or heterologous prime/boost regimen. 
Immunisations were administered s.c. at the base of the tail in a 100 µl dose. 
Plasmid DNA immunisations were given by i.m. injection into the tibialis anterior 
muscle in 2 x 50 µl injections. Details of immunisations are presented below (Table 5 
and Table 6). Each series of experiments followed the same experimental design 
(Figure 4), with duplicate experimental groups in each experiment used for either 
immunogenicity or protection evaluations. 
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Figure 4: Experimental design for all in vivo VLP and capsomere experiments. BALB/c 
mice (n=10/group) were immunised three times at three week intervals with either VLPs, 
capsomeres, peptides by s.c. injection at the base of the tail in a 100 µl volume in a 
homologous regimen. Other groups received two primes with PyCSP plasmid DNA in the 
tibialis anterior muscle with 50 µg administered i.m. to each hind leg. Sera were collected 14 
d post-immunisation for doses 1 and 2, and 5 days after dose 3. The sera were 
subsequently used for antibody analysis by ELISA and IFAT. T cell responses were 
assessed by ELISpot, cytometric bead arrays and intracellular cytokine staining, using 
splenocytes harvested 7 days after the final immunisation (n=5 mice/group). For the analysis 
of protective efficacy, 8 d after the final immunisation, mice (n=5 mice/group) were 
challenged with an i.v. injection of 1000 cryopreserved P. yoelii 17XNL sporozoites. 
Protective efficacy was determined by harvesting livers 42 h post-challenge and quantifying 
parasite RNA using qRT-PCR. 
 
Antibody responses were assessed by ELISA and IFAT using sera collected post-
immunisation. ELISA capture antigens included PST-tagged PyCSP B cell repeat 
peptide and PyCSP recombinant protein (section 2.10.2.1). IFAT was used to assess 
the capacity of induced antibodies to recognise the surface of P. yoelii sporozoites 
(section 2.10.2.3). 
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T cell responses were assessed by ELISpot, cytometric bead arrays (CBA) and 
intracellular cytokine staining (ICS), using splenocytes harvested 7 days after the 
final immunisation (n=5 mice/group) as previously described (section 2.10.1). 
For the analysis of protective efficacy, 8 d after the final immunisation, mice (n=5 
mice/group) were challenged with an i.v. injection of 1000 cryopreserved P. yoelii 
17XNL sporozoites. Protective efficacy was determined by harvesting livers 42 h 
post-challenge and quantifying parasite RNA using qRT-PCR (section 2.10.3.2). 
The first series of experiments was designed to evaluate the immunogenicity and 
protective capacity of individual and pooled VLPs using peptides corresponding to 
the epitope insert in the VLP chimeras as comparators (Table 5). Additionally the 
relative capacity of homologous versus heterologous DNA prime/VLP boost regimen 
was evaluated.  
Table 5: Immunisations for first series of VLP experiments 
Group Immunisations 
CD8 VLP 30 µg of CD8280-288 VLP 
CD4 VLP 30 µg of CD459-79 VLP 
B cell VLP 30 µg of B cell VLP 
Pooled VLP 10 µg of each CD8280-288, CD459-79 and B cell VLPs 
CD8 peptide 30 µg of CD8280-288 peptide with 50 µg polyIC 
CD4 peptide 30 µg of CD459-79 peptide with 50 µg polyIC 
B cell peptide 30 µg of B cell peptide with 50 µg polyIC 
Pooled peptide 30 µg of each CD8280-288, CD459-79 and B cell peptides with 50 µg polyIC 
DNA+pooled VLP 2 x primes with 100 µg PyCSP pDNA (pVR2516) + boost with pooled VLPs 
DNA+pooled peptide 2 x primes with 100 µg PyCSP pDNA (pVR2516) + boost with pooled peptides 
Wild VLP 30 µg of wild-type VLP 
Ovalbumin 30 µg of each CD8257-264 and CD4323-339 ovalbumin peptides with 50 µg polyIC 
PBS 100 µl PBS 
 
In the second series of experiments, the immunisations were consistent with the first 
series (Table 5); however, the dose of chimeric VLPs in the pooled VLP groups was 
increased to 30 µg of each construct for a better comparison to individual VLP 
immunisations. An additional group received three doses of PyCSP plasmid DNA 
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only (100 µg) to further distinguish the immunological benefits of the pooled VLP or 
peptide boost.  
A third series of experiments, was designed to compare the immunogenicity and 
protective capacity of chimeric VLPs and capsomeres. Due to constraints imposed 
by the large number of groups, mice were immunised only with pooled VLPs, 
capsomeres or corresponding peptides. Specifically, BALB/c mice (n=10/group) were 
immunised with three doses at 3 week intervals with constructs as described below 
(Table 6). In the heterologous DNA prime-boost regimen, mice received 100 µg of 
PyCSP plasmid DNA for the first two immunisations, followed by a final dose of 
pooled capsomeres, VLPs or peptide as for the homologous regimen.  
Table 6: Immunisations for third series of VLP experiments 
Group Immunisations 
VLP 10 µg of each CD8280-288, CD459-79 and B cell VLPs 
VLP+pIC 10 µg of each CD8280-288, CD459-79 and B cell VLPs with 50 µg polyIC 
Caps+pIC 10 µg of each CD8280-288, CD459-79 and B cell capsomeres with 50 µg polyIC 
Pep+pIC 30 µg of each CD8280-288, CD459-79 and B cell peptides with 50 µg polyIC 
DNA+VLP 2 x primes with 100 µg PyCSP pDNA (pVR2516) + boost with VLP 
DNA+VLP+pIC 2 x primes with 100 µg PyCSP pDNA (pVR2516) + boost with VLPs+pIC 
DNA+Caps+pIC 2 x primes with 100 µg PyCSP pDNA (pVR2516) + boost with Caps+pIC 
DNA+Pep+pIC 2 x primes with 100 µg PyCSP pDNA (pVR2516) + boost with Pep+pIC  
DNA 3 x doses of 100 µg PyCSP pDNA (pVR2516) 
Wild VLP+pIC 30 µg of wild-type VLP with 50 µg polyIC 
Wild Caps+pIC 30 µg of wild-type capsomeres with 50 µg polyIC 
PBS 100 µl PBS 
 
3.4. Results 
3.4.1. Construction of chimeric VLPs 
Six chimeric MuPyV VP1-S4-G4S proteins were constructed each confirmed by 
sequencing. Following bacterial expression, total and soluble fractions were 
separated by electrophoresis to evaluate expression and solubility of chimeric 
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proteins. Each chimeric construct was expressed by the bacteria, however, the CD8 
subdominant and CD4 dominant 1 and 2 chimeric proteins were predominantly 
insoluble (Figure 5). Repeated transformations and cultures failed to increase the 
yield of soluble protein with these chimeras.  
The molecular weight of each chimera was: Wild-type, 69.6 kDa; CD8 dominant, 
70.5 kDa; CD8 subdominant, 70.8 kDa; CD4 dominant 1, 71.4 kDa; CD4 dominant 2, 
71.3 kDa; CD4 subdominant, 72.0 kDa; and B cell, 70.6 kDa (Appendix F).  
 
 
Figure 5: Protein expression and solubility of chimeric MuPyV VP1-S4-G4S 
constructs. Rosetta DE3 pLysS E. coli were transformed with plasmid DNA from each 
chimeric VP1 construct. Colony isolates were selected for overnight starter cultures which 
were subsequently used to inoculate 400 ml of TB media with ampicillin [50 µg/ml] and 
chloramphenicol [24 µg/ml] in 2 L baffled flasks. At OD450 ~ 0.5, cultures were induced with 
IPTG [0.2 mM]. Cultures were incubated overnight at 26°C with shaking at 180 RPM, then 
bacteria were harvested by centrifugation and pellets lysed by sonication. A total (T) fraction 
was taken directly from lysed bacteria, whilst the soluble (S) fraction was taken from the 
supernatant of lysed and centrifuged bacteria. Fractions were run on a 10% SDS-PAGE gel 
then stained with coomassie. A molecular weight ladder (Novex sharp pre-stained) was run 
(left lane) in parallel with other samples. 
The CD8 dominant, CD4 sub-dominant and B cell constructs each progressed 
through the purification process with good yields after GST purification and thrombin 
digestion followed by s200 column size-exclusion chromatography (Figure 6). 
However, the yields for the CD8 subdominant and CD4 dominant 1 and 2 constructs 
were very low as compared with the other constructs. An SDS-PAGE analysis 
showed that for these constructs, most of the protein was passing through the 
column and not being captured by the column matrix. Nonetheless, whilst the yields 
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were low for these constructs, sufficient protein was available for thrombin digestion. 
Following thrombin digestion to separate the GST-tag, protein instability was 
observed in the CD8 sub-dominant, and CD4 dominant 1 and 2 constructs, as 
determined by protein aggregation. The quantity of protein in eluted fractions from 
the s200 column were too low for both of the CD4 dominant constructs and so no 
further work could be done with them. The CD8 sub-dominant yield was also low but 
was sufficient to determine if VLPs would form. 
Figure 6: Thrombin digested 
chimeric proteins following size 
exclusion chromatography. Chimeric 
proteins isolated using a GST column 
were digested with thrombin and 
isolated using a Sephadex s200 
chromatography column. Isolated 
proteins were run on an 10% SDS-
PAGE gel and then stained with 
coomassie. Successive lanes from left 
to right lanes contained a molecular 
weight ladder (Novex sharp pre-
stained) followed by post-thrombin 
digested wild VLP pre- and post-s200 
purification, and s200 purified protein 
fractions from CD8 dominant, CD4 
sub-dominant and B cell chimeric 
MuPyV VP1-S4-G4S proteins. 
 
Hereafter the chimeric CD8280-288 dominant VLP, CD459-79sub-dominant VLP and B 
cell VLP are named CD8 VLP, CD4 VLP and B cell VLP respectively. Following 
dialysis in assembly buffer and then PBS, VLPs were quantified using UV280 nm 
absorbance (section 3.2.3.4) and characterised by transmission electron microscopy 
and AF4-MALS (section 3.2.4). VLP formation was observed in wild-type, CD8280-
288 dominant, CD459-79 subdominant and B cell chimeras (Figure 7). The chimeras 
had a similar morphology to wild-type VLPs. The mean radius of VLPs: Wild type, 
19.99 nm; CD8 VLPs, 20.75 nm; CD4 VLPs, 21.16 nm; B cell VLPs, 20.99 nm, were 
slightly larger than wild type VLPs as expected with the addition of exogenous amino 
acids.  
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Figure 7: Structural analysis of in 
vitro assembled chimeric murine 
polyomavirus virus-like particles. 
Wild and chimeric MuPyV VP1-S4-G4S 
proteins were expressed in E. coli and 
purified by liquid chromatography. 
Proteins were dialysed against an 
assembly buffer to form VLPs, then 
against PBS. Post-assembly solutions 
were analysed to detect the formation of 
(A) wild-type VLPs, and (B) CD8280-288, 
(C) CD459-79, and (D) B cell VLP 
chimeras using asymmetrical flow field- 
flow fractionation coupled with multi-
angled lights scattering (AF4-MALS) 
and transmission electron microscopy. 
UV280 absorbance is presented relative 
to peak absorbance (solid line) for each 
sample, and particle size is presented 
as root-square-radius (open circles). 
TEM scale bar represents 100 nm. 
 
The CD8 sub-dominant chimera also formed VLPs, however, the protein yield was 
approximately one-sixth of the other constructs, despite having double the original 
culture volume. Despite repeated attempts, the yield of VLPs for this construct was 
insufficient to proceed to animal experiments. Of the six chimeric VLPs originally 
intended for this project, only three were sufficient to proceed in animal experiments 
as a result of the mentioned protein instability and yield issues.  
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3.4.2. Proliferative capacity of CD8 chimeric VLPs and capsomeres 
To determine if the PyCSP CD8280-288 T cell epitope included in chimeric VLPs and 
capsomeres would be processed, presented and recognised by host cells with 
transgenic CS-TCR cells, an in vitro CFSE stained CS-TCR proliferation assay was 
used. Peptides, VLPs and capsomeres were studied at 10 µg/ml with proliferation 
indicated by the dilution of CFSE in cells resulting in lower MFI values. Proliferation 
was detected in all groups presenting the respective CD8+280-288 T cell epitope 
(Figure 8). The highest rate of proliferation was seen in the peptide and capsomere 
groups both of which induced rapid proliferation, significantly higher than respective 
controls and to the CD8280-288 VLPs as seen after 2 days in culture (p<0.0001). The 
CD8280-288 VLPs induced a less efficient proliferation response and was not 
significantly different to wild-type VLPs until after 3 days of incubation. Furthermore, 
after 2 and 3 days of incubation proliferation induced by CD8280-288 VLPs was 
significantly less than both CD8280-288 peptide and CD8280-288 capsomeres 
(p<0.0001). However, significance between the CD8280-288 constructs was lost by day 
4, following rapid VLP280-288 induced proliferation (Figure 8). 
 
 
 
 
 
Figure 8: Proliferation of CS-
TCR CD8+ T cells following in 
vitro stimulation with VLPs, 
capsomeres and peptide. CD8+ 
T cells from naive CS-TCR 
transgenic mice were purified by 
positive selection, stained with 
CFSE, and combined with 
splenocytes from naive BALB/c mice (n=5). Cells were incubated in media supplemented 
with either PyCSP CD8280-288 peptide, CD8280-288 chimeric VLPs, CD8280-288 chimeric 
capsomeres, wild-type VLPs or wild-type capsomeres, all at 10 µg/ml, or in media alone. 
Cultures were analysed by flow cytometry after 2, 3, 4, and 5 days to determine the median 
fluorescence intensity (MFI) of CFSE in Thy1.1+CD8+ CS-TCR viable cells.  
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3.4.3. Chimeric VLPs with 10 µg/construct in pooled immunisations 
Having established that the PyCSP CD8+280-288 T cell epitope presented in the 
context of chimeric VLPs or capsomeres was capable of inducing epitope-specific 
proliferation of TCR-specific CD8+280-288 T cells, immunogenicity and protective 
efficacy were evaluated in subsequent experiments.  
3.4.3.1. Cellular immunogenicity 
To assess the ability of chimeric VLPs to induce cellular immune responses, 
splenocytes from immunised mice were harvested and single cell suspensions were 
restimulated for ELISpot, CBA and ICS assays. Comparisons were made between 
single and pooled construct immunisations to look for evidence of any synergistic or 
inhibitory effects. 
CD8 T cell chimeric VLP induced responses 
ELISpot results (Figure 9) showed that the CD8280-288 VLP induced significant IFN- 
spot forming cells (SFCs) when stimulated with pooled peptide or transfected A20 
cells as compared with the PBS control (p<0.001). The peptide-specific IFN- 
response induced by the CD8280-288 VLP was similar to that induced by 
immunisations with CD8280-288 peptide formulated in polyIC. When restimulated with 
PyCSP transfected A20 cells immunisations with CD8280-288 VLPs resulted in 
significant IFN- responses (p<0.01), which were absent in the peptide immunised 
mice. CBA analysis of IFN- production following pooled peptide restimulation 
(Figure 10) corroborated the ELISpot results with significant CD8280-288 VLP induced 
responses relative to the PBS control (p<0.0001). An IFN- response could also be 
detected by ICS but this was not significant (Figure 11). 
CD4 T cell chimeric VLP induced responses 
Despite the demonstrated immunogenicity of CD8280-288 chimeric VLPs, the CD459-79 
chimeric VLP immunisations failed to generate any significant cytokine responses as 
assessed by IFN- ELISpot, CBA or ICS assays. Significant IFN- and TNF 
responses could be detected from the positive control comparator CD459-79 peptide + 
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polyIC immunised mice when their splenocytes were restimulated with either pooled 
peptide (p<0.0001) or transfected A20 cells (p<0.01) in ELISpot assays (Figure 9). 
This group also had significant IFN- (p<0.0001) and TNF (p<0.01) responses in 
CBA analysis (Figure 10) as well as CD4+ T cells expressing IFN- (p<0.0001) or IL-
2 (p<0.001) in ICS assays (Figure 11), when restimulated with pooled peptides as 
compared to PBS controls.  
 
Figure 9: IFN- ELISpot responses induced by individual (30 µg) or pooled (10 µg 
each) chimeric VLP immunisations. BALB/c mice (n=5/group) received three s.c. 
immunisations at 2 week intervals of wild type VLPs (30 µg), individual VLP constructs (30 
µg,) or pooled VLPs (10 µg each), individual (30 µg) or pooled peptides (30 µg each) with 
polyIC (50 µg), or a prime boost regimen using two i.m. PyCSP plasmid DNA (100 µg) 
primes then an s.c. boost using either pooled VLPs or peptides with polyIC. Splenocytes (5 x 
105/well) were cultured and restimulated with irradiated A20 cells (1.5 x 105/well) either with 
pooled PyCSP CD8280-288, CD459-79 and B cell peptides, or with pVR2516 PyCSP plasmid 
DNA transfected and irradiated A20 cells (5 x 104/well) for 40 h. IFN- spot forming 
cells/million splenocytes are presented as group means + SEM. Statistical comparisons are 
made to the PBS control group, and between homologous VLP and peptide groups using 
log-transformed data with significance determined using one-way ANOVA followed by 
Bonferroni‟s post-hoc test. p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****. 
B cell chimeric VLP induced responses 
The B cell chimeric VLP was designed to induce antibody but not cellular immune 
responses. As expected, no cytokine responses could be detected in ELISpot 
(Figure 9) or ICS assays (Figure 11).  
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Pooled VLP induced responses 
In this experiment, mice in the pooled VLP immunisation group received 10 µg of 
each chimeric construct per dose. Significant IFN- responses were detected when 
restimulated with pooled peptides (p<0.01) or PyCSP transfected A20 cells (p<0.01) 
in an ELISpot assay (Figure 9), as well as pooled peptides (p<0.001) in the CBA 
analysis (Figure 10).To determine whether pooling VLPs had an influence (positive 
or negative) on immunogenicity, statistical comparisons were made to single 
construct VLP immunisations. No significant effect of pooling chimeric VLPs was 
evident in any of the cellular assays (Figure 9, Figure 10, Figure 11). 
Figure 10: IFN- or TNF expression induced by individual (30 µg) or pooled (10 µg 
each) chimeric VLP immunisations. Mice (n=5/group) were immunised as previously 
described (Figure 9). Splenocytes (5 x 105/well) were cultured with irradiated A20 cells (1.5 x 
105) and restimulated with pooled PyCSP CD8280-288, CD459-79 and B cell peptides for 72 h. 
Data are presented as mean + SEM for IFN- and TNF cytokines (pg/ml) detected in culture 
supernatant by CBA analysis. Statistical comparisons are made to the PBS control group, 
and between homologous VLP and peptide groups using log-transformed data with 
significance determined using one-way ANOVA followed by Bonferroni‟s post-hoc test. 
p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****. 
Heterologous DNA prime/boost regimen 
To evaluate if the immunogenicity induced by a homologous VLP regimen could be 
enhanced using a prime/boost regimen, mice received two PyCSP plasmid DNA 
primes followed by a single boost with either pooled VLPs or pooled peptides 
formulated in polyIC. The heterologous DNA/pooled VLP group had a moderate, but 
non-significant increase in IFN- responses as compared to mice immunised with 
homologous pooled VLPs (Figure 11). Moreover, this only group to achieve a CD8+ 
77 
 
T cell IFN- positive population that was significant relative to the controls (Figure 
11). However, due to constraints in the size of the study a plasmid DNA only 
immunised group could not be included in this study. It is possible that the significant 
IFN- responses induced could be due to the DNA prime alone.  
TNF and other cytokine responses 
The primary readout for cellular immunogenicity assays was IFN- since this is the 
cytokine implicated in PyCSP protection. Other than IFN-, the only notable cytokine 
response was TNF as assessed by CBA (Figure 10) and ICS (Figure 11). However, 
although TNF responses could be detected following VLP immunisations, the levels 
of TNF were low in both the CBA (Figure 10) and ICS (Figure 11) assays and were 
not significantly different from controls. In contrast, immunisations with pooled 
peptides with and without plasmid DNA priming induced significant TNF responses in 
the CBA assay (p<0.01 and p<0.001 respectively), as well as CD4+ T cell IL-2 
responses in the ICS (p<0.05 and p<0.0001 respectively). These responses appear 
to be modulated by the CD4 peptide.  
However, other cytokines were also analysed, specifically: IL-1β, IL-2, IL-4, IL-5, IL-
6, IL-10, IL-12p70 and IL-13 in pooled culture supernatants were assessed by CBA. 
Most of these cytokines were very low, at or near the limit of detection for this assay 
(data not presented). The CD459-79 peptide, pooled peptide and DNA/peptide 
immunised groups had a spike in IL-6 (159,172 and 98 pg/ml respectively) and IL-13 
(1394, 1892 and 673 pg/ml respectively) when stimulated with pooled peptides, but 
no robust cytokine response could be detected in all other groups including VLP 
immunised mice. 
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Figure 11: IFN-, IL-2 and TNF expressing T cells induced by individual (30 µg) or 
pooled (10 µg each) chimeric VLPs. Mice (n=5/group) were immunised as previously 
described (Figure 9). Splenocytes (5 x 105/well) were cultured with irradiated A20 cells (1.5 x 
105/well) and restimulated with pooled PyCSP CD8280-288, CD459-79 and B cell peptides for 18 
h. For the final 6 h, wells were supplemented with GolgiPlug (0.1%). Cells were stained for 
CD8+ and CD4+ T cell receptors then intracellular stained for IFN-, IL-2 and TNF cytokines. 
Cells were analysed by flow cytometry. Statistical comparisons are made to the PBS control 
group, and between homologous VLP and peptide groups using log-transformed data with 
significance determined using one-way ANOVA followed by Bonferroni‟s post-hoc test. 
p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****. 
3.4.3.2. Antibody responses 
To assess antigen-specific antibody responses induced by the chimeric VLP 
immunisations, ELISA assays were conducted using the polystyrene-tagged PyCSP 
B cell repeat peptide as a capture antigen. Results show that immunisations with B 
cell VLPs administered individually or as pooled VLPs induce robust antibody 
responses (Figure 12 and Figure 13). However, the data show that a single VLP 
dose is insufficient to induce robust antibody responses with two to three doses 
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required (Figure 12). Following the final immunisation the endpoint titre of B cell VLP 
immunised mice was 4-fold higher than the pooled VLP immunised mice (Figure 
12B). Titres increased 2-fold between the second and third immunisation of B cell 
VLPs in contrast to the pooled VLPs which had stabilised after the second 
immunisation. Endpoint titres were determined in individual mice following the final 
immunisation in the pooled VLP groups with and without DNA priming and B Cell 
VLP mice (Figure 13) with no significant differences detected between these groups. 
After the second VLP dose, a dominant IgG1 response was evident, with a class 
switch to IgG3 occurring after the third immunisation (Figure 12A). 
 
Figure 12: Anti-B cell peptide antibody responses following immunisations. Mice 
(n=5/group) were immunised as previously described (Figure 9). Sera collected pre-
immunisation (0) and following successive doses (1,2 and 3) was assayed by ELISA to 
detect antibody responses against the PyCSP B cell peptide. (A) Pooled sera collected after 
each immunisation was diluted 1:800 to determine IgG isotype responses displayed as 
cumulative OD450 values. (B) Pooled sera were used to determine the total IgG endpoint 
titres following each dose. 
An ELISA was conducted using individual sera against the PST-tagged PyCSP B 
cell repeat peptide to determine endpoint IgG titres (Figure 13). Sera used in this 
assay were obtained following immunisations for this experiment, as well as from a 
subsequent experiment in which pooled VLPs were given at 30 µg per construct 
(section 3.4.4). The endpoint titre of each group was significantly higher than the 
PBS group (p<0.0001). In homologous VLP immunisations, there were minor and 
non-significant variations between groups, and each group was significantly better 
than homologous DNA immunisations (p<0.0001). In the prime/boost regimen, the 
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lower 10 µg/construct boost resulted in significant higher endpoint titres as compared 
to the 30 µg/construct boost (p<0.01). 
 
Figure 13: IgG comparisons between VLP experiments using 10 or 30 µg per 
construct in pooled VLP immunisations. In two series of experiments mice (n=10/group) 
immunisations as previously described with 10 µg/construct (Figure 9) or 30 µg/construct 
(section 3.4.4) in pooled VLPs. Sera collected following the final immunisations were 
simultaneously analysed by ELISA to determine the anti-B cell peptide-specific IgG endpoint 
titre. Data is presented as mean endpoint titre + SEM. Statistical comparisons are made 
between immunisation groups using log-transformed data with significance determined using 
one-way ANOVA followed by Bonferroni‟s post-hoc test. p<0.01 **, p<0.0001 ****. 
3.4.3.3. Protection 
To evaluate the protective efficacy of chimeric VLPs, immunised mice (n=5/group) 
were challenged with 1000 P. yoelii 17XNL sporozoites. Parasite RNA in 
homogenised livers was quantified by q-RT-PCR286 and reported as a ratio to mouse 
GAPDH housekeeping gene (Figure 14). There were no significant differences 
detected between any of the immunisation groups. However, mice immunised with a 
DNA prime and pooled VLP boost had a 38% reduction in liver-stage parasite 
burden relative to the PBS control group, and two mice in that group had no parasite 
RNA detected in their liver. 
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Figure 14: Protective capacity induced by individual (30 µg) or pooled (10 µg each) 
chimeric VLPs using homologous or heterologous immunisation regimens. Mice 
(n=5/group) were immunised as previously described (Figure 9). Mice were challenged 8 
days after the final immunisation by i.v. injection of 1000 P. yoelii 17XNL cryopreserved 
sporozoites. Parasite burden was assessed by qRT-PCR analysis of Py18s RNA extracted 
from livers harvested 42 h post-challenge and calculated as a ratio to the GAPDH 
housekeeping-gene RNA. Data was normalised to the PBS control and presented as a 
relative parasite burden. Individual results are shown with bars representing the group mean. 
Log-transformed ratio data was analysed using one-way ANOVA followed by Bonferroni‟s 
post-hoc test. No significant differences were detected between groups. 
3.4.4. Chimeric VLPs with 30 µg/construct in pooled immunisations 
In the next series of experiments, the pooled VLP immunisations were modified to 
include 30 µg of each chimeric VLP per dose. By doing so, equivalent dose 
comparisons could be made between individual and pooled constructs in the cellular 
immunogenicity assays. To identify the cell phenotype responses in assays for these 
experiments, PyCSP CD8+280-288 or CD4
+
59-79 T cell peptides were used individually 
and pooled to restimulate splenocytes. 
3.4.4.1. Cellular immunogenicity 
CD8 chimeric VLP induced IFN- responses 
Consistent with data from the previous experiment (section 3.4.3.1), CD8280-288 
chimeric VLPs induced significant IFN- responses when restimulated with either the 
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CD8280-288 peptide (p<0.0001) or PyCSP transfected A20 cells (p<0.0001) in the 
ELISpot assay (Figure 15). Consistent with this ELISpot detected response, the CBA 
assay detected significant levels of IFN- in culture supernatant with splenocytes 
from CD8280-288 VLP immunised mice (p<0.0001) (Figure 16). No significant 
responses were detected with the CD8280-288 VLP immunised mice in the ICS 
analysis (Figure 17). In each assay, there were only minor but not significant 
differences between the CD8280-288 VLP and CD8280-288 peptide immunisations. This 
confirmed the capacity of CD8280-288 chimeric VLPs to induce robust CD8
+ T cell 
responses. 
CD4 chimeric VLP induced IFN- responses 
Also consistent with data from the previous experiment (section 3.4.3.1), no 
significant IFN- responses following immunisations with the CD459-79 VLP could be 
detected by ELISpot, or ICS assays (Figure 15, Figure 17). There was a significant 
(p<0.01) albeit a very small IFN- response detected in the CBA (Figure 16). In 
contrast, robust IFN- responses were detected with experimental groups immunised 
with the positive control comparator CD459-79 T cell peptide in polyIC in each assay 
(p<0.0001).  
Pooled VLP induced IFN- responses 
Immunisations with pooled (CD8280-288, CD4 and B cell) VLP construct induced 
significant IFN- responses (p<0.0001) when restimulated with CD8280-288 peptide, 
pooled peptides or transfected A20 cells in the ELISpot analysis (Figure 15). 
Responses to the individual peptides showed that the response was dominated by 
the CD8280-288 peptide with very low CD4 peptide-induced activation, consistent with 
the lack of responses detected following immunisations with the chimeric CD459-79 
VLP construct. Consistent with the ELISpot data, the CBA results (Figure 16) 
showed robust IFN- responses with significant responses detected when 
restimulated with pooled peptide (p<0.0001) or CD8280-288 peptide (p<0.0001) at a 
similar magnitude. In the CBA assay, very low (87 pg/ml) but nonetheless significant 
response was detected in the pooled VLP immunised mice following CD459-79 peptide 
restimulation (p<0.01). Pooled VLP immunisations induced significant CD8+ T cells 
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producing IFN- (p<0.01) detected in ICS analysis (Figure 17). Overall, there was no 
evidence to indicate any synergistic or inhibitory antigen-specific immune effects 
from pooling VLPs. 
 
Figure 15: IFN- ELISpot responses induced by individual (30 µg) or pooled (30 µg 
each) chimeric VLP immunisations. BALB/c mice (n=5/group) received three s.c. 
immunisations at 2 week intervals of wild type VLPs (30 µg), individual VLP constructs (30 
µg,) or pooled VLPs (30 µg each), individual (30 µg) or pooled peptides (30 µg each) with 
polyIC (50 µg), with three i.m. PyCSP plasmid DNA (100 µg) or a prime boost regimen using 
two i.m. PyCSP plasmid DNA (100 µg) primes then an s.c. boost using either pooled VLPs 
or peptides with polyIC. Splenocytes (5 x 105/well) were cultured and restimulated with 
irradiated A20 cells (1.5 x 105/well) either with individual or pooled PyCSP CD8280-288,CD458-
79 and B cell peptides, or with irradiated and pVR2516 PyCSP plasmid DNA transfected A20 
cells (5 x 104/well) for 40 h. IFN- spot forming cells/million splenocytes are presented as 
group means + SEM. Statistical comparisons are made to the PBS control group, and 
between homologous VLP and peptide groups using log-transformed data with significance 
determined using one-way ANOVA followed by Bonferroni‟s post-hoc test. p<0.05 *, p<0.001 
*** and p<0.0001 ****. (nt, not tested). 
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Heterologous DNA prime/boost regimen induced IFN- responses 
The relative effectiveness of heterologous DNA prime/VLP boost versus homologous 
pooled VLP regimens was investigated. Significant IFN- responses were detected in 
heterologous as well as homologous regimens when splenocytes were restimulated 
with pooled peptide (p<0.0001) or PyCSP transfected A20 cells (p<0.0001) in the 
ELISpot assay (Figure 15). Consistent with earlier experiments, the response was 
primarily attributed to the CD8280-288 peptide epitope (p<0.0001), with a small but 
never the less significant response to the CD459-79 peptide (p<0.001). The magnitude 
of the detected responses was not significantly higher in the heterologous versus 
homologous regimens, despite a 2-fold increase in the mean SFCs. A similar result 
was noted by CBA of IFN- in culture supernatants (Figure 16) with significant 
responses detected with pooled (p<0.0001), CD8280-288 (p<0.0001) and CD459-79 
(p<0.001) peptide restimulation, with a skew towards the CD8280-288 peptide. In the 
ICS analysis (Figure 17), significant CD8+ T cells producing IFN- were detected with 
pooled peptide restimulation when compared to the PBS control (p<0.01).  
In this experiment, the inclusion of a PyCSP plasmid DNA group allowed for some 
determination as to the capacity of each component in the prime/boost regimen to 
stimulate immune responses. Immunisations with DNA only was clearly effective at 
inducing IFN- responses when restimulated with the CD8280-288 peptide alone or 
pooled peptides, and to a lesser extent with the CD4 peptide, as shown in each 
cellular immune assay (Figure 15, Figure 16, Figure 17).  
TNF and other cytokine responses 
As with the earlier series of experiments (section 3.4.3.1), IFN- was the primary 
readout for cellular responses. Other cytokines, specifically: IL-1β, IL-2, IL-4, IL-5, IL-
6, IL-10, IL-12p70, IL-13, TNF and IFN- in culture supernatants were detected by 
CBA analysis. Data was consistent with earlier experiments with predominant IFN- 
and TNF responses (Figure 16, Figure 17), whilst other detected cytokines were at 
or near the levels of detection for the assay.  
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Figure 16: IFN- or TNF expression induced by individual (30 µg) or pooled (30 µg 
each) chimeric VLP immunisations. Mice (n=5/group) were immunised as previously 
described (Figure 15). Splenocytes (5 x 105/well) were cultured with irradiated A20 cells (1.5 
x 105/well) and restimulated with individual or pooled PyCSP CD8280-288, CD458-79 and B cell 
peptides for 72 h. Data are presented as mean + SEM for IFN- and TNF cytokines in pg/ml 
detected in culture supernatant by CBA analysis. Statistical comparisons are made to the 
PBS control group, and between homologous VLP and peptide groups using log-
transformed data with significance determined using one-way ANOVA followed by 
Bonferroni‟s post-hoc test. p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****. (nt, not 
tested). 
The peptide immunisation groups had increased IL-6 and IL-13 levels which 
appeared to be driven by the CD4 peptide and were absent in VLP immunised 
groups. Splenocytes from pooled peptide immunised mice which were restimulated 
with pooled peptides, CD8280-288 or CD459-79 peptides had increased IL-6 (110, 9 and 
117 pg/ml respectively) and IL-13 (834, 64 and 904 pg/ml respectively) responses 
detected in the CBA assay. 
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The CBA data showed VLP-induced TNF responses were low (Figure 16), consistent 
with the earlier VLP experiment (Figure 10). In the ICS analysis, VLPs did not induce 
significant CD8+ or CD4+ T cells expressing either IL-2 or TNF. The peptide 
immunised groups did not achieve significant IL-2 responses in any restimulation, 
and TNF responses were only evident in CD4+ T cells following pooled peptide or 
CD459-79 peptide restimulation. 
 
Figure 17: IFN- expressing T cells following immunisation and PyCSP peptide 
restimulation. Mice (n=5/group) were immunised as previously described (Figure 15). 
Splenocytes (5 x 105/well) were cultured with irradiated A20 cells (1.5 x 105/well) and 
restimulated with (A) pooled PyCSP CD8280-288, CD458-79 and B cell repeat peptides or (B) 
with individual peptides; for 18 h with wells supplemented with GolgiPlug (0.1%) for the final 
6h. Cells were stained for CD8+ and CD4+ T cell receptors then intracellular stained for IFN-
. Statistical comparisons are made to the PBS control group, and between homologous 
VLP and peptide groups using log-transformed data with significance determined using one-
way ANOVA followed by Bonferroni‟s post-hoc test. p<0.05 *, p<0.01 **, p<0.001 *** and 
p<0.0001 ****. (nt, not tested). 
 
87 
 
 
Figure 18: Cellular immune response comparisons between VLP experiments. In two 
series of experiments mice (n=5/group) received three s.c. immunisations at 2 week 
intervals of either wild type VLPs (30 µg), pooled VLPs at either 10 or 30 µg of each 
construct, three i.m. PyCSP plasmid DNA (100 µg), or a prime boost regimen using two i.m. 
PyCSP plasmid DNA (100 µg) primes then a boost using either pooled VLPs at either 10 or 
30 µg of each construct. Data from (A) ELISpot (B) cytometric bead array and (C) 
intracellular cytokine staining have been normalised to data from mice immunised with a 
DNA prime/pooled peptide boost regimen. Data is presented as mean + SEM in relative 
units for each assay. Statistical comparisons are made between groups with VLP doses at 
10 or 30 µg per construct per dose or between mice receiving DNA in a homologous or 
heterologous regimen, using log-transformed data with significance determined using one-
way ANOVA followed by Bonferroni‟s post-hoc test. p<0.001 ***. 
To determine whether pooled VLPs were more immunogenic at either 10 
µg/construct or 30 µg/construct in either homologous or heterologous DNA 
prime/boost regimens, data between the two sets of VLP experiments were 
normalised based on the DNA/pooled peptide immunised mice. Data from ELISpot, 
CBA and ICS immunogenicity assays (Figure 18) show no significant effect of VLP 
dose. DNA only immunisations were consistently higher than any other regimen in 
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each of the data sets (Figure 18). Significant differences between DNA only or 
prime/boost immunisations were only detected in ICS data with CD8+ T cells 
expressing IFN- (p<0.001) (Figure 18C). The data also shows trend of higher 
cellular responses in the prime/boost immunisations as compared to the homologous 
regimen but the differences were not significant (p>0.05). 
3.4.4.2. Antibody responses 
To assess the capacity of VLPs to induce antigen-specific antibody titres, an ELISA 
was conducted using pooled sera collected after each immunisation, and the PST-
tagged PyCSP B cell repeat peptide as the capture antigen (Figure 19A). Consistent 
with the previous study (section 3.4.3.2), this data indicated that a second VLP 
immunisation was required for VLP induced robust antibody responses. The 
DNA/VLP regimen with only a single dose of VLPs had an endpoint titre of only 
12.5% of that of the pooled VLP homologous regimen. DNA immunisations are poor 
at inducing antibody responses, and consistent with earlier results (Figure 12), 
peptides with and without DNA priming were also ineffective.  
 
 
 
Figure 19: Immunisation induced 
anti-B cell peptide and PyCSP 
antibody responses. Mice 
(n=5/group) were immunised as 
previously described (Figure 15). (A) 
Sera collected pre-immunisation (0) 
and following successive doses (1,2 
and 3) was pooled then used with 
ELISA to detect PyCSP B cell 
peptide-specific total IgG endpoint 
titres. (B) PyCSP recombinant 
protein-specific IgG endpoint titres 
were determined by ELISA using 
pooled sera collected following the 
final immunisation. 
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To confirm that the chimeric VLP induced antibodies were able to recognise PyCSP 
protein in addition to peptide epitope, an ELISA was conducted using PyCSP 
recombinant protein as the capture antigen (Figure 19B). Using pooled sera 
collected after the final immunisation, a high anti-PyCSP antibody titre was present 
in mice immunised with three doses of pooled VLPs. A low endpoint titre was 
detected in the DNA/VLP immunised mice receiving only a single VLP immunisation. 
Using individual sera against the PST-tagged PyCSP B cell repeat peptide (Figure 
13), the pooled VLP endpoint titre was significantly higher than DNA alone or the 
DNA/VLP regimen (p<0.0001). 
3.4.4.3. Protection 
 
Figure 20: Protective capacity induced by individual (30 µg) or pooled (30 µg each) 
chimeric VLPs using homologous or heterologous immunisation regimens. Mice 
(n=5/group) were immunised as previously described (Figure 15). Mice were challenged 16 
days after the final immunisation with i.v. injection of 1000 P. yoelii 17XNL cryopreserved 
sporozoites. Parasite burden was assessed by qRT-PCR analysis of Py18s RNA extracted 
from livers harvested 42 h post-challenge and calculated as a ratio to the GAPDH 
housekeeping-gene RNA. Data was normalised to the PBS control and presented as a 
relative parasite burden. Individual results are shown with bars representing the group mean. 
Log-transformed ratio data was analysed using one-way ANOVA followed by Bonferroni‟s 
post-hoc test. p<0.01 ** 
To evaluate the protective efficacy of chimeric VLPs with the higher dose of pooled 
VLP constructs (30 µg each), immunised mice (n=5/group) from each group were 
challenged with 1000 sporozoites, then parasite RNA was quantified from 
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homogenised livers using qRT-PCR286. A significant reduction in the ratio of parasite 
Py18S RNA to mouse GAPDH RNA was noted in mice immunised with the 
heterologous DNA prime and pooled VLP boost (p<0.01) (Figure 20). This equates 
to a mean 72% reduction in the liver parasite burden relative to the PBS immunised 
group. Whilst protection in the pooled VLP immunised mice did not reach 
significance, there was a mean 57% reduction in liver-stage parasite burden relative 
to the PBS control.  
3.4.5. Chimeric capsomeres  
Next, the immunogenicity and protective capacity of chimeric capsomeres was 
evaluated, in comparison to chimeric VLPs. Due to constraints in the size of this 
study, capsomere immunisations were administered in pools and not individual 
constructs. Capsomeres were co-administered with polyIC as an adjuvant to 
enhance immune responses with a bias towards a Th1 response. Chimeric VLPs 
used in this series of experiments were the same as previously described (section 
3.4.1) and characterised (Figure 7) 
3.4.5.1. Construction of chimeric capsomeres 
Chimeric capsomere constructs were made using the VP1ΔNΔC170 backbone with 
either PyCSP CD8, CD4 or B cell epitope sequences (consistent with VLPs) 
genetically inserted into the N-terminus, the S4 loop, and the C-terminus. Chimeric 
capsomeres were expressed in E. coli then purified using a GST-affinity column 
followed by size exclusion chromatography. Endotoxin was removed using ion-
exchange columns, and then capsomeres were dialysed against PBS. Capsomeres 
lacked the ability to form VLPs and therefore were not analysed by TEM or AF4-
MALS. The predicted molecular weight of each chimera was: CD8 dominant, 61.9 
kDa; CD8 subdominant, 62.8 kDa; CD4 dominant 1, 64.5 kDa; CD4 dominant 2, 64.0 
kDa; CD4 subdominant, 66.2 kDa; and B cell, 62.0 kDa (Appendix F). The yield and 
solubility were similar to the results described for the chimeric VLP constructs with 
low solubility in the CD8 subdominant, CD4 dominant 1 and CD4 dominant 2 
constructs. Due to the low solubility and to maintain consistency with the VLP 
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constructs, only the chimeric PyCSP CD8280-288 dominant, CD459-79 subdominant and 
B cell capsomeres were used in subsequent pooled immunisations.  
 
Figure 21: Protein expression and solubility of chimeric capsomere constructs. 
Rosetta DE3 pLysS E. coli were transformed with plasmid DNA from each chimeric 
VP1ΔNΔC construct. Colony isolates were selected for overnight starter cultures which were 
subsequently used to inoculate 400 ml of TB media with ampicillin [50 µg/ml] and 
chloramphenicol [24 µg/ml] in 2 L baffled flasks. At OD450 ~ 0.5, cultures were cooled in tap 
water for 10 min, and then induced with IPTG [0.2 mM]. Cultures were incubated overnight 
at 26°C with shaking at 180 RPM, then bacteria were harvested by centrifugation and pellets 
lysed by sonication. A total (T) fraction was taken directly from lysed bacteria, whilst the 
soluble (S) fraction was taken from the supernatant of lysed and centrifuged bacteria. 
Fractions were run on a 10% SDS-PAGE gel then stained with coomassie. A molecular 
weight ladder (Novex sharp pre-stained) was run (left lane) in parallel with other samples. 
3.4.5.2. Cellular immunogenicity 
To determine if immunisations with chimeric capsomeres could induce antigen-
specific cellular immune responses, splenocytes from immunised mice were 
harvested and single cell suspensions restimulated for ELISpot, CBA and ICS 
assays. In parallel, chimeric VLPs were evaluated to determine if capsomeres were 
more or less efficacious than VLPs. Additionally, VLPs co-administered with polyIC 
were evaluated to determine if VLP immune responses could be enhance with 
adjuvants. 
92 
 
 
Figure 22: IFN- ELISpot analysis of responses induced by capsomere or VLP 
immunisations. BALB/c mice (n=5/group) received three immunisations at 2 week intervals 
with; (A) wild-type VLPs or wild-type capsomeres (30 µg), pooled chimeric VLPs or 
capsomeres (CD8, CD4 and B cell: 10 µg/construct), or pooled PyCSP peptides (30 
µg/peptide), all co-administered with polyIC (50 µg) by s.c. injections. One group received 
pooled VLPs without adjuvant: or (B) three i.m. doses of PyCSP plasmid DNA (100 µg), or a 
heterologous DNA prime-boost regimen with two i.m. PyCSP plasmid DNA primes followed 
by a single s.c. boost with VLPs or capsomeres as described above, with a PBS injected 
control. Splenocytes (5 x 105/well) were cultured and restimulated with pVR2516 PyCSP 
plasmid DNA transfected and irradiated A20 cells (5 x 104/well) or with irradiated A20 cells 
(1.5 x 105/well) with individual or pooled PyCSP CD8 (280-288) CD4 (58-79) and B cell peptides, 
or for 40 h. IFN- spot forming cells (SFCs) were quantified with data displayed as mean 
SFCs per 106 splenocytes + SEM. Statistical comparisons made to the PBS injected control 
group, and between immunisation groups with significance determined using one-way 
ANOVA followed by Bonferroni‟s post-test. p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 
****. 
Like VLPs, capsomeres induced significant IFN- responses following restimulation 
with either PyCSP transfected A20 cells, PyCSP CD8280-288 peptide or pooled 
(CD8280-288, CD459-79 and B cell) peptides (p<0.0001) as compared to the PBS control 
group (Figure 22). There were no significant differences between responses induced 
by immunisations with capsomeres versus VLPs. There were only minor and non-
significant differences with any of the vaccine groups immunised with the 
homologous (Figure 22A) or heterologous DNA prime-boost regimen (Figure 22B). 
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However, significant increases were detected in the heterologous groups boosted as 
compared to respective homologous immunisations with capsomeres (p<0.001), 
VLPs and VLPs with polyIC (p<0.0001) following PyCSP transfected A20 
restimulation, or capsomeres (p<0.01), VLPs and VLPs with polyIC (p<0.0001) 
following peptide restimulation. 
When splenocytes were stimulated with either PyCSP CD8280-288 or CD459-79 
peptides, it was apparent that most of the capsomere and VLP immunisation 
responses were directed to the CD8+280-288 T cell epitope (Figure 22). The peptide-
specific response induced by capsomeres was similar to that induced by peptide 
formulated in adjuvant for the CD8280-288 peptide, but was significantly lower for the 
CD459-79 peptide. Notably, the capsomeres did induce a significant IFN- response to 
the CD459-79 peptide, relative to the PBS control (p<0.0001). The highest IFN- 
responses were induced by the heterologous DNA primed/VLP and polyIC boost 
regimen. However, these responses weren‟t significantly higher than the groups 
immunised with heterologous DNA/capsomeres or DNA/VLPs, or with three doses of 
PyCSP plasmid DNA alone, each of which had a similar magnitude of response.  
A broad array of cytokines including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-
13, TNF and IFN- were assayed by CBA using pooled culture supernatant. Most 
cytokine levels at or near the level of detection for this assay (data not presented). 
Robust IFN- and TNF responses were detected in individual culture supernatants 
(Figure 23). The IFN- profile was similar to that detected by ELISPOT (Figure 22). 
Significant levels of IFN- detected as compared to the naive control group (p<0.001) 
for all capsomere and VLP groups. Capsomeres did not induce a TNF response 
against either peptide, whereas VLP immunisations did induce a response against 
both peptides.  
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Figure 23: IFN- or TNF expression induced by chimeric capsomere or VLP 
immunisations. BALB/c mice (n=5/group) were immunised as previously described (Figure 
22). Splenocytes (5 x 105/well) were cultured with irradiated A20 cells (1.5 x 105) and 
restimulated with either individual or pooled PyCSP CD8280-288, CD458-79, and B cell peptides 
and incubated for 72 h. Culture supernatant was assayed using a cytometric bead array to 
quantify IFN- and TNF cytokine levels. Data is separated into mice receiving no plasmid 
DNA primes (left) or those receiving the prime/boost regimen (right) and displayed as mean 
pg/ml + SEM. Statistical comparisons were made to the PBS injected control group. 
Significance was determined using one-way ANOVA followed by Bonferroni‟s post-test. 
p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****.  
Consistent with the ELISpot and CBA data, ICS data showed that capsomere 
immunisations induce IFN- but not TNF responses with the IFN- predominantly 
being generated by CD8+ T cells (Figure 24). Significant responses were detected in 
DNA prime/capsomere boost regimens, but increases appear to be a result of the 
DNA priming as opposed to the capsomere boost. 
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Figure 24: IFN- and TNF expressing T cells induced by chimeric capsomere or VLP 
immunisations. BALB/c mice (n=5/group) were immunised as previously described (Figure 
22). Splenocytes (5 x 105/well) were cultured with irradiated A20 cells which had been either 
transfected with PyCSP plasmid DNA, or incubated with pooled PyCSP CD8280-288, CD458-79 
and B cell peptides for 6 h with 0.1% Golgi Plug supplemented media. Cells were stained for 
CD8 and CD4 receptors, then permeabilized and stained for IFN- and TNF cytokines then 
analysed by flow cytometry. The frequency of CD8 or CD4 positive cytokine expressing cells 
are shown as the group mean + SEM (n=5 mice/group) with CD8+ and CD4+ T cells 
represented by solid black bars or empty bars respectively. Statistical comparisons are 
made to the PBS injected control group with significance determined using one-way ANOVA 
with Bonferroni‟s post-test. p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****.  
3.4.5.3. Antibody responses 
ELISA assays against the PST- PyCSP B cell repeat peptide were performed using 
individual mouse sera collected 10 days following the final immunisation (Figure 
25A). Capsomere or VLP ± polyIC immunisations all induced significant antibody 
titres when compared to the PBS control group (p<0.0001), but capsomeres were 
significantly less effective than VLPs (p<0.05) or VLPs with polyIC (p<0.01). In 
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contrast to cellular immune responses, antibody responses were reduced by 
heterologous immunisations with VLP relative to the homologous regimen (p<0.01). 
However, antibody responses were increased by heterologous immunisation with a 
capsomere boost, relative to the homologous regimen. VLPs co-administered with 
polyIC induced the highest IgG antibody titres, however, these were not significantly 
increased relative to VLPs without polyIC. 
 
Figure 25: IgG antibody responses against the PyCSP B cell peptide and PyCSP 
protein following capsomere or VLP immunisations. Mice (n=10/group) were immunised 
as previously described (Figure 22). Sera collected from mice five days after final 
immunisation was analysed by ELISA. (A) Using a PyCSP B cell repeat epitope linked to a 
polystyrene binding tag as a capture antigen, individual IgG endpoint titres were determined. 
(B) Using PyCSP protein as the capture antigen, IgG endpoint titres were detected with 
pooled sera. Data is displayed as mean endpoint titre + SEM. Inter-group significance was 
determined using log-transformed data analysed using one-way ANOVA followed by 
Bonferroni‟s post-test. p<0.05 *, p<0.01 **, and p<0.001 ***. 
To confirm that the antibodies induced by capsomeres and VLPs could recognise the 
native PyCSP protein, pooled sera collected after the final immunisation was 
assayed using ELISA with the recombinant protein as the capture antigen (Figure 
25B). Higher endpoint titres were detected with a profile similar to those obtained 
against the B cell peptide (Figure 25A). 
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Figure 26: Dose-related antibody responses and isotype differentiation induced by 
capsomere or VLP immunisations. Sera was collected from BALB/c mice (n=5/group) 
following each immunisation of VLP, capsomeres or peptides in a three dose homologous or 
a heterologous PyCSP DNA prime boost regimen. Pooled sera was analysed by ELISA 
using the PyCSP B cell repeat epitope linked to a polystyrene binding tag as the capture 
antigen. (A) Immunisation related peptide-specific total IgG titres were assessed using sera 
collected following each immunisation. (B) Sera collected 5 days after the final immunisation 
was used to assess peptide-specific IgG1, IgG2a, IgG2b and IgG3 antibody isotypes. 
The kinetics of the antibody responses were investigated using pooled sera collected 
after each immunisation, IgG responses to the PyCSP B cell repeat peptide (Figure 
26A). Antibody titres increased in each of the homologous capsomere and VLP 
immunisation groups after successive immunisations. In groups receiving the 
heterologous regimen, DNA primes induced low antibody responses which were 
increased by boosting with capsomeres or VLPs but only with the co-administration 
of polyIC. 
Antibody isotype responses against the PyCSP B cell repeat peptide were also 
determined (Figure 26B). Capsomeres, VLPs and VLPs with polyIC induce similar 
IgG1 responses; however, it was only the VLP groups where IgG3 responses were 
detected. The homologous VLP immunisation groups had higher levels of IgG3 but 
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similar levels of IgG1 indicating that doses 2 and 3 shift responses towards an IgG3 
bias. IgG2a responses are increased with the inclusion of polyIC in the VLP but not 
with the capsomere mice. Moderate IgG2a responses were also present in the DNA 
group and the heterologous DNA prime groups. 
 
 
 
 
Figure 27: IgG3 responses following 
capsomere or VLP immunisations. 
BALB/c mice (n=5/group) were 
immunised three times with 
capsomeres with polyIC, VLPs ± 
polyIC, or B cell VLPs. Five days after 
the final boost sera from individual 
mice was collected, diluted 1:400 and analysed for IgG3 antibodies specific for the PyCSP B 
cell repeat epitope linked to a polystyrene binding tag. Plates were developed and OD450 
values are displayed for individual mice with bars representing the group mean. Inter-group 
significance was determined using one-way ANOVA followed by Bonferroni‟s post-test 
p<0.0001 ****. 
To confirm that the IgG3 response was consistent within groups, an ELISA against 
the PyCSP B cell repeat peptide was conducted with individual sera obtained after 
the final immunisation (Figure 27). In this assay, individual sera from mice 
immunised with B cell VLPs (only) in the first series of experiments were also 
included. Mice immunised with B cell VLPs or pooled VLPs ± polyIC had significant 
increases in IgG3 when compared to the capsomere immunised sera (p<0.0001). 
The capsomere induced IgG3 titre was not significantly different to the wild type VLP 
control (p>0.05). 
To confirm that induced antibodies recognised native sporozoites, an IFAT was 
conducted using P. yoelii 17XNL sporozoites, with pooled sera from mice immunised 
with capsomeres, VLPs ± polyIC both in the homologous and heterologous 
immunisation regimens (Figure 28). Each of the displayed immunisation groups were 
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considered positive for sporozoite recognition. PyCSP plasmid DNA alone and with 
pooled peptides was also positive, however, the intensity of the staining was lower, 
consistent with the lower titres detected by ELISA (Figure 25). All negative control 
groups and the pooled peptide with polyIC group were negative for surface staining.  
 
Figure 28: IFAT detection of capsomere or VLP immunisation induced anti-sporozoite 
antibodies. Mice (n=10/group) were immunised using a three dose regimen with either 
homologous VLPs, capsomeres or PyCSP plasmid DNA, or a heterologous PyCSP plasmid 
DNA (x2) prime followed by a single VLP or capsomere boost as previously described 
(Figure 22). Sera collected from mice five days after final immunisation was pooled, diluted 
to 1:400 and then used against P. yoelii 17XNL sporozoite coated slides. Slides were then 
stained using FITC conjugated anti-mouse IgG antibodies and viewed on an EVOS 
fluorescence microscope. Scale bars are 10 µm. 
3.4.5.4. Protection 
To evaluate protection, immunised mice were challenged with 1000 P. yoelii 17XNL 
cryopreserved sporozoites. Parasite RNA in homogenised livers detected by qRT-
PCR286 reactions are calculated as a ratio to the mouse GAPDH housekeeping gene 
then normalised to the PBS control (Figure 29). No protection was apparent in any of 
the groups. This lack of protection is consistent with earlier experiments (Figure 14 
and Figure 20), with the exception of the DNA prime/VLP boost regimen which 
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showed protective capacity when the VLP boost included 30 µg of each construct 
(Figure 20). 
 
Figure 29: Protective capacity of chimeric VLPs or capsomeres against sporozoite 
challenge. BALB/c mice (n=5/group) received three immunisations with either homologous 
pooled VLPs or capsomeres, or a heterologous DNA prime-boost regimens. Mice were 
challenged 12 days after the final immunisation with 1000 P. yoelii 17XNL cryopreserved 
sporozoites. Parasite burden was assessed by qRT-PCR analysis of Py18s RNA extracted 
from livers harvested 42 h post-challenge and calculated as a ratio GAPDH housekeeping-
gene RNA. Data was normalised to the PBS control and presented as a relative parasite 
burden. Individual results are shown with bars representing the group mean. No significant 
differences were detected between groups. 
3.5. Discussion 
3.5.1. Chimeric MuPyV VP1-S4-G4S and VP1ΔNΔC expression 
and assembly  
Six chimeric MuPyV VP1-S4-G4S and VP1ΔNΔC constructs were successfully 
generated, each incorporating a single CD8+280-288 T cell
73,75, CD4+59-79 T cell
71,72,74 or 
B cell repeat63 epitope derived from PyCSP. Each chimera was able to produce 
recombinant protein in transformed E. coli as detected on an SDS-PAGE gel. There 
was, however, some variation with regards to the level of protein being expressed 
and importantly for purification, the solubility of the protein (Figure 5). GST-
purification of lysate was performed using only the soluble fraction, and as a result of 
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the low protein solubility associated with the CD8 subdominant, and CD4 dominant 1 
and 2 chimeras, the recovered protein fractions were very low. For the constructs 
under study, each epitope was inserted into the S4 surface-exposed loop on MuPyV 
VP1 flanked by G4S linker sequences173.  
It was anticipated that the insertion of epitopes into this region would be less likely to 
interfere with the VLP formation and surface exposure would optimise the generation 
of target-specific antibodies152,175. However, following the insertion of any epitopes, 
the retention of the protein characteristics and the ability to form VLPs is currently 
unpredictable156,157. This insert disruption effect was clearly displayed by Rueda et 
al.158 when various ovalbumin chimeras with different flanking arrangements resulted 
in highly variable expression. In fact, the variation of a single amino resulted in a 
highly efficient protein expression being reduced to barely detectable levels158. There 
are four surface loops on the MuPyV VP1 protein306 and the insertion site is likely to 
influence the stability of the protein. In one study, epitopes of various sizes were 
inserted into four sites of the HaPyV but only two of the four sites efficiently 
expressed recombinant protein and formed VLPs whereas the other two sites had 
drastically reduced expression176. A similar result was reported using a bovine 
papillomavirus L1 protein where only one of four chimeras formed using loop regions 
resulted in proper formation of VLPs157. In my study four of the six epitopes inserted 
into the S4 surface loop successful formed VLPs, however, only three of these had 
sufficient yields to continue to animal experiments (Figure 7). It is possible that 
alternative insertion sites may have resulted in better expression of the remaining 
constructs. Given that the majority of the epitopes used in this study were targeting 
cellular and not antibody responses, there was no requirement to insert them into 
surface exposed regions, and they could have been inserted in non-exposed 
terminal regions of the VP1 protein. It may be that T cell epitopes bound to terminal 
regions could result in increased T cell immune responses as shown by Crisci et al. 
where ovalbumin CD8 epitopes inserted into N-terminal of rabbit hemorrhagic 
disease virus VLPs resulted in higher IFN-, significantly higher target-specific lysis 
and protection from vaccinia virus expressing OVA protein155. 
The chimeric capsomere constructs had a similar profile to VLPs with regards to the 
level of expression of soluble proteins (Figure 21). It would appear that the reduction 
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in soluble protein expression was directly related to the inserted epitopes. However, 
because the capsomere constructs also had each epitope inserted into the S4 
surface loop, no determination can be made as to the effect of the position of the 
epitope on solubility of the protein. 
3.5.2. Cellular responses 
Whilst the antibody inducing capacity of chimeric MuPyV VLPs and capsomeres has 
been well established170,173,188, their ability to induce epitope-specific T cell 
responses has been as poorly studied.  
In vitro proliferation of CD8+ T cells  
To evaluate the recognition and subsequent proliferation of epitope-specific CD8+ T 
cells, CFSE-stained CS-TCR cells were incubated in vitro with CD8280-288 chimeric 
VLPs and capsomeres. Both constructs induced robust proliferation, confirming that 
the inserted epitope was able to be processed using the MHC class I pathway and 
properly presented to the transgenic T cells. Whilst the processing pathway was not 
determined, it is likely that immature DCs from the naive mouse spleen, have taken 
up the VLPs as a result of their size193, become activated as a result of their self-
adjuvanting highly ordered repetitive array127,130, and by cross-presentation195 have 
displayed the epitope recognised by CS-TCR cells. Capsomeres do not possess the 
same size and structural characteristics as VLPs165,166 and have been shown to 
require the inclusion of adjuvants to enhance antibody generation170,173 and to 
enhance cellular responses179 to levels equivalent to that induced by VLPs. 
However, this adjuvant requirement is not universal with one study showing non-
adjuvanted HPV L1 capsomeres to be potent CTL inducers169. The results with 
MuPyV VLPs and capsomeres (Figure 8) indicate that whilst both platforms resulted 
in CS-TCR proliferation at similar levels, the capsomere induced response 
commenced earlier. This may be a result of the fact that capsomeres have triple the 
amount of the CD8280-288 epitope within the VP1 protein, or due to the location of the 
epitopes at both terminal regions as well as S4 loop in capsomeres, as opposed to 
the VLPs with a single insertion at the S4 loop. These insertion sites have been 
standard for the MuPyV VLP and capsomere constructs used in other 
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models170,173,188. There is no PyCSP CD4+ T cell equivalent model to assess the 
CD459-79 VLP or capsomere constructs. 
Cellular immune responses induced by immunisations with chimeric VLPs or 
capsomeres 
The data presented in this chapter obtained from independent experiments have 
established that immunisations with either CD8280-288 VLP constructs alone, or as 
pooled VLPs were able to induce moderate levels of IFN- production by CD8+ T 
cells. This antigen-specific recognition confirms that the CD8 chimeric VLP had been 
presented post-immunisation to naive CD8+ T cells, and that this presentation was 
via MHC class I molecules195. These results are consistent with previous studies 
reporting chimeric VLPs with a single CD8 epitope induced CTL activity mediated by 
CD8+ T cells155,214. Data from intracellular cytokine staining assays have shown a 
maximum mean frequency of CD8+ T cells expressing IFN- to be 0.59% when mice 
were immunised with pooled VLPs using 30 µg of each construct (Figure 17) which 
may have been insufficient for protection210. There was no evidence to support any 
additive or synergistic effects on CD8+ T cell antigen-specific stimulation when VLPs 
were administered as a pool with the CD459-79 VLP. 
In the studies reported in this chapter, both chimeric capsomeres and VLPs were 
able to induce antigen-specific IFN- responses upon restimulation with the CD8+280-
288 T cell peptide and PyCSP transfected cells as evaluated by ELISpot. 
Capsomeres tended to result in higher magnitude responses which may be a result 
of higher antigen load per construct, or a result of the positioning of epitopes155, or 
due to a reduced anti-carrier effect176. Furthermore, the ICS assay confirmed that the 
bulk of these responses were produced by CD8+ T cells (Figure 24) with a mean 
CD8+ T cell IFN- expressing frequency of only 0.4% with the homologous pooled 
capsomere regimen. The activation of this population confirms that in vivo both 
platforms are capable of inducing CD8+ T cell responses and the CD8280-288 epitopes 
must therefore have been processed and displayed on MHC class I molecules. 
The PyCSP CD4+59-79 T cell epitope has reportedly been able to induce functional 
CD4+ T cell populations of either TH1 or TH2 phenotype capable of inducing T cell 
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proliferation responses and helping antibody responses71. Experimental data 
obtained in the studies reported here show that the chimeric PyCSP CD459-79 VLPs 
could induce only very weak epitope-specific cellular responses. However, 
immunisations with capsomeres presenting the same epitope induced stronger CD4 
peptide-specific cellular response detected in the ELISpot assay (Figure 22). In 
contrast, the response of mice immunised with pooled peptides adjuvanted with 
polyIC were robust. This may be a dose related effect with peptide immunisations 
including 30 µg of the CD459-79 peptide, whilst the epitope component in chimeric 
VLPs and capsomeres was only 0.52 µg and 1.77 µg respectively per dose. It is not 
feasible to increase the VLP dose to nearly 600 µg which would be required to give a 
30 µg epitope equivalent dose. There was little immunological benefit obtained by 
inclusion of the CD459-79 chimeric capsomere or VLP with the pooled immunisations. 
It may have been beneficial to immunise mice with CD8280-288 VLPs combined with 
the CD459-79 peptide in adjuvant which induced epitope-specific robust responses. 
The carrier MuPyV VP1 protein is likely to contain CD4+ T helper epitopes similar to 
those in the HBV core protein152,202, however, those would provide no immunological 
assistance when challenged by the Plasmodium parasite. For this reason, mice were 
immunised with pooled VLPs including the CD459-79 VLP, aiming to induce a 
synergistic CD8+ T cell response by providing CD4+ T cell help for optimal CD8
+ T 
cell effector activity. Data from immunogenicity assays did not show any synergistic 
or additive responses provided by the CD4 helper epitope after restimulation with the 
CD8280-288 peptide or transfected cells. This is likely to be due to the poor induction of 
CD4+ T cell responses by VLPs and capsomeres. Further, increasing the dose from 
10 µg to 30 µg per construct in the pooled VLP groups had minimal effect on 
antigen-specific cellular responses.  
Determination of the appropriate dose for the VLP and capsomere experiments 
relied on earlier experimental data (sections 3.4.3 and 3.4.4) as well as the fact that 
current licensed VLP vaccines contain between 10 to 40 µg of each construct per 
dose137,142-145. Various doses have been utilised in mice experiments. In one study, 
high doses of 100 µg did not significantly improve vaccine effectiveness over a 20 µg 
dose307, but in another 40 µg was significantly better than 8 µg155, although each of 
these used different carrier VLPs. In a study using MuPyV VLPs with intranasal 
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administration, the optimal dose was for IFN- responses was 16.6 µg with only a 
slight decrease with a 5.55 µg dose, whereas an increased dose of 50 µg resulted in 
a greater than 10-fold decrease217 
3.5.3. Antibody responses 
It is well established that VLPs are very effective at inducing antigen-specific 
antibody responses (reviewed in130) perhaps due to their ability cross-link B cell 
surface receptors308 acting in a T cell independent manner309,310. Previous studies 
using chimeric capsomeres with adjuvants, have shown that platform to also be 
strong inducers of antibodies directed against inserted antigens170,173,188. Herein it 
was shown that VLPs induced high IgG titres against the PyCSP B cell epitope. 
These antibody titres increased following successive doses indicative of the 
generation of both memory and plasma B cell responses which in turn suggests the 
involvement of T helper cells311. These T helper epitopes may be carrier related, as 
titres in pooled VLPs were similar to B cell VLP only immunisations. Importantly, at 
least two doses were required for each platform to achieve high IgG titres, with a 
third also beneficial. A single dose was ineffective. This is consistent with other 
studies170,175,217,219 as well as the requirement for three immunisations with licensed 
VLP vaccines125. 
Capsomere immunisations resulted in IgG titres which were significantly less than 
VLPs with and without polyIC (Figure 25). The reduced efficacy of capsomeres 
relative to VLPs is inconsistent with other studies170,173, and is likely a result of the 
adjuvant choice with previous studies using alhydrogel known to be a strong inducer 
of antibodies170,173. PolyIC, however, is known to be an effective adjuvant skewing 
towards a Th1 response, enhancing T cell responses221,312,313. Isotype analysis 
showed that capsomeres generated an IgG1 response but not an IgG3 response 
which was induced with VLPs with and without adjuvant, or an IgG2a and IgG2b 
response induced by VLPs with polyIC (Figure 26). The inclusion of polyIC increased 
titres consistent with previous studies with VLPs with a skewed TH1 isotype profile
221. 
The IgG3 antibody isotype reported here with VLP immunisations contrasts with 
results observed using Group A Streptococcus J8 peptide antigen chimeric VLPs 
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and capsomeres where IgG1 was the dominant IgG isotype and no IgG3 was 
detected173. It would appear therefore, that the development of IgG3 is related to the 
chimeric epitope presented in the VLP structure rather than to the platform itself. In 
the first series of experiments (section 3.4.3), mice immunised with three doses of 
homologous chimeric B cell VLPs had a similar IgG3 responses to those receiving 
pooled VLPs. This established that it wasn‟t the inclusion of the CD8+280-288 or 
CD4+59-79 T cell epitopes in pooled chimeric VLP immunisations that were 
responsible for the IgG3 subclass. We speculate that the IgG3 response present in 
mice immunised with VLPs but not capsomeres, may be related to APC uptake and 
induced activation status. IgG3 antibodies have previously been identified as 
important for protection against various pathogens314,315 including Plasmodium 
parasites300 and IgG3 monoclonal antibodies raised against the PyCSP repeat 
(QGPGAP) have previously protected BALB/c mice from a P. yoelii 17XNL 
sporozoite challenge63.  
Antibodies generated by each platform were capable of recognising the B cell repeat 
epitope, as well as recombinant PyCSP protein as shown by ELISA, and the native 
parasite as shown by IFAT against sporozoites. This shows that the confirmation of 
the epitope was on the VLP was similar to that presented in the context of the native 
protein. 
3.5.4. Impact of adjuvant 
All licensed human VLP based vaccines are administered with aluminium containing 
adjuvants125. The effect of formulating VLPs with adjuvant has been contradictory 
with reports that adjuvants are beneficial316,317 essential216 or not necessary161,188,215. 
In the case of capsomeres, adjuvant inclusion appears to be essential, at least for 
antibody induction170,173,308. To assess adjuvant enhancement of VLPs in this study, 
one group was immunised with VLPs which were co-administered with polyIC. 
PolyIC is a synthetic double-stranded RNA adjuvant which targets TLR3 and has 
previously been used to enhance antibody responses but particularly TH1 T cell 
immune responses in other vaccine platforms294,295,297,312. In our studies, we saw a 
general increase in cellular immune responses when VLPs were co-administered 
with polyIC, however, these were not statistically significant. However, polyIC 
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inclusion resulted in higher antibody titres and included both IgG2a and IgG2b 
isotypes which were not detected in VLP without adjuvant or capsomere regimens.  
3.5.5. Impact of a heterologous prime/boost regimen 
Plasmid DNA encoding PyCSP is immunogenic in mice and is capable of inducing 
sterile protection in BALB/c mice from a low dose sporozoite challenge76. However, 
several studies have shown that plasmid DNA as a homologous delivery platform, 
does not provide complete protection against sporozoite challenge in the murine 
model76,318,319. However, when incorporated in a heterologous prime/boost regimen, 
there are many examples of enhanced immunogenicity and protection with DNA 
prime-boost regimens using various antigen delivery systems encoding the same 
antigen or epitope93,320-324 including VLPs325 as a boost immunogen. Our data show 
that a heterologous prime-boost regimen with either a VLP or a capsomere boost 
was better at inducing cellular responses than the homologous counterpart, 
achieving levels similar to that induced by plasmid DNA alone. The DNA prime/VLP 
with polyIC boost consistently induced the highest cellular immune responses, 
however, these responses were not significantly better than those induced using the 
homologous DNA regimen. The prime-boost gain in induced cellular responses was, 
however, countered by a decrease in antibody titres. In the homologous VLP 
regimen, antibody titres were low after the first dose but were increased with 
subsequent boosts. Therefore a heterologous regimen involving a DNA prime 
followed by multiple VLP boosts would likely result in higher antibody responses and 
maintain robust T cell activity. A second VLP boost may also result in significant 
enhancement of IFN- responses as seen in a previous study217.  
3.5.6. VLP and capsomere induced protective efficacy 
Following sporozoite inoculation from an infected mosquito, or by i.v. challenge, the 
sporozoite tracks to the liver where it invades hepatocytes. During a murine infection 
with P. yoelii, the parasite replicates within the hepatocyte and merozoites are 
subsequently released into the circulation after a minimum of 46 hours326. Livers 
were harvested from mice 42 hours post challenge (section 2.10.3.2) to enable 
maximal opportunity for protective immune responses to clear infected cells, whilst 
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ensuring that the parasites had not left the liver. This published protocol produces a 
reliable quantitative measure of the degree of infection, and hence the degree of 
protection afforded by immunisations286. Infections were not allowed to progress to 
the blood stage as the PyCSP antigens incorporated with the VLP and capsomere 
constructs would not be effective due to the non-expression of CSP during that 
phase of the Plasmodium life-cycle59,60. 
 Despite the levels of cellular and antibody responses generated by mice within the 
various VLP and capsomere immunisation groups, both platforms had a poor 
capacity to confer protection against sporozoite challenge. Liver-stage protection has 
previously been achieved by adoptively transferring a CD8+280-288 T cell clone
299, or 
by passive transfer of monoclonal antibodies specific to the PyCSP central repeat63. 
These protective antigenic epitopes were incorporated within capsomere and VLP 
chimeras, and did generate epitope-specific cellular and antibody responses. In 
studies reported herein, the immunological data supports the potential of VLPs to 
protect, the failure to protect suggests the magnitude of VLP or capsomere induced 
responses were insufficient to reach a protective threshold301. This is consistent with 
other studies where protection correlated with the number of adoptively transferred 
clonal CD8+280-288 T cells where sterile protection was achieved with 20 x 10
6 cells73, 
or with the number of memory CD8+ T cells stimulated by immunisations210,301, or 
with the amount of passive transferred monoclonal antibodies63. 
3.6. Conclusion 
Studies reported in this chapter confirmed that the MuPyV chimeric VLP and 
capsomere platforms were capable of inducing antigen-specific antibody responses, 
and established for the first time in this model, their capacity to induce cellular 
immune responses. IFN- readouts showed that both capsomeres and VLPs induced 
a similar and moderate level of CD8+ T cell responses, although these responses 
were not as robust as those induced by plasmid DNA. In contrast, CD4+ T cell 
responses induced by VLP immunisations were very low, whereas capsomere 
immunisations were modest perhaps as a result of increased epitope concentrations 
or positional changes within the capsomere. High levels of antibody responses were 
generated by immunisations with VLPs with a lower antibody response induced by 
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capsomeres; these responses were markedly better than those induced by plasmid 
DNA alone. The prime/boost regimen incorporating the benefits of each platform, 
produced a broad cellular and antibody; data suggest that this would be further 
enhanced with the inclusion of a second VLP or capsomere boost to raise antibody 
titres. These data support expanding evaluation of VLP and capsomere platforms 
into a wider range of liver-stage Plasmodium antigens targeted by a T cell response. 
In this study only a narrow range of antigenic targets were assessed against a 
complex pathogen with a multi-staged lifecycle an over 5300 putative proteins53. 
Previous studies have suggested that multiple antigen targets may be required for 
protection from Plasmodium challenge111,121,327. With approximately 2000 active 
genes, and 816 identified proteins present during Plasmodium liver-stage of 
infection328 there are an extensive range of targets which could be assessed. 
However, it would be appropriate to first evaluate alternative epitope insertion sites 
within the MuPyV VP1 protein in order to determine if other sites allow for increased 
protein stability and enable high expression of soluble proteins, and further to 
evaluate site-specific immune responses. In the studies reported herein, VLP and 
capsomeres were administered by s.c. injections. Different routes of administration 
of VLPs329 and other platforms has been shown to alter immunological329,330 and 
protective outcomes330 and should also be considered in future studies. 
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Chapter 4: Development of the minicell platform  
4.1. Introduction 
Although bacterial minicells were first reported in the 1930s, it was not until 1966 
when minicells were purified from a mutated strain of E. coli that their research 
potential was realised225,226. Minicells are spherical cell-like structures and are 
comprised of the bacterial cell wall and cytoplasm components of the bacteria222,225. 
They are enzymatically active, but contain no chromosomal DNA so they are unable 
to replicate222,226. Minicells can however, contain plasmid DNA, and have the 
required machinery to produce plasmid-encoded proteins223,224,233,234. Minicells form 
as a result of the incorrect placement of the bacterial septum during cell division 
caused by either disruptions to the minCDE genes or over-expression of the FtsZ 
gene230-232. 
In my studies, the proposed use for minicells as a vaccine delivery platform was to 
deliver recombinant protein antigens and plasmid DNA for mammalian expression of 
the target antigen, and target the minicells to DCs using BsAbs. The E. coli mutant 
minicell producing strains P678-54222, DS410278 and VIP205232, each derived from 
the K12 strain, were obtained for the purpose of this study (section 2.1). P678-54 
was the original mutant strain produced by Adler and colleagues222, and the DS410 
strain was derived from P678-54 after mating it with the Hfr donor CSH74278. Both 
strains constitutively produce minicells. The VIP205 strain was derived by uncoupling 
the FtsZ gene from the natural promoter and placing it under the control of a tac 
promoter in order to control FtsZ protein expression with IPTG232. In this case IPTG 
supplementation was required for normal cell division but increasing IPTG resulted in 
over-expression of FtsZ protein and minicell formation232. 
The originally published minicell purification protocol overlayed a concentrated 
culture on a continuous sucrose gradient resulting in one normal-sized bacteria per 
103 to 104 minicells222. Whilst numerous methods have since been 
utilised225,227,236,331-334, most use a combination of differential low and high force 
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centrifugation, followed by density gradient centrifugation using a linear sucrose 
gradient, as described by Frazer and Curtiss225. This method does not remove all 
contaminating bacteria with approximately 1 bacteria per 105 to 106 minicells 
reported335,336. Whilst this may be satisfactory for genetic or functional analyses, it is 
not acceptable for parenteral administration to animals. Giacalone et al.236,237 
modified the standard purification procedure to include treatment with ciprofloxacin 
which reduced contamination to between 1.5 and 2.0 parent bacteria per 108 
minicells. Subsequently MacDiarmid et al.227 described a minicell purification method 
incorporating differential and density gradient centrifugation with various filtration 
steps, salt induced elongation and antibiotic treatments, removing all viable bacteria.  
Some in vitro studies have shown that phagocytic cells (but not non-phagocytic cells) 
including macrophages and DCs are capable of internalising minicells227,236, 
however, the efficiency of uptake by those cells as determined by expression of 
plasmid-encoded proteins was only between 0.02 and 0.2%236. Efficient receptor 
mediated endocytosis in non-phagocytic cells was, however, observed when 
minicells were targeted to cell receptors including integrins on Cos-7 cells235 and the 
epidermal growth factor receptor (EGFR) on human cancer cells227. In the latter 
study, targeting was achieved using Fc receptor cross-linked monoclonal antibodies 
to EGFR and the O-antigen on the minicell surface227. 
The advantage of targeting delivery of antigens to particular cells is to increase up-
take and reduce dose requirements. There have been many studies showing that 
antigens targeted to various DC receptors can enhance cellular and antibody 
immune responses (reviewed in337,338). Most studies have focused on the DEC205 
endocytic receptor, however, there has been recent interest in targeting the C-type 
lectin Clec9a receptor with studies showing potent induction of CD4+ T cell 
responses339, and high antibody titres without the requirement of DC stimulants340. 
Antigens targeted to either DEC205 or Clec9a can induce CD8+ T cell responses 
and CTL activity if administered with adjuvants for DC activation including LPS and 
polyIC339. 
The minicell OM contains a large amount of LPS which in itself acts as a TLR4 
agonist341 likely to activate DCs. However, LPS causes endotoxic shock when sepsis 
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occurs, and as such it is important that no viable bacteria are administered in minicell 
immunisations. To address safety concerns over the administration of minicells, 
safety studies have been conducted on pigs and showed only minor inflammatory 
responses and fever which were diminished by 4 h and 2 h respectively227. 
Furthermore, studies on mice and dogs have not reported any signs of illness 
following doses of up to 1010 minicells with multiple immunisations227,236-238. 
Importantly, EnGeneIC Ltd (Sydney, Australia) reports that a first-in-man phase I 
clinical trial has recently been completed showing an excellent safety profile for 
minicells (http://www.engeneic.com/profile.html accessed 8 July 2014). 
4.2. Materials and Methods 
4.2.1. Mice 
All animal work for the minicell platform used specific pathogen-free female BALB/c 
mice aged 6-8 weeks, purchased from the Animal Resource Centre (Perth, 
Australia). 
4.2.2. Minicell producing E. coli strains 
Minicell producing E. coli strains VIP205222 and DS410278 were a gift from Dr Miguel 
Vicente, Spanish National Biotechnology Centre, Spain. The E. coli P678-54 strain232 
was a gift from Dr Judya Praszkier, University of Melbourne.  
4.2.3. Vectors 
Table 7: Vectors used in the minicell platform 
Name Expression Antibiotic 
selection 
Protein 
tag 
Comments and source 
pVR1020 Mammalian Kanamycin Nil Empty vector, Vical Inc. 
modVR1020 Mammalian Kanamycin Nil Empty vector pVR1020 with 
additional restriction sites in 
MCS, introduced by Dr. Don 
Gardiner, QIMR 
(unpublished) 
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pIASO Mammalian Chloramphenicol V5 Mod VR1020 modified to be 
chloramphenicol resistant 
and includes a V5 epitope 
(section 4.2.9.1) 
pVRV5 Mammalian Kanamycin V5 ModVR1020 modified to 
include a V5 epitope 
(section 4.2.9.2) 
pBAD/Myc-
His A 
Bacterial Ampicillin c-Myc 
+ His 
Protein expression induced 
by addition of L-arabinose, 
Invitrogen 
pTrcHis2A Bacterial Ampicillin c-Myc 
+ His 
Protein expression induced 
by addition of IPTG, 
Invitrogen 
pDual GC Bacterial 
and 
mammalian 
Kanamycin c-myc 
+ His 
Dual expression vector, 
bacterial expression 
induced by IPTG, 
Stratagene, La Jolla, CA, 
USA 
4.2.4. Plasmid construction for minicell platform 
All plasmid constructs were made using standard molecular cloning techniques as 
described above (section 2.6). Each insert was confirmed by sequencing.  
4.2.5. Molecular cloning of constructs 
Plasmid DNA constructs were generated using standard molecular cloning 
techniques as described in (section 2.6). The PyCSP and PyAMA-1 genes were 
PCR amplified from pVR2516 or P. yoelii 17XNL genomic DNA respectively (section 
2.6.2) and cloned into the pBAD/Myc-His A, pTrcHis2A, pIASO and pVRV5 vectors. 
Chicken ovalbumin cDNA and a fusion gene Tfr-Ova280 were PCR amplified from 
plasmid DNA (section 2.6.2) and cloned into the pDual GC vector. GFP was 
amplified from plasmid DNA and cloned into pBAD/Myc-His A, pTrcHis2A, and pDual 
GC vectors. Finally, RFP was PCR amplified from plasmid DNA and cloned into 
pIASO and pVRV5 vectors. 
4.2.5.1. Bacterial expression plasmids 
For the minicell platform, genes encoding PyCSP, PyAMA-1, and green fluorescent 
protein (GFP) were separately inserted into the vectors pBAD/Myc His 2A and pTrc 
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His 2a both from Invitrogen (Table 7) For recombinant protein expression using the 
Rapid Translation System (RTS; 5 Prime GmbH, Hamburg, Germany) (section 4.2.6) 
both PyCSP and PyAMA-1 genes were separately inserted into pIVEX-HIS/HA279.  
4.2.5.2. Mammalian expression plasmids 
The genes encoding PyCSP, PyAMA-1 and a red fluorescent protein (RFP) were 
separately inserted into the pIASO and pVRV5 vectors (section 4.2.9.2). 
4.2.5.3. Dual expression plasmids  
The pDual GC vector (Table 3) has a single insertion site using restriction enzyme 
Eam1 104, also recognised by the EarI restriction enzyme. This restriction site was 
also present in the ovalbumin and tfr-ovalbumin genes. Following the manufacturer‟s 
guidelines, in gene PCR reactions, dCTP was replaced by 5-methyl-dCTP (NEB). All 
other cloning techniques were as earlier described (section 2.6). Cloning was done 
in Omnimax 2T1 bacteria which are suitable to highly methylated DNA 
transformations. GFP, which did not have any internal Eam1 1011 restriction sites, 
was inserted into pDual GC using standard techniques. 
4.2.6. PyAMA-1 protein expression and purification 
The vector pIVEX-HIS 3.2 vector (Roche Applied Science, Castle Hill, NSW) was 
previously modified so that the expressed protein would include a C-terminal HA tag 
(pIVEX HIS/HA279). The PyAMA-1 gene was ligated into the pIVEX-HIS/HA vector 
then recombinant protein expression utilised the RTS 100 E. coli HY kit (5 Prime 
GmbH, Hamburg, Germany) which is a cell-free protein system using E. coli lysate. 
Following the manufacturer‟s protocol, 50 µl reactions were incubated for 6 h at 25°C 
and 500 RPM in an Eppendorf thermomixer (Eppendorf, NSW, Australia).  
The recombinant PyAMA-1 was purified using 1 ml of cobalt Talon resin (Clontech 
Laboratories Inc., Mountain View, CA). The Talon resin was equilibrated in Talon 
wash buffer (Appendix A) with 8 M urea. The RTS products were pooled and diluted 
in the wash buffer with 8 M urea which was then added to the resin and incubated for 
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20 min at 4°C. The resin was then transferred into an Econo-Pac chromatography 
column (BioRad, CA, USA) and washed twice in wash buffer. To remove endotoxin, 
the column was washed using 10 column volumes of wash buffer including 0.1% 
Triton X-114 at 4°C, then washed with 20 column volumes of wash buffer. The 
protein was then eluted using Talon wash buffer with imidizole increased to 150 mM. 
The elution buffer was then exchanged with PBS by doing three washes using a 4 ml 
10K Amicon ultra filtration tube (Merck Millipore, Billerica, MA). The tubes were 
centrifuged (4000 x g, 15 min) with 4 ml of PBS added after each spin. Finally the 
concentrated protein was diluted in 420 µl of PBS. Protein concentration was then 
measured using a nanodrop spectrometer (Thermo Fischer Scientific) and further 
characterised by western blot using antibodies against the histidine tag.  
4.2.7. Optimisation of minicell culturing conditions 
4.2.7.1. General incubation conditions 
Unless otherwise stated, all incubations were performed at 37°C with shaking of 
liquid cultures at 220 RPM. All media was supplemented with either ampicillin (60 
µg/ml), kanamycin (50 µg/ml), or chloramphenicol (34 µg/ml) alone or in 
combination, as appropriate for selection of transformants.  
4.2.7.2. Incubation conditions for E. coli VIP205 
E. coli VIP205 contains the FtsZ gene in the bacterial genome which is under the 
control of the bacterial Ptac lacIq expression system232. As a result, IPTG is required 
for FtsZ gene expression required for binary fission, and excessive IPTG results in 
over-expression of the FtsZ gene resulting in the formation of minicells. For regular 
growth conditions, the media was supplemented with kanamycin (50 µg/ml) and 
IPTG (10 µM). For the formation of minicells, the concentration of IPTG was 
increased to 30 µM. This strain is resistant to kanamycin. 
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4.2.7.3. Single and dual transformations 
Each minicell producing E. coli strain was made competent using protocols standard 
for traditional cloning as previously described (Section 2.6.1). Competent bacteria 
were transformed with bacterial expression plasmids or dual transformed with 
bacterial and mammalian expression plasmids (section 4.2.3). In some cases, a two-
step procedure was adopted where bacteria were transformed with a single plasmid, 
returned to a competent state, and then transformed with the second plasmid. 
Green fluorescent protein (GFP) was used as a model for protein production. GFP 
plasmids in pBAD, pTRCHis2A and pDUAL GC (Table 7) were used as single 
transformants, or coupled with pIASO or pVRV5 plasmids with red fluorescent 
protein (RFP) as double transformants. Transformed colonies isolated on agar plates 
with appropriate antibiotic selection were used to inoculate starter cultures which 
were incubated overnight in LB media with selection antibiotics. These were 
subsequently used to inoculate LB media and the bacterial culture grown until the 
OD600 was approximately 0.5. Cultures were then induced to express GFP using 
either L-arabinose (Sigma-Aldrich, MO, USA) or IPTG (Promega, WI, USA) at 
various concentrations and incubated at either 26°C or 37°C and 220 RPM to 
investigate optimal culture conditions for protein expression. Culture samples were 
taken before and at various time-points after induction and snap frozen on dry ice. 
These samples were centrifuged (4000 x g, 5 min) and resuspended in PBS then 
analysed by flow cytometry to assess the percentage of GFP expressing bacteria as 
well as the GFP median fluorescence intensity. 
4.2.7.4. Growth media 
To assess the influence of culture media on protein and minicell yield, pDual GC-
GFP transformed minicell producing E. coli were grown in LB, TB, 2YT or BHI media. 
A transformed colony isolate was vortexed in LB and then used to inoculate each 
type of media to generate a starter culture. This starter culture was incubated 
overnight then used to inoculate media (the same media as the starter culture) and 
the bacterial culture grown until the OD600 was approximately 0.5. Cultures were then 
induced with a titration of IPTG at 0, 0.2, 0.5 and 1 mM, and incubated overnight. 
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OD600 was determined and the median fluorescence intensity of GFP measured 
using flow cytometry with minicells gated on forward and side scatter. Minicells were 
purified by differential centrifugation followed by an OptiPrep density gradient 
centrifugation (section 4.2.8) then visualised using the EVOS microscope (Advanced 
Microscopy Group, USA) using the x 40 objective and either bright-field or GFP 
fluorescence settings. Minicells were quantified based on the OD600 (section 4.2.8). 
4.2.7.5. Temperature conditions 
The effect of incubation temperature on protein yield was assessed using five 
colonies from DS410 and P678-54 strains either single or dual transformed with 
pTrcHis2A-GFP and pVRV5-RFP. Starter cultures were grown until reaching an 
OD600 ~ 0.5. Cultures were then induced with 0.5 mM IPTG and incubated overnight 
at 26 or 37°C. The percentage of bacteria expressing GFP and the median 
fluorescence intensity (MFI) of GFP was determined by flow cytometry as described 
above. 
In a separate experiment, a colony of DS410 transformed with pDUAL GC-OVA was 
used to inoculate 4 L of LB broth which was incubated until OD600 ~ 0.5. Half of the 
culture was then cooled in tap water for 10 min with mixing and then induced with 0.5 
mM IPTG and incubated overnight at 26°C and 200 RPM. The other half was 
maintained at 37°C and induced with 0.5 mM IPTG and incubated overnight at 200 
RPM. Minicells were then purified as described in section 4.2.8, and the amount of 
minicells was quantified for each condition. Purified minicells were used for a 
western blot (section 2.8) using anti-His peroxidase (Roche Diagnostics, Germany) 
and developed using Amersham ECL Prime western blot detection reagent (GE 
Healthcare, PA, USA). A serial dilution of maltose binding protein (MBP, 42.5 kDa) 
with a histidine tag was run in adjoining lanes to quantify the expressed OVA protein 
in minicells. 
4.2.8. Minicell purification 
For large-scale cultivation prior to purification, transformed E. coli DS410 were used 
to make starter cultures which were in-turn used to inoculate 400 ml of LB in 1 L 
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bottles. Cultures were incubated at 37°C and 200 RPM until an OD600~0.5 was 
reached, at which time IPTG [0.5 mM] was added, and the incubations continued 
overnight. 
Cultures were cooled to 4°C and then centrifuged (1500 x g, 15 min, 4°C) in 1L 
centrifuge bottles using a JLA 8-1000 rotor (Beckman Coulter, CA, USA). The 
supernatant was harvested and then re-centrifuged (15000 x g, 45 min, 4°C). The 
pellets were resuspended in working media (150 mM NaCl + 30 mM Tris-HCl + 3 
mM EDTA in milliQ water) at 10 ml per L of culture. A discontinuous 5-25% 
OptiPrep™ gradient was prepared in 50 ml polycarbonate screw cap centrifuge 
bottles, using the OptiPrep™ density gradient medium (Axis-Shield, Oslo, Norway) in 
diluent media (150 mM NaCl + 10 mM Tris-HCl + 1 mM EDTA in milliQ water). Six ml 
of the resuspended pellet was then layered on top of the discontinuous OptiPrep™ 
gradient and centrifuged (1500 x g, 45 min, 4°C) in a JS-13.1 swinging bucket rotor 
(Beckman Coulter) with slow acceleration and no brake. Minicells were detected by 
microscopic examination in the 5% to 10% OptiPrep™ bands. These layers were 
harvested, diluted in working media and then centrifuged (15000 x g, 15 min, 4°C) in 
the JS-13.1 rotor to pellet. Media used during centrifugation was kept chilled. 
Pellets were resuspended in 10 ml of LB broth with selection antibiotics and 0.5 mM 
IPTG, and then incubated for 1 h at 37°C and 200 RPM. The NaCl concentration 
was then increased to 0.8 M and cultures incubated for a further 3 h. To kill 
remaining parent bacteria, the cultures were treated with gentamycin (200 µg/ml) 
and chloramphenicol (34 µg/ml), followed by a further 3 h incubation. 
The cultures were then diluted in working media and centrifuged (15000 x g, 15 min, 
4°C). Pellets were resuspended in working media at 6 ml per L of original culture and 
then layered on top of a density gradient and centrifuged as described above. The 
minicell layers were harvested then diluted in working media and centrifuged (15000 
x g, 15 min, 4°C). The pellet was resuspended in saline with 100 mM D-trehalose 
(Sigma-Aldrich, USA) as a lyoprotectant at 5 ml per L of culture.  
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The quantification of minicells was calculated using the formula 235 
                                         
   
To confirm the absence of viable parent bacteria, 1010 minicells were spread onto an 
antibiotic free agar plate and incubated overnight at 37°C. Minicells were frozen at -
70°C then freeze-dried and stored at -70°C. 
4.2.9. Vector construction 
4.2.9.1. Construction of pIASO 
The designed minicell platform required bacteria to transformed with a mammalian 
expression vector. It was intended to use the modVR1020 (D. Gardiner, 
unpublished) which is a modified version of the pVR1020 (Vical Inc., CA, USA) 
vector which has kanamycin as a selection marker (Table 3). However, the minicell 
producing E. coli VIP205 is resistant to kanamycin, making the strain incompatible 
with the vector. It was therefore necessary to modify the vector by changing the 
antibiotic resistance gene. The kanamycin resistance gene was not flanked with 
restriction sites so the antibiotic resistance genes could not be simply digested and 
ligated. Instead a multi-staged reconstruction was required, as depicted (Figure 30). 
For the purpose of adding restriction sites which flank the antibiotic resistance gene, 
primers were designed to PCR amplify regions A and C from modVR1020 with each 
primer including either vector-specific SpeI or BglII restriction sites or new restriction 
sites ApaI or MfeI (Appendix D). Also primers including ApaI or MfeI (Appendix D) 
were used to PCR amplify the region B(2) chloramphenicol resistance gene from a 
Gateway entry vector (Invitrogen). 
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Figure 30: Schematic following the construction of the pIASO vector. (A) Regions A, 
B(2) and C were PCR amplified using primers designed to introduce restriction sites MfeI and 
ApaI. (B) The purified PCR products were digested with MfeI and ApaI restriction enzymes 
and ligated with T4 DNA ligase. The ligation mix was used as a PCR template for 
amplification of the ligated product. The purified PCR was then A-tailed and ligated into the 
pGEMT vector. (C) The pGEMT A+B(2)+C was purified following clonal expansion, then this 
vector and modVR1020 was digested with SpeI and BglII restriction enzymes. The combined 
A, B(2) and C was ligated to region D using T4 DNA ligase. (D) The vector was digested 
using BglII and NotI restriction enzymes and the annealed V5 oligonucleotides were ligated 
into the vector using T4 DNA ligase. The resulting vector was chloramphenicol resistant and 
has the V5 epitope at the c-terminal of the multiple cloning site. 
Each region was PCR amplified, using a standard 50 µl PCR mix (section 2.6.2) 
using 1 µl of 10 µM forward and reverse primers corresponding to region (Appendix 
D). PCR reactions followed the standard protocol (section 2.6.2) using 30 cycles with 
a 50°C annealing temperature and a 2 min extension. PCR products were loaded 
into a 0.8% agarose gel and separated by electrophoresis. Bands of the appropriate 
size (region A 1880 bases, region B(2) 680 bases, region C 654 bases) were excised 
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and purified using the QIAquick gel extraction kit (Qiagen, Valencia, CA, USA) 
following the manufacturer‟s protocol with DNA eluted in water. PCR products from 
each region (Figure 30) were then digested using restriction enzymes specific to 
both primer-encoded palindromes using 10 µl reactions, incubated for 4 h at 37°C. 
Products were separated by electrophoresis and DNA bands extracted as previously 
described. Regions A, B(2) and C were then combined in a 25 µl ligation mix (section 
2.6.3.3) with 400 ng of each digested product and incubated overnight at 16°C. This 
ligation mix was then used as a template for a PCR reaction combining all three 
regions from SpeI to BglII into a single length of DNA at 2850 bases. This PCR 
product was excised from an agarose gel as described above. 
The A, B(2) and C combined product was then A-tailed and ligated into the 
intermediate pGEMT vector (Promega Corporation, USA), following the 
manufacturer‟s protocol. Ligated product was then transformed into chemically 
competent E. coli DH5α by heat shock (section 2.6.3.4) and incubated overnight on 
LB agar plates with 60 µg/ml of ampicillin with IPTG and x-gal for blue/white insert 
screening. White colonies were screened by colony PCR (section 2.6.3.5) to confirm 
the presence of inserts. A selected PCR positive colony was incubated overnight in 
LB broth with ampicillin then plasmid DNA extracted (section 2.6.3.6). 
The pGEMT-AB(2)C and modVR1020 vectors were then digested with both SpeI and 
BglII restriction enzymes (section 2.6.3.2) then excised from an agarose gel as 
described above. A ligation reaction (section 2.6.3.3) in a 6:1 ratio (modVR1020 
region D:AB(2)C) was transformed into E. coli DH5α (section 2.6.3.4) then incubated 
overnight on LB agar plates with 25 µg/ml chloramphenicol. Colony PCR on isolates 
was used to confirmed the presence of the B(2) chloramphenicol resistance gene. 
Complimentary primers were designed to encode the V5 epitope and to have 
overhanging NotI (5‟) and BglII (3‟) regions complimentary to BglII and NotI digested 
DNA for direct ligation. These primers were annealed by combining 1 µl of each at 
10 mM, with18 µl of water in a PCR tube. Samples were heated to 94°C and then 
cooled by 1°C/min to 20°C. Purified chloramphenicol resistant modVR1020 was 
digested with BglII and NotI restriction enzymes and gel extracted. The insert was 
ligated into the vector (section 2.6.3.3) in a 6:1 ratio (V5 insert:vector) and then 
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transformed into E. coli DH5α (section 2.6.3.4) then incubated overnight on LB agar 
plates with 25 µg/ml chloramphenicol. Colony PCR (section 2.6.3.5) confirmed V5 
insertion. 
To confirm that the vector contained all modifications, the vector was digested using 
pre-existing SpeI and BglII and newly inserted ApaI or MfeI. Fragment lengths were 
then determined by gel electrophoresis. The MCS region was sequenced to confirm 
restriction sites were intact, and that a single V5 epitope was inserted. This vector 
was named pIASO. 
4.2.9.2. Construction of pVRV5 
When using the minicell producing E. coli DS410 and P678-54 strains the antibiotic 
resistance incompatibility as described above with VIP205 was no longer present. It 
was decided to use the original modVR1020 vector and modify it by inserting the V5 
epitope into the C-terminal of the MCS so that host cell produced protein could be 
identified using anti-V5 antibodies. The V5 epitope was inserted into modVR1020 as 
described above for the construction of the pIASO vector. The annealed V5 primers 
were ligated into modVR1020 digested with SpeI and BglII restriction enzymes. All 
incubations were done in media supplemented with kanamycin and the MCS was 
sequenced, confirming a single V5 insert. The vector was named pVRV5. 
4.2.10. Hybridoma generation 
The minicell platform in this study was targeted to DCs using BsAbs. A monoclonal 
antibody against the surface of the minicells was required for inclusion into the 
BsAbs, however, a commercial antibody could not be sourced, so a hybridoma was 
generated. The protocol for hybridoma development was derived from a well 
established protocol described by Harlow and Lane342. Bacterial minicells isolated 
from cultures of E. coli DS410 and E. coli P678-54 were injected i.p. into BALB/c 
mice at a dose of 1010 minicells in saline, with three doses at 3 week intervals. The 
mouse with the highest anti-parent bacterial titre then received 1010 minicells diluted 
in saline, with 100 µl i.v. and 400 µl i.p. injections. Three days later the spleen was 
aseptically extracted and fused with a cultured mouse myeloma cell line SP2/0.  
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A single cell suspension was prepared by passing the spleen through a 100 µm cell 
strainer (BD Falcon) and suspended in 5 ml of serum-free media (SFM) (Invitrogen), 
then centrifuged (100 x g, 5 min, 15°C) and washed 3 times in 5 ml SFM. The fusion 
protocol required that 1/10th of the cells be myeloma cells. Cultured myeloma cells 
were counted, pelleted, and resuspended in 10 ml of SFM and washed three times 
(100 x g, 5 min, 15°C), then resuspended in 20 ml SFM. The splenocytes and 
myeloma cells were combined in a 50 ml tube at a 1:10 ratio and incubated for 5 min 
in a 37°C water bath, and then centrifuged (100 x g, 5 min, 15°C). After removing all 
supernatant, the tube was gently tapped to loosen the pelleted cells. To achieve cell 
fusion, 1 ml of pre-warmed (37°C) hybrimax 50% polyethylene glycol (PEG) 1500 
MW (Sigma-Aldrich, MO, USA) was slowly added and stirred for 1 min, then stirred 
for a further minute. SFM was added at 1 ml/min for 2 min with stirring, and then a 
further 8 ml added over 3 min. SFM was added to a total volume of 45 ml. The cells 
were centrifuged (90 x g, 3 min, 15°C) and resuspended in 40 ml of SFM 
supplemented with 15% FCS and 1:1000 IL-6 supernatant. The cells were then 
transferred into four 96-well flat bottom plates at 100 µl per well, and incubated 
overnight at 37°C and 5% CO2. For hybridoma selection, cells were cultured with 
hypoxanthine-aminopterin-thymidine (HAT; Invitrogen) supplemented hybridoma 
media from the second day. Every three days, 100 µl of well supernatant was 
replaced with fresh HAT supplemented hybridoma media. 
When wells were approximately at 50% confluence, the supernatant was screened 
to assess the presence of antibodies with affinity to parent bacteria. Cultures of both 
bacterial strains were incubated with supernatant, washed and resuspended in anti-
mouse IgG secondary antibody, and then analysed by flow cytometry. Bacteria were 
gated on forward and side scatter, and then wells were assayed for the MFI of the 
secondary antibody fluorochrome. Wells with a high MFI (high affinity) with both 
strains of bacteria, and good cell growth were then sub-cultured in progressively 
larger wells and further screened. 
Selected wells were then single cell sorted using the FACS Aria (BD Biosciences, 
USA) into 96-well plates each with HAT supplemented hybridoma media. Following 
cell growth, supernatant was screened to identify clones producing antibodies to the 
surface of the bacteria. The optimal wells were screened antibody isotypes using a 
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mouse immunoglobulin isotyping kit (BD Biosciences, USA) following the 
manufacturer‟s protocol. Clones were frozen and stored under liquid nitrogen or 
cultured for antibody purification (section 4.2.11 ). 
4.2.11. Antibody purification 
Hybridomas producing antibodies against the LPS endotoxin core (HB-8298, ATCC, 
USA), minicells (section 4.2.10) and DEC-205 (NLDC-145 clone) were cultured in 
tissue culture flasks increasing from 25 cm2 to 175 cm2 in hybridoma culture media 
(Appendix A). Once cells were established in the larger flasks, they were diluted in 1 
L of culture media with FCS decreased to 2%. Cell cultures were continued for 3 
weeks by which time cells were predominantly dead. 
To remove cells and debris, flask contents were centrifuged (300 x g, 10 min, 4°C) 
then the supernatant was filtered using a 0.22 µm bottle-top filter. The filtrate was 
then stirred at 4°C whilst ammonium sulphate was slowly added adding 350 g per 
litre of filtrate (55% saturation). Stirring continued for a further 3 h at 4°C allowing 
time for proteins to precipitate.  
After the mixture was centrifuged (10000 x g, 20 min, 4°C), the supernatant was 
discarded and the pellets combined and resuspended in 200 ml of saturate 
ammonium sulphate diluted to 50% saturation in PBS. This was again centrifuged 
(10000 x g, 20 min, 4°C), and the pellet resuspended in 48 ml of PBS and then 
dialysed using 12,000 to 14,000 MWCO dialysis tubing (Thermo Fisher Scientific, 
MA, USA). The tubing was inserted into 2 L of binding buffer (Appendix A) and 
stirred at 4°C overnight, then for two 4 h periods each in fresh binding buffer. The 
dialysed protein was removed from the dialysis tubing and diluted with 48 ml of 
binding buffer then antibodies were purified using a protein G gamma sepharose 
column (GE Healthcare, PA, USA) and a UV detector (BioRad, CA, USA). All fluids 
were run at 1 ml per min. The column was pre-equilibrated in binding buffer before 
loading the dialysed protein. The column was then washed with binding buffer then 
antibodies were eluted using 0.5 M acetic acid in MilliQ water. Peak fractions were 
collected and pH neutralised to pH 7.0 by adding Tris-HCl pH 9.0, and then filtered 
through a 0.22 µm syringe filter. Antibody quantification was done using a nanodrop 
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2000 (Thermo Fisher Scientific, MA, USA) detecting UV280nm absorbance. Aliquots 
were stored at 4°C. 
4.2.12. Bi-specific antibodies 
4.2.12.1. Formation of bi-specific antibodies 
The formation of bi-specific antibodies (BsAbs) using protein A/G has been 
previously described227, however, the protocol was modified as follows. BsAbs were 
formed by coupling the Fc regions of antibodies using Pierce recombinant protein 
A/G (Thermo Scientific, IL, USA) in a 9:9:1 ratio. Into a 1.5 ml Eppendorf tube, 27 µg 
of α-minicell and 27 µg of either anti-DEC205 or anti-Clec9a antibody was added 
and mixed, followed by 3 µg of protein A/G. The mix was diluted by adding 200 µl of 
saline, and then incubated overnight at 4°C on a rocker.  
4.2.12.2. Coupling bi-specific antibodies to minicells  
Lyophilised minicells (5 x 1010) were resuspended in 250 µl of saline and 50 µl of 
BsAbs, and then incubated for 1 h at RT on a rocker. To remove excess unbound 
antibodies, minicells were centrifuged (13000 x g, 15 min) and the pellet was 
resuspended in 500 µl of saline ready for immunisations. 
4.2.12.3. Confirmation of formation 
Antibodies against minicells and DEC205 were biotinylated using the lightning-link 
biotin conjugation kit (Innova Biosciences, Cambridge, UK) following the 
manufacturer‟s protocol. BsAb conjugates were formed using α-minicells and α-
DEC205 either alone (mono-specific) or combined (bi-specific) with antibodies with 
and without biotinylation. GFP packaged DS410 strain minicells (2 x 109) were 
incubated with 20 µl of 1:100 diluted biotinylated α-minicells and α-DEC205 or with 
20 µl of 1:20 diluted mono-specific or bi-specific antibody conjugates for 1 h at RT on 
a rocker, and then centrifuged (13000 x g, 15 min). Pellets were resuspended in 20 
µl of 1:800 diluted streptavidin-DyLight 649 (Biolegend, USA) and incubated for 20 
min at RT. Controls included unstained minicells and minicells incubated with 
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streptavidin-DyLight 649 only. Minicells were then washed and resuspended in PBS, 
and then analysed on a BD LSR Fortessa (BD Biosciences, CA, USA). Post-
acquisition analysis was done using FlowJo software version 9.4 (Treestar, OR, 
USA). Analysis gates were set using empty minicells and GFP minicells to 
distinguish minicells from debris.  
4.2.13. Confirmation of the presence of plasmid DNA in minicells 
To confirm the presence of plasmid DNA in minicells, a PCR reaction similar to a 
colony PCR (section 2.6.3.5) was performed. DS410 minicells (5 x 109) containing 
pDual-OVA or pDual-Empty (no insert) single transformants, or pTrc-AMA1 and 
pVRV5-AMA1 or pTrc-Empty and pVRV5 empty dual transformants were used in 
each reaction. Minicells were resuspended in 20 µl of water in PCR tubes and 
heated to 94°C for 4 min then vortexed and centrifuged for 30 s. Five microlitres was 
then used in each PCR reaction. Reactions included the T7 forward and pDual GC 
SV40 reverse vector-specific primers for pDual minicells, and the PyAMA1-pVRV5 
forward and reverse primers for dual transformed minicells. Remaining reagents and 
run protocols were as previously described. Samples were separated by 
electrophoresis in 0.8% agarose gels. 
4.2.14. Minicell safety assessment 
4.2.14.1. Immunisation protocols 
Female BALB/c mice (n= 4/group) were immunised with three s.c. or i.p. injections at 
3 week intervals with either DS410 strain empty minicells at 1010, 108 (s.c) or 106 
(s.c.) per dose, or P678-54 strain empty minicells at 1010 (s.c.) per dose, or LPS with 
100 mM trehalose at a dose equivalent to 1010 minicells, or saline with 100 mM 
trehalose. The total volume of each injection was 100 µl. 
4.2.14.2. Weight variation 
Prior to each injection mice were weighed using digital scales, then weighed again 
daily for the next 5 days. To assess weight variance, the daily weight was subtracted 
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from the pre-injection weight and the differential area under the curve (AUC) was 
calculated using GraphPad Prism software version 6.0 (Graph-Pad, CA, USA). 
Statistical comparisons were made between the differential AUC of each group and 
the saline using the same administration route using one-way ANOVA with 
Bonferroni‟s multiple comparisons test. Between groups and between doses 
comparisons were done using two-way ANOVA with Bonferroni‟s multiple 
comparisons test. 
4.2.14.3. Assessment of serum cytokines 
Prior to each injection and 1, 4, 6 and 24 h post-injection, 10 µl of blood was 
collected from the tail tip of each mouse and diluted in 10 µl of MACS buffer in 96-
well V-bottomed plates. Plates were centrifuged (600 x g, 4 min, 4°C) then 5 µl of 
individual and group pooled supernatant was collected and stored at -70°C. Pooled 
supernatant from each group at each time-point was analysed by CBA as previously 
described (section 2.10.1.9). 
4.3. Results 
4.3.1. Purification of minicells 
In the development of the minicell vaccine delivery platform, it was necessary to 
purify minicells from bacterial cultures with a high yield and with no contamination by 
viable parent bacteria. To achieve this, differential centrifugation was employed to 
remove the bulk of the parent bacteria which were pelleted using a slow speed 
centrifugation. The minicell containing supernatant still had a large amount of parent 
bacteria. Next therefore, minicells were further purified using centrifugation coupled 
with a 5 - 25% discontinuous OptiPrep™ density gradient in 2.5% increments. To 
determine the optimal conditions for density gradient separation, samples were 
layered onto a gradient and centrifuged at various forces. The best separation of 
minicells from parent bacteria whilst maintaining a tight minicell band, was achieved 
at 1500 x g (Figure 31A). Minicells were still present in more dense gradient regions, 
however, parent bacteria became increasingly prevalent. Subsequent gradients were 
centrifuged at 1500 x g, with a 5 - 20% discontinuous gradient with 5% increments 
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between layers for ease of production, whilst maintaining visible band separation 
(Figure 31B). 
 
Figure 31: Minicell purification using a density gradient centrifugation. Following 
differential centrifugation the minicell enriched pellet was resuspended and layered onto a 
discontinuous OptiPrep density gradient. (A) Using a wide range of densities and various 
centrifugal forces, bands of minicells with varying degrees of parental bacterial 
contamination were separated. (B) Using the optimal centrifugal force (1500 x g) 
distinguishable zones were formed which were extracted to further enrich minicells. 
Minicell enriched zones were extracted from density gradients and samples were 
viewed under the microscope which confirmed the presence of minicells with only 
minimal parental bacteria. At this stage very few elongated bacteria were detected, 
however, this did not exclude the possibility of freshly divided (hence small) viable 
bacteria. Culturing the harvested fractions allowed time for viable bacteria to 
elongate which was proposed to be enhanced with the increase of NaCl [0.8 M], 
although this effect was not observed using microscopic examination. After the 
subsequent density gradient centrifugation, some parental bacteria were detected in 
lower bands which were excluded. 
Using pDual-GFP transformed DS410 in LB broth with overnight expression at 37°C, 
the minicell yield ranged from 0.73 x 1011 to 2.97 x 1011 and had a mean of 1.82 x 
1011 minicells/L. The yields could be increased using alternative media, however, 
antigen protein yields were also affected by media changes. Purified minicells 
(Figure 32) devoid of contamination by viable parental bacteria were able to be 
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produced using this method for each of the bacterial strains in this study. The size of 
the minicells was determined using transmission electron microscopy and ranged 
between 435 nm to 562 nm. 
 
Figure 32: Microscope images of minicells. Minicell producing E. coli DS410 were 
transformed with pTrcHis2A-GFP cultured and induced with IPTG. (A)+(B) Prior to 
purification minicells can be seen in cultures. (B) Minicells bud off from the polar regions of 
bacteria and are released into the media. (C) The minicells are purified using differential and 
gradient centrifugation. (D) Purified minicells were visualised using transmission electron 
microscopy. Scale bars are (A) 20 µm, (B) + (C) 5 µm and (D) 1 µm. 
4.3.2. Recombinant protein expression 
4.3.2.1. Dual transformation causes reduced protein expression  
A high level of GFP expression was detected when E. coli VIP 205 transformed with 
pBAD-GFP was induced with L-arabinose (Figure 33A). However, GFP expression 
was lost when the bacteria were dual-transformed with pBAD-GFP and pIASO-RFP 
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(Figure 33B). This loss was observed in repeated dual transformations. To confirm 
that this was not a short-term loss of expression due to transformation shock, several 
colonies were passaged over five days with no restoration of GFP expression 
detected. To examine if expression loss was strain-specific, DS410 and P678-54 
strains were transformed with pTrc-GFP with and without pVRV5-RFP. In each strain 
there was a reduction in GFP expression in dual-transformants (Figure 33C). In 
single transformants DS410 strain expressed significantly more GFP than the P678-
54 strain (p<0.0001). Subsequent experiments were done only with the DS410 strain 
based on these expression results. To remove the loss of expression following dual 
transformation, GFP and OVA proteins were cloned into the pDual GC vector which 
has both bacterial and mammalian promoters in a single plasmid. After 6 h or 
overnight induction with IPTG, similar GFP expression to single transformants 
(Figure 33D). 
4.3.2.2. Effect of media on protein expression and minicell yield  
In an effort to enhance both antigen-protein expression and minicell yields, a 
comparison was done using LB, TB, 2YT and BHI culture media. Single colony 
starter cultures were dispersed into the various media and when OD600 ~0.5, induced 
with 0.5 mM IPTG. Using flow cytometry to determine the GFP MFI and fluorescent 
microscopy to visualise expression, it was clear that LB cultures had superior GFP 
expression approximately double the other cultures (Figure 34). The minicell yield 
was however, greatly decreased with less than half that of the TB culture. 
4.3.2.3. Effect of IPTG concentration and induction temperatures on 
protein expression 
Protein expression was induced using various concentrations of IPTG in pDual-GFP 
transformed DS410 bacteria. Leaky expression was evident with GFP being 
expressed without IPTG, but expression was significantly increased at 0.2, 0.5 and 1 
mM IPTG concentrations (Figure 33D). In another experiment using alternative 
media with various IPTG concentrations (Figure 34A), the same trend was observed. 
It was decided to induce later cultures with 0.5 mM IPTG. 
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Figure 33: GFP expression in single and double transformed minicell producing E. 
coli strains. (A) VIP205 transformed with pBAD-GFP were cultured and induced with a 
titration of L-arabinose. Samples taken over 6 h post-induction were analysed for GFP 
expression using flow cytometry to determine the median fluorescence intensity. (B) Dual 
transformation of VIP205 with pBAD-GFP and pIASO-RFP resulted in a reduction of GFP 
intensity and low frequency of GFP expressing cells with data showing overnight (O/N) 
cultures post-induction. (C) DS410 and P678-54 strains transformed with the empty vector 
pTrcHis2A or pTrcHis2A-GFP alone (n=4), or with both pTrcHis2A-GFP and pVRV5 (n=1) 
were induced with 0.5 mM IPTG and cultured for 6 h or O/N then GFP median fluorescence 
intensity was measured using flow cytometry. (D) DS410 transformed with pDual-GFP (n=5) 
were induced with 0.2, 0.5 and 1 mM IPTG then cultured at 37°C (or 26°C where stated). 
Samples taken after 6 h and O/N were analysed by flow cytometry for GFP expression. Data 
is presented as mean + SEM. Significance determined using log transformed data with one-
way ANOVA followed by Bonferroni‟s post-test. p<0.0001 ****. 
To assess if the induction temperature effects on protein yield, induced cultures were 
incubated at either 37°C or 26°C. After 4 h the effect on the frequency of bacteria 
expressing GFP and the GFP MFI was minimal in dual transformed pTrc-GFP and 
pVRV5-RFP DS410 and P678-54 strains (Figure 35A). In subsequent experiments 
using pDual-GFP transformed DS410 there was significant increases in GFP 
intensity at 37°C (Figure 33D). In larger scale cultures of DS410 transformed with 
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pDual-OVA, this temperature protein relationship was observed using a western blot 
with purified minicells (Figure 35B). 
 
Figure 34: The effect of culture media on GFP expression and minicell yield. E. coli 
DS410 was transformed with pDual-GFP then a single colony was used to inoculate BHI, 
2YT, TB or LB media. Cultures were induced with various concentrations of IPTG then 
incubated overnight (O/N) at 37°C and 220 RPM. Minicells were then purified by differential 
and gradient centrifugation only. (A) Cultures either non-induced (0 mM) or induced with 
either 0.2 mM, 0.5 mM or 1 mM of IPTG were analysed by flow cytometry to determine the 
median fluorescence intensity of GFP. (B) Using samples from the 0.5 mM induced cultures, 
minicells were purified and GFP expression was confirmed by fluorescence microscopy 
(left), and brightfield microscopy shows a comparison of minicell yields for different media 
(right). (C) The culture OD600 and minicell yields are shown for the 0.5 mM IPTG induced 
cultures. 
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Figure 35: Effect of temperature on protein expression. (A) E. coli DS410 and p678-54 
transformed with pTrcHis2A-GFP (n=1) or with both pTrcHis2A-GFP and pVRV5-RFP (n=5) 
were cultured in LB at 37°C until OD600 ~ 0.5, and then induced with 0.5 mM IPTG. 
Cultures continued for 4 h at either 26°C or 37°C, and then samples were analysed by flow 
cytometry to determine the frequency of bacteria expressing GFP, and the median 
fluorescence intensity of GFP. (B) Following the same protocol, E. coli DS410 transformed 
with pDual-OVA was cultured in LB, induced with 0.5 mM IPTG followed by overnight 26°C 
or 37°C incubations. Purified OVA minicells (1010) were analysed by western blot with anti-
his detection antibodies. A his-tagged serial-diluted protein standard (µg/well) was run to 
estimate OVA protein yield in each minicell dose. 
4.3.3. Minicells contain both mammalian and bacterial expression 
vectors 
This vaccine platform was designed to deliver both recombinant protein expressed 
by transformed bacteria, and plasmid DNA for mammalian expression of the 
homologous protein. Minicells should contain plasmids for both bacterial and 
mammalian protein expression. To confirm the presence of both plasmids, purified 
minicells were used as a PCR template to amplify insert regions. The expected DNA 
lengths were pDual-OVA (1667 bp) and pDual-Empty (1541 bp), pTrc-AMA1 (2072 
bp) and pVRV5-AMA1 (1692 bp). Agarose gel electrophoresis of the PCR product 
confirmed the presence of respective plasmids (Figure 36). The presence of the 
band using pDual-empty is because an ampicillin resistance gene is located between 
the cloning restriction site. 
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Figure 36: Confirmation of plasmid DNA in purified minicells. E. coli DS410 transformed 
with (A) pDual-OVA or pDual empty vector or with (B) pTrc-AMA1 and pVRV5-AMA1 or 
pTrcHis2A and pVRV5 empty vectors were used as a template for a PCR reaction. 
Amplifications used pDual and pTrc vector-specific, and pVRV5-AMA1 forward and reverse 
primers. Products were separated by electrophoresis on 0.8% agarose gels. A 1kb NEB 
DNA ladder was run in the left lane of each gel. 
4.3.4. Confirmation of bi-specific antibody formation 
Antibodies to the LPS endotoxin core purified from a hybridoma (8298-HB, ATCC) 
failed to show affinity to the surface of DS410 or P678-54 minicells (data not shown). 
Consequently, a hybridoma was generated producing antibodies to an unknown 
antigen on the minicell surface. Affinity was confirmed by flow cytometry using both 
strains as capture antigens.  
For the targeting strategy of this platform, hybridoma produced monoclonal 
antibodies to the surface of the minicells are bound to antibodies to either DEC205 
or Clec9a using protein A/G which binds to the Fc region of antibodies. The 
assessment of BsAb formation required primary antibodies to be biotinylated as 
secondary antibodies used for detection would bind non-specifically to protein A/G. 
Using GFP minicells as a capture target, a BsAb formed with anti-minicell antibodies 
and biotinylated anti-DEC205 successfully targeted minicells and was positive for 
biotinylation (Figure 37). This confirmed that the BsAb comprised both antibodies, 
and was able to retain its ability to bind to the minicell surface. 
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Figure 37: Confirmation of bi-specific antibody formation. Purified GFP expressing 
DS410 minicells were used as a capture antigen in a flow cytometry based assay. Minicells 
and debris was isolated by (A) forward and side scatter and GFP positive events gated using 
non-GFP minicells (left) to remove debris. GFP Minicells were incubated with (B) biotinylated 
primary antibodies against minicells or DEC205 then with streptavidin-Dylight 649 or (C) with 
antibodies conjugated using protein A/G. For BsAb structure confirmation, an anti-minicell 
conjugated to a biotinylated DEC205 was used with secondary streptavidin staining. 
4.3.5. Minicell safety assessment 
Since this novel delivery platform has a high content of LPS which could be 
associated with non-specific toxicity, it was necessary to evaluate health related 
effects on mice following a series of three immunisations. Weights, and serum 
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cytokines, were measured as well as physical examinations looking for signs of 
distress. 
4.3.5.1. Body weight following minicell injections 
Over the duration of the experiment, there was an increase in weight with each 
group including the PBS control groups, without significant inter-group variance 
(Figure 38A). To examine the short term effects, the weight variation of individual 
mice was calculated. The most rapid weight loss occurred on day 1 following the first 
dose with mean group losses in LPS i.p. (10.0%, p<0.0001), LPS s.c. (9.1%, 
p<0.0001) and 1010 minicells i.p (7.3%, p<0.0001) significant to respective starting 
weights. These losses lost significance after day 2, and by day 5 all groups were 
above their starting weight. After the second dose, losses were less extreme in the 
LPS i.p. (6.8%, p<0.001) and 1010 minicells i.p (4.4%, p<0.01) but weight recovery 
was prolonged. This persistent weight reduction was also detected after the third 
dose. Here weight reductions were detected in LPS i.p. (5.0%, p<0.0001) and 1010 
minicells i.p (5.8%, p<0.0001), and for the first time also in s.c. injections of 1010 
DS410 minicells (5.7%, p<0.0001) and P678-54 minicells (4.8%, p<0.0001). 
To assess the prolonged weight difference, individual percentage variations were 
used to calculate the AUC of weight variance for individual mice (Figure 38B). Data 
indicates that for the first and second doses the administration route impacts on 
weight loss with mice receiving i.p. doses tending to lose more percentage of weight. 
There was also a non-significant trend of greater percentage weight reduction as the 
dose of minicells was increase. The strain of minicells did not appear to alter the 
outcome.  
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Figure 38: Weight variation following doses with minicells. BALB/c mice (n=4/group) 
received three doses of DS410 strain minicells at 1010, 108 or 106 minicells per dose (or 
P678-54 were stated), or LPS (endotoxin equivalent of 1010 minicells), or PBS by s.c. or i.p. 
injections at 3 week intervals. (A) Mice were weighed before and then daily after each 
immunisation. Data shows the mean weight for each group. (B) Individual percentage weight 
variation calculated from start weight at each dose was used to calculate the AUC of weight 
variance. Data is shown as min to max whiskers plots. Statistical comparisons were made to 
the PBS control with the same route of administration, using one-way ANOVA followed by 
Bonferroni‟s post-test. p<0.05 *, p<0.01 ** and p<0.001 *** 
4.3.5.2. Serum cytokines following minicell injections 
To look at systemic cytokine responses to injections of minicell, serum was collected 
at various time-points and analysed by CBA. Pooled serum for doses 1 and 3 were 
assayed for multiple cytokines specifically: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-
12p70, IL-13, IFN- and TNF (section 4.2.14.3). For all cytokines except IL-6, IL-10 
and TNF, the detected responses were at or near detection levels, and only minor 
differences were observed between groups or time-points. IL-6, IL-10 and TNF 
138 
 
responses were quantified using pooled serum at individual time-points (Figure 39A) 
and that data used to generate AUC data to evaluate the breadth of response after 
each dose (Figure 39B). There was a large IL-6 response peaking after 6 h in the 
mice injected i.p. with either LPS or 1010 minicells and to a lesser extent LPS s.c. 
These groups also had rapid increases in both IL-10 and TNF with peaks at 1 h. The 
cytokine intensity was greatly decreased following the second and third doses.  
 
Figure 39: Serum cytokine analysis following minicell injections. BALB/c mice 
(n=4/group) received three doses of DS410 strain minicells at 1010, 108 or 106 minicells per 
dose (or P678-54 were stated), or LPS (endotoxin equivalent of 1010 minicells), or PBS by 
s.c. or i.p. injections at 3 week intervals. (A) Serum samples were taken at 0, 1, 4, 6 and 24 
h after each injection. Pooled samples were analysed using a cytometric bead array to 
quantify IL-6, IL-10 and TNF circulating cytokines. (B) The AUC for each cytokine is 
displayed for each dose (1, 2 and 3). 
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This data indicates that the administration route influences the intensity of cytokine 
responses in a similar way as seen with weight variations (Figure 38). The loss of 
cytokine intensity in the second and third doses is consistent with the loss of weight 
reductions. Only minor variations were detected between DS410 and P678-54 
strains and minicell doses. A reduction in IL-6 cytokine responses was evident with 
lower minicell doses. 
4.4. Discussion 
The use of minicells as a delivery vehicle for vaccines incorporating both protein 
antigen and plasmid DNA has recently been evaluated showing the their ability to 
induce antibody and cellular immune responses, as well as protection against LCMV 
challenge236,237. Minicells as a delivery vehicle for chemotherapeutic drugs and 
siRNA has been effective against tumours when minicells are targeted to surface 
receptors of cancerous cells227,238. For several decades, researchers have adopted a 
minicell purification protocol described by Fraser and Curtiss225, which was recently 
improved upon by the inclusion of antibiotics236,237, or with antibiotic treatment, 
filtration and elongation for the complete elimination of viable parent bacteria227,238. 
The purification method developed for this study was based upon the protocol 
reported by MacDiarmid et al.227, however, the filtration steps were removed and 
replaced with the additional gradient centrifugation post-elongation and antibiotic 
treatment for greater purification. At that stage, any parent bacteria should have 
elongated and then been killed. The increased size and density of the parent 
bacteria was sufficient for separation. A spread plate using antibiotic free media and 
1010 minicells confirmed the sterility of purified minicells and fluorescent microscopy 
examination of GFP producing minicells showed an absence of elongated cells. 
4.4.1. Factors effecting minicell and antigenic protein yield 
In order to obtain a high minicell yield with a high antigen protein load, variations to 
bacteria strains, plasmid vectors, culture media and temperature conditions were 
trialled. The production of minicells occurs throughout the growth cycle, with highest 
levels of production in late-log phase and as long as 7 h into the stationary 
phase225,343. Whilst minicells are capable of forming in all media which support 
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growth of the parent bacteria343, optimal yields are achieved using nutrient rich 
media which supports faster growth rates and vigorous aeration343. Experimental 
data supported these established findings, with TB and BHI cultures producing high 
minicell yields as opposed to LB and 2YT media (Figure 34). However, optimal GFP 
yields were achieved using LB media incubated at 26°C post-induction. The reduced 
temperature resulted in slight increases in protein yield but this also reduced the 
growth of the bacteria which would be expectedly reduced minicell yields343. The use 
of LB as media for recombinant protein expression in E. coli is supported by various 
studies344-346, although modifications to broth formulations are capable of enhancing 
yields347. A review of the literature did not reveal a single media formulation which 
would be universally beneficial to increase recombinant protein yield, with media 
selection dependant on the protein of interest.  
Codon optimisation for E.coli was considered as a possible cause of the low protein 
yield. It is well established that different organisms carry their own codon bias and 
that the lack of transfer RNA (tRNA) can result in difficulties in the expression of 
recombinant proteins348,349. An analysis of PyAMA-1 and ovalbumin genomic 
sequences, however, shows that low frequencies of rare E. coli K12 tRNA codons 
are present. It is possible that reducing the frequency of AGA (arginine) which was 
present in PyAMA-1 (1.8%) and ovalbumin (2.4%), but only makes up 2.1% of the 
endogenous tRNA population348, could have enhanced protein expression as has 
been shown with other proteins including those from P. falciparum350,351. There are 
however, other possible explanations for the low protein yield including toxicity of the 
recombinant protein to the bacterium349. A study involving E. coli expression of 1000 
P. falciparum genes established that only one-third of the proteins were capable of 
being expressed by the bacterium352. The cause of poor expression rates correlated 
directly with high molecular weight, protein disorder, and the lack of homology to E. 
coli proteins, rather than codon usage and the higher adenosines and thymidines352. 
Codon-optimisation of the target antigens was not performed during these 
experiments, however this option should be considered for future studies. 
This platform was designed to deliver both a bacterial produced antigen protein, 
together with plasmid DNA with a mammalian promoter for expression of the 
homologous antigen post-immunisation. This required bacteria to be transformed 
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with both plasmids done either simultaneously or in stages. Using selective 
antibiotics it was evident that bacteria contained both plasmids, however, the dual 
transformation had an unexpected and large reduction in GFP expression (Figure 33 
and Figure 35). It is possible that the plasmids were incompatible due to competition 
for replication factors353. Whilst it is possible to dual transform with incompatible 
plasmids as long as antibiotic pressure is maintained354, competition pressures may 
result in fluctuations of plasmid copy numbers355 resulting in reduced protein 
expression. To overcome competition factors, compatible plasmids with different 
origins of replication could be utilised356. Another alternative is to use a single 
plasmid which contains the same gene cassette but has within itself, both bacterial 
and mammalian promoters. One such vector was engineered by Giacalone et al. 
where expressed protein and plasmid DNA quantities were very similar in bacterial 
and dual expression vectors236. Using the same system but replacing GFP with the 
LCMV nucleoprotein a reduction in mean protein load from 6.8 µg to 1.2 µg was 
reported in 1010 minicells237, suggesting that protein expression will vary depending 
on the protein itself. With the aim to reduce competing pressures, genes were 
inserted into multiple vectors including pDual GC (Stratagene, USA) which has a 
dual promoter system. In comparing vectors for GFP expression in dual 
transformants or single for pDual GC, variations were observed between vectors with 
pDualGC providing a higher median fluorescence intensity (Figure 33C and D, 
Figure 35A). 
There were four antigen targets planned for assessment in the minicell model, 
however, only PyAMA-1 and ovalbumin minicells produced sufficient protein for 
progression into the mouse model for immunisation studies. In these constructs, the 
antigen load was approximately 1 µg and 0.1 µg per dose of 1010 minicells. Western 
blot analysis was unable to confirm the presence of PyCSP, and only very low 
amounts of the fusion Tfr-ovalbumin protein were detected.  
4.4.2. Targeting dendritic cells using bi-specific antibodies 
The novelty of the proposed minicell platform is the targeted delivery using BsAbs to 
the minicell surface and either DEC205 or Clec9a both of predominantly found on 
DCs and facilitate antigen uptake, processing and presentation340,357,358. The 
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formation of BsAbs required monoclonal antibodies to respective targets. The anti-
minicell antibodies required the generation of a hybridoma as attempts to find a 
commercial antibody with the desired affinity were unsuccessful. The BsAb formation 
was confirmed by flow cytometry using minicells as capture antigens and a BsAb 
comprised of anti-minicell + protein A/G + biotinylated DEC205 with a subsequent 
streptavidin-fluorochrome stain.  
It was anticipated that targeting minicells to DCs would enhance the low level of 
transfection efficiency observed in previous studies236. The bulk of purified E. coli 
minicells has a diameter of between 400 – 500 nm359 similar to the sizes obtained for 
this study as determined by TEM (Figure 32). This size exceeds the DC optimal 
uptake particle size of between 40 – 50 nm as previously described196 and it is this 
limitation which is anticipated to be overcome by inducing receptor-mediated 
endocytosis. This enhanced minicell uptake by targeting surface receptors of non-
phagocytic cells has been reported227,238, however, there are no publications where 
minicells have been targeted to DCs. 
4.4.3. Minicell safety study 
An important step to increasing the safety aspects of this platform was to remove all 
of the viable parent bacteria to limit the chances of the onset of toxic shock. The 
safety study of MacDiarmid et al. used pigs receiving a weekly i.v. dose of 5 x 109 
minicells, and two dogs receiving weekly i.v. doses of 3 x 109 or 1010 minicells227. In 
the dogs, there was no increase in pro-inflammatory TNFα or IL-6 with serum 
samples taken 16 h post injection, and the only adverse effect was a temperature 
increase of 1°C which returned to normal within 4 h227. In pigs, spikes in TNFα and 
IL-6 were observed after the third dose, and returned to background levels within 
24h, and pigs developed a minor fever from which they recovered within 2 h227. The 
dose evaluated herein was up to 1010 minicells delivered to mice with a much lower 
body weight, as such any adverse effects would be expected to be greater. Similar to 
the pig study, there was a rapid onset of the inflammatory cytokines IL-6 and TNF 
which was resolved within 24 h, however, there was a major increase in cytokine 
concentrations. Surprisingly, the induced cytokine responses were observed after 
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the first dose with greatly reduced responses from subsequent doses which is the 
reverse of data from the pig study.  
As a measure of well-being, the weights of mice were recorded for 5 d post 
immunisation. Minicells administered i.p. resulted in mean weight losses of 7.4% 
within 24 h of injection following the initial dose. These losses were generally 
recovered within 5 d observation period. In subsequent doses the severity of weight 
reductions was lessened, however, as seen by the AUC values (Figure 38) the 
reductions were more sustained perhaps as a result in the decreased growth rate of 
the more mature mice. There was no difference between the DS410 and P678-54 
strains, and the responses were influenced by both the dose and administration 
route.  
4.5. Conclusion 
During this study, minicells were purified using a novel technique derived from a 
combination of previous methods225,227, which resulted in a high minicell yield and 
the complete removal of viable bacteria. The use of incompatible plasmid DNA in 
dual transformations was overcome by using a dual promoter vector, and culturing 
conditions were optimised. Whilst optimal minicell yields were achieved using high 
growth media, antigen expression is likely to require optimisation for different 
proteins. The combined weight and cytokine data supports the further evaluation of 
the platform using s.c. route with a 1010 minicell dose.  
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Chapter 5: Evaluation of antigen-specific 
immunogenicity and protective efficacy of 
ovalbumin and PyAMA-1 loaded minicells 
5.1. Introduction 
Minicells are small anucleate cells which can form when the mechanisms for septum 
formation at the mid-point of the bacterium have been disrupted222,226,232. Minicells 
form as a result of the premature formation of the septum at the polar regions of the 
bacterium229,232. The minicells bud off from the parent bacteria with cellular contents 
including cytoplasmic proteins and plasmid DNA, however, they are devoid of 
chromosomal DNA and as such are unable to replicate223,224.  
There has been very limited research done into the vaccine potential of bacterial 
minicells. The first report of the immunological potential of minicells was by 
Tankersley et al.336 in 1974, when Salmonella typhimurium minicells were injected 
into rabbits resulting in antibodies with affinity to both minicells and parent bacteria. 
In 1979, the first study showing the potential for heterologous minicell antigen 
delivery was reported360. In that study, the immunisation of cows with minicells 
containing plasmid-induced K99 antigen proteins prevented fatal diarrhoea against 
challenge with an enterotoxigenic E. coli. However, in the pursuing 27 years almost 
no minicell vaccine related research was conducted.  
In 2006, an E. coli minicell vaccine delivery platform was developed by Giacalone et 
al.235 to deliver both recombinant antigenic protein and plasmid DNA. Their studies 
showed that minicells administered to mice could induce both antibody and cellular 
antigen-specific responses235,237. They also showed in vitro that macrophage cell 
lines J774A.1 and RAW 264.7, as well as BMDM and BMDDCs, were inefficiently 
transfected (between 0.02% to 0.2%)236.  
Whilst DCs are professional APCs and are efficient at the up-take and processing of 
particles up to 2 µm in diameter197, they preferentially take up particles between 40 
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to 50 nm in diameter resulting in the induction of robust antibody and T cell-mediated 
responses196. Minicells produced in this study were between 435 nm and 562 nm in 
diameter (section 4.2.8) which is comparable with previously reported 
dimensions235,360. However, this size falls outside of the preferential range for DCs 
and is more likely to be phagocytised by macrophage cells196, likely explaining the 
inefficient transfection rate in the Giacalone study236. 
In an attempt to overcome this inadequate minicell uptake by APCs, in particular 
DCs, studies in this chapter were designed to directly target minicells to DCs using 
BsAbs to the DEC205 and Clec9a receptors found on DCs. This targeting method 
derives from other minicell studies where chemotherapeutics where packaged in 
minicells and delivered to cancer cells via the epidermal growth factor receptor227,238. 
In those studies, the otherwise non-phagocytic cells took up the targeted minicells 
due to receptor mediated endocytosis. Furthermore, targeting is beneficial in that 
antigens are concentrated to the target cells, in this case professional APCs, 
reducing the required quantity of antigen and increasing vaccine efficacy337. 
Targeting DC receptors including DEC205 and Clec9a with proteins has been shown 
to enhance both cellular358,361-363 and antibody340,364,365 responses against target 
proteins in other models363. In each of those studies, the co-administration of an 
adjuvant with the targeted protein was required for the induction of cellular immune 
responses. Antibody responses could be induced by targeting each receptor, 
however, whilst DEC-205 targeting required an adjuvant364,366, Clec9a induced 
antibody responses were equivalent with or without adjuvant337,340. In the minicell 
platform studied here, the bacterial components of the minicells, in particular the 
TLR4 agonist LPS367, was intended to provide the adjuvant relied upon for DC 
maturation.  
5.2. Experimental design 
OVA minicells and PyAMA-1 minicells were produced in E. coli DS410 as previously 
described (Chapter 4:). The antigen load in these purified minicells was 0.1 µg and 
1.0 µg respectively per 1010 minicell dose. 
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In the ovalbumin studies, PTP mice (n=4-5/group) received an i.v. transfer of 0.3 x 
106 OTI CD8+ and 0.3 x 106 OTII CD4+ T cells. Mice were immunised by three s.c. 
injections at 2 week intervals at the base of the tail with either: ovalbumin loaded 
minicells (OVA minicells) with or without BsAbs to target DEC 205 or a non-specific 
isotype control (LTF2); ovalbumin protein at 100 µg/dose alone, or with either empty 
minicells (1010) or CT (1 µg); negative controls included PBS or empty minicells 
(1010). Blood samples collected 12 days (doses 1 and 2) and 5 days (dose 3) after 
immunisations were analysed by flow cytometry to determine the frequency of 
transferred cells. Six days after the final immunisation, cells obtained from naive PTP 
mice were incubated with or without OVA257-264 peptide (SIINFEKL) and differentially 
stained high and low respectively with VPD450. These cells were transferred i.v. into 
immunised mice (4.75 x 106 cells of each group) and then 24 h later mice were 
sacrificed to quantify frequency of donor OTI and OTII cells in the blood, draining 
lymph nodes (inguinal) and spleen, as well as to assess killing of SIINFEKL-coated 
cells. Sera were collected post-immunisations for detection of ovalbumin-specific 
antibodies via ELISA. 
In the ovalbumin dose titration experiment (section 5.3.3), PTP mice (n=5/group) 
were immunised as described above, however, the original i.v. cell transfer was 
increased to 0.5 x 106 OTI CD8+ and 0.5 x 106 OTII CD4+ T cells, to increase the 
starting population making the transferred cells more detectable in non-proliferation 
immunisation groups. Mice were immunised with either 100 µg, 10 µg or 0.1 µg of 
ovalbumin protein alone or co-administered with CT, empty minicells (1010) or the 
equivalent LPS content of 1010 minicells. Targeted minicell delivery was done using 
BsAbs to Clec9a instead of DEC205. The original project design was to evaluate 
targeting minicells to the DEC205 receptor, however, after the initial experiment we 
obtained an anti-clec9a antibody from the Shortman laboratory at the Walter and 
Elisa Hall Institute in Melbourne. We then wanted to evaluate both targets. One 
group had no adoptive transfer of cells to examine the endogenous killing capacity of 
ovalbumin + CT. 
In the PyAMA-1 minicell experiment (section 5.3.4), BALB/c mice (n=5/group) were 
immunised with three s.c. doses at 3 week intervals with: PyAMA-1 protein and 
plasmid DNA loaded minicells (1010) alone or coupled with BsAbs to either DEC205, 
147 
 
Clec9a or a non-specific isotype control (LTF2); with empty minicells (10
10) with and 
without 1 µg of PyAMA-1 purified protein; or with PBS as a control. The positive 
control mice received two i.m. doses of 100 µg PyAMA-1 plasmid DNA (50 µg per 
tibialis anterior muscle/dose) at 3 week intervals followed by an i.p. boost with 10 µg 
PyAMA-1 protein mixed 1:1 with Alhydrogel96. Sera were collected nine days after 
each immunisation for antibody analysis. Ten days after the final immunisation, mice 
were challenged with 1000 P. yoelii 17XNL sporozoites delivered by i.v. injection. 
Blood taken pre and post-challenge was used to assess serum cytokines (section 
2.10.1.7), antibodies (section 2.10.3.1), and parasitemia (section 2.10.3.1). 
5.3. Results 
The ability of minicells to generate antigen-specific T cell and antibody responses 
was assessed in both murine ovalbumin and malaria models. In the ovalbumin 
model, cellular responses were assessed by proliferation of OTI CD8+ and OTII 
CD4+ T cells in both in vitro and in vivo adoptively transferred models, the latter 
coupled with an in vivo antigen-specific cytolytic assay. Antibody responses specific 
for ovalbumin protein were detected by ELISA. In the malaria model, blood samples 
collected pre- and post-challenge with P. yoelii 17XNL sporozoites were assessed 
for cytokine responses, cell phenotypic activation markers and antibody responses 
by ELISA and a flow cytometry-based IFAT. To assess protection, parasitemia was 
evaluated using the flow cytometric assessment of blood (FCAB) assay. 
5.3.1. In vitro proliferation of OTI or OTII cells by migrating 
dendritic cells 
It was anticipated that following s.c. immunisation with minicells, DCs would migrate 
to lymphocyte rich lymph nodes and spleen, and present processed antigens. These 
migrating DCs would be expected to be high in expression of MHCII and CD11c 
surface receptors which could be quantified by surface staining and flow cytometry 
analysis. Accordingly, OVA minicells with or without BsAbs targeting DEC205 were 
injected into mice and DLNs harvested at 6 h intervals. Data (Figure 40) indicated 
that peak migration occurred at 24 h post-immunisation. The percentages of 
migrating DCs (mDCs) at 24 h were similar between all minicell immunisations with 
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no apparent impact of targeting DEC205. However, there was an increase in mDCs 
in the targeted minicell draining lymph nodes (DLNs) 42 h and 48 h. Only one mouse 
was immunised at each time-point so no statistical comparisons could be made to 
determine the significance of the increase. 
 
Figure 40: Frequency of migrating dendritic cells in draining lymph nodes following 
minicell immunisations. Mice (n=1/condition) were immunised s.c. with ovalbumin (100 µg) 
plus cholera toxin (CT; 1 µg), empty minicells (1010), or ovalbumin minicells (1010) with or 
without bi-specific antibodies targeting DEC205. At various time-points (24h to 48h) post-
immunisation draining lymph nodes were harvested and stained for MHCII and CD11c 
receptors then analysed by flow cytometry. Migrating dendritic cells were classified based on 
high expression of both MHCII and CD11c high. Data shows the frequency of migrating 
dendritic cells. 
To further assess whether these mDCs could take-up, process and display target 
antigen epitopes, an in vitro experiment examined epitope-specific CD8+ or CD4+ T 
cell proliferation using APCs from the DLN of immunised mice. OVA minicells were 
injected into mice (n=5/group), then based on the earlier results (Figure 40), mDCs 
were harvested at 24 h and incubated with CFSE stained OTI CD8+ or OTII CD4+ T 
cells. The number of CD11c+ MHCII+ CD103 high and low cells harvested form DLNs 
were too low for individual analysis, so the lymphocytes for each group were pooled 
for assay. After 72 h, proliferation could only be detected in the positive control mice 
immunised with ovalbumin (100 µg) with CT (Table 8). Proliferation could not be 
detected in any mice that had received ovalbumin minicells. 
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Table 8: MFI of CFSE stained OTI and OTII cells following in vitro stimulation with 
CD11c+ MHCII+ CD103 high and low cells. 
 
To confirm that this lack of detectable proliferation was not a timing issue since all 
DLNs removed at 24 h post-immunisation, in a subsequent experiment mice 
(n=1/condition) were immunised with ovalbumin minicells at 6 hourly intervals 
between 24 h and 48 h before harvesting DLNs. DLN single cell suspensions were 
incubated with CFSE stained OTI or OTII cells and the MFI of CFSE was determined 
(Table 9). Consistent with the previous study, proliferation was only detected with 
ovalbumin (100 µg) co-administered with CT, with no detectable proliferation in any 
of the minicell immunised mice. 
Table 9: MFI of CFSE stained OTI and OTII cells following in vitro stimulation with 
cells from DLNs  
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5.3.2. Evaluation of ovalbumin minicells 
5.3.2.1. Cell-mediated immune responses 
To assess the ability of ovalbumin packaged minicells to be processed, presented 
and recognised by OTI CD8+ T cells (OVA257-264) and OTII CD4
+ T cells (OVA232-339), 
an adoptive transfer experiment quantified the frequency of donor cells over three 
immunisations. The frequency of the transferred cells (Figure 41), distinguishable by 
the CD45.2 (Ly5.2) allele, was determined in peripheral blood samples collected 
post-immunisation.  
Ovalbumin protein (100 µg/dose) co-administered with either CT or empty minicells 
resulted in significant increases in donor cell frequency after the 2nd (OVA + CT 
p<0.01) or 3rd dose (OVA + CT p<0.0001: OVA + Empty p<0.05) with increases 
detected after each dose. Whilst the data indicates similar proliferation mean values 
with both of these groups, there was a greater variance within the ovalbumin + empty 
minicell group (Figure 41).  
The requirement for an adjuvant in this system was indicated by the failure of 
ovalbumin alone (100 µg) to generate significant increases in the frequency of donor 
cells (Figure 41). The minicell component of this platform has adjuvant properties as 
demonstrated by the ovalbumin + empty minicells. Despite this, OVA minicells 
administered with or without bi-specific antibodies to DEC205 failed to generate 
significant increases in frequency of transferred cells. A reasonable assumption was 
formed that this may be a result of the low ovalbumin dose within the minicells which 
was approximately 0.1 µg. This was evaluated in a subsequent ovalbumin dose 
titration experiment (section 5.3.3). 
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Figure 41: Frequency of adoptively transferred T cells in blood post-immunisation. 
Mice (n=4-5/group) received an i.v. transfer of OTI CD8+ and OTII CD4+ T cells (0.3 x 106 
cells of each cell type) followed by three s.c. immunisations at 2 week intervals with either 
OVA minicells (1010) with and without bi-specific antibodies to DEC205 or a non-specific 
target, empty minicells (1010), or ovalbumin protein (100 µg) alone or co-administered with 
either CT (1 µg) or with empty minicells (1010). Blood samples collected 12 days (dose 1 and 
2) or 5 days (dose 3) post-immunisation were stained to detect adoptively transferred cells 
(CD45.2+Vα2+) and analysed by flow cytometry. Data is presented as mean and SEM of the 
frequency of transferred T cells post-immunisation (1, 2 or 3). Statistical significance was 
determined with log transformed data as compared to the PBS group using one-way ANOVA 
followed by Bonferroni‟s post-test p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****. 
To determine if the observed donor cell frequency in the blood was consistent with 
that within the DLN and spleen, site-specific samples were analysed 6 days after the 
final immunisation (Figure 42). The profile of donor cell frequency in the blood was 
consistent with the final dose samples taken 5 days after the final immunisation 
(Figure 41) with the exception of the adjuvanted ovalbumin groups. The donor cell 
frequency in those groups had increased approximately 2-fold in the day between 
taking the blood samples (Figure 42A). This suggests that either donor cell 
proliferation continued after 5 days or that cells were further stimulated by the 
presence of SIINFEKL peptide-coated cells administered for the in vivo CTL assay. 
There was significantly lower numbers of donor cells within the DLN of the empty 
minicells plus ovalbumin group compared with the CT adjuvanted group (p<0.0001), 
152 
 
and this did result in significantly different killing ability as determined by the CTL 
assay (Figure 42B). OVA minicells and ovalbumin (100 µg) without adjuvant did not 
induce significant CTL responses (Figure 42B). 
 
Figure 42: Frequency of adoptively transferred T cells and in vivo target cell lysis. 
Mice (n=4-5/group) received an i.v adoptive transfer of cells and immunisations as 
previously described (Figure 44). Six days after the final immunisation mice received an i.v. 
transfer of naive splenocytes with and without SIINFEKL peptide coating and differentially 
stained with VPD450 (4.75 x 106 of each high and low stained cells). After 24 h spleen, 
draining lymph nodes and blood were harvested and cells stained to detect adoptively 
transferred cells (CD45.2+Vα2+) and analysed by flow cytometry. (A) Site-specific frequency 
of donor cells is presented as mean and SEM. (B) SIINFEKL coated-specific cellular lysis is 
presented in box and whiskers plots. Statistical significance was determined with log 
transformed data as compared to the PBS group using one-way ANOVA with Bonferroni‟s 
post-hoc test p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****. 
Whilst OVA minicells did not induce proliferation of adoptively transferred cells 
(Figure 42A), it was possible that endogenous CD8+ T cell populations may have 
been activated by the immunisations. To assess this, mice received an i.v. transfer of 
naive PTP mice splenocytes pre-incubated with or without SIINFEKL peptide and 
differentially stained with the VPD450 dye which is retained by viable cells. Cells 
harvested from the blood, draining lymph nodes and spleen were analysed for the 
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frequency of donor derived cells (Figure 42A) and the specific lysis of SIINFEKL 
coated cells (Figure 42B). Non-adjuvanted ovalbumin generated an antigen-specific 
cellular response despite its inefficiency in stimulating proliferation of the adoptively 
transferred T cells. In the non-adjuvanted ovalbumin group, significant antigen-
specific lysis was evident in each sample site (p<0.01 – p<0.001) although there was 
high intra-group variability (Figure 42B). Immunisations with ovalbumin when co-
administered with CT or empty minicells induced significant lysis of SIINFEKL target 
cells at each sample site (p<0.0001). Ovalbumin with CT was highly effective, 
inducing 98.8%, 99.2% and 99.4% of target cell lysis in the blood, DLN and spleen 
respectively. OVA minicells with or without BsAbs were ineffective at inducing either 
proliferation of donor cells or generating a cytolytic response.  
5.3.2.2. Antibody responses 
To evaluate the capacity of ovalbumin packaged minicells to induce ovalbumin-
specific antibody responses, sera collected after the final immunisation was used in 
an ELISA with ovalbumin protein as the capture antigen (Figure 43). Data show that 
OVA minicells with or without BsAbs targeting DEC205 or a non-specific target were 
able to induce a significant anti-ovalbumin IgG responses. The distribution of 
endpoint titres within these groups had high variability with titres ranging from 400 to 
409,600 (Ns BsAb), 12,800 to 204,800 (DEC205) and 12,800 to 819,200 (OVA 
minicells), with inter-group analysis not detecting significant differences.  
Ovalbumin protein (100 µg) induced significant antibody responses compared to the 
PBS group (p<0.0001). These titres were significantly increased with the co-
administration of CT (p<0.0001) or empty minicells (p<0.05) as an adjuvant, with CT 
clearly a potent adjuvant with each endpoint titre recorded at 3,276,800. Endpoint 
titre comparisons between ovalbumin with or without empty minicells, and the OVA 
minicell group were not significant despite the OVA minicells (1010) having a 0.1 µg 
ovalbumin protein load.  
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Figure 43: Ovalbumin-specific IgG responses following immunisations. Mice (n=4-
5/group) received an i.v adoptive transfer of cells and immunisations as previously described 
(Figure 44). Sera collected 5 days after final immunisation was used to detect anti-ovalbumin 
IgG responses by ELISA with data presented as mean and SEM endpoint titres. Statistical 
significance was determined with log transformed data comparing groups to the PBS group 
and between adjuvanted groups using one-way ANOVA with Bonferroni‟s post-hoc test 
p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****. 
5.3.3. Evaluation of ovalbumin protein dose-related responses and 
minicell adjuvant effects 
The low antigen load in OVA minicells may be the reason why there was a minimal 
induction of T cell responses to OVA minicell immunisations (section 5.3.2). To test 
the effect of dose on cellular and antibody responses, a dose titration of ovalbumin 
protein (0.1, 10 and 100 µg/dose) with or without empty minicells or CT was 
conducted. To evaluate whether factors other than LPS influenced the adjuvant 
effect of minicells, one group received ovalbumin (100 µg) with a 1010 minicell 
equivalent of LPS. OVA minicells were administered with or without BsAbs to the 
Clec9a receptor to evaluate the platform efficacy with an alternate target than 
DEC205 used in the previous study.  
5.3.3.1. Cell-mediated immune responses 
Ovalbumin dose related responses 
To compare the effect of ovalbumin dose (antigen load) on antigen-specific cellular 
responses, the frequency of transferred cells was determined in blood samples 
collected after each immunisation (Figure 44). A dose related response was detected 
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with a step-wise increase in the frequency of transferred cells as ovalbumin doses 
were increased from 0.1 µg to 10 µg and again to 100 µg with or without adjuvant. 
An ovalbumin dose of 0.1 µg was insufficient to cause an increase in donor cells 
despite the inclusion of adjuvant.  
 
Figure 44: Frequency of adoptively transferred T cells in blood post-immunisation. 
Mice (n=5/group) received an i.v. transfer of OTI CD8+ and OTII CD4+ T cells (0.5 x 106 cells 
of each cell type) followed by three s.c. immunisations at 2 week intervals with either OVA 
minicells (1010) with and without bi-specific antibodies to Clec9a or a non-specific target, 
empty minicells (1010), or ovalbumin protein (100 µg, 10 µg or 0.1 µg/dose) alone or co-
administered with either cholera toxin (CT; 1 µg),or with empty minicells (1010) or ovalbumin 
protein (100 µg) with LPS (0.75 µg). Blood samples collected 12 days (dose 1 and 2) or 5 
days (dose 3) post-immunisation were stained to detect adoptively transferred cells 
(CD45.2+Vα2+) and analysed by flow cytometry. Data is presented as mean and SEM of the 
frequency of transferred T cells post-immunisation (1, 2 or 3). Statistical significance was 
determined with log transformed data as compared to the PBS group using one-way ANOVA 
followed by Bonferroni‟s post-hoc test p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****. 
A dose dependant increase in donor cell frequency was also detected in the blood, 
DLN and spleen following the final immunisation (Figure 45A). In each sample site, 
an ovalbumin dose of 100 µg significantly increased donor cell frequencies as 
compared to a 10 µg dose when doses were co-administered with CT or empty 
minicells (p<0.05 to p<0.0001). A 10 µg ovalbumin dose was sufficient to induce 
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significant increases in adoptively transferred cell frequency when co-administered 
with empty minicells (in blood p<0.01and DLNs p<0.05), or with CT in all sample 
sites (p<0.0001). In contrast immunisations with 0.1 µg of ovalbumin with and 
without adjuvant did not induce significant increases in donor cell frequency in any 
sample site. 
 A trend of increased antigen-specific cellular lysis with dose was observed between 
the different ovalbumin dose groups whether administered with or without adjuvants 
(Figure 45B). With a 100 µg ovalbumin dose with or without adjuvant, target-specific 
lysis was very efficient with significance detected at each sample site (p<0.0001). 
When the ovalbumin was reduced to 10 µg per dose, target-specific lysis was still 
very efficient in all groups (p<0.0001), however, the non-adjuvanted group was 
significantly less effective than the 100 µg dose responses (p<0.01 in DLN and 
p<0.0001 in blood and spleen). At the lowest dose using 0.1 µg of ovalbumin, 
significant lysis was only detected in the DLN sample from mice when ovalbumin 
was co-administered with CT (p<0.0001). 
Adjuvant capacity of minicells as compared to CT or LPS 
To assess of adjuvant capacity of minicells and to compare this adjuvant effect to CT 
or an equivalent dose of LPS, mice were immunised with ovalbumin with or without 
each adjuvant. The frequency of transferred cells was quantified in blood following 
each immunisation (Figure 44). At a 100 µg dose of ovalbumin, the co-administration 
of empty minicells significantly increased the frequency of transferred cells 
(p<0.0001) compared to the PBS control and when compared to ovalbumin alone 
after the first dose only (p<0.05). At doses of 10 µg and 0.1 µg of ovalbumin, empty 
minicells were not sufficient to significantly increase responses.  
CT is a highly potent adjuvant368 and was the only adjuvant capable of significantly 
increasing donor cell frequency at 10 µg ovalbumin doses (Figure 44). When 
assessed at 100 µg ovalbumin dose, following the final immunisation, the CT 
induced donor cell frequency was not significantly different to the ovalbumin plus 
empty minicells. However, CT induced significant increases as compared to 
ovalbumin alone (p<0.05) or with LPS (p<0.05). Empty minicells and LPS adjuvanted 
responses were statistically similar. 
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Figure 45: Frequency of adoptively transferred T cells and in vivo target cell lysis. 
Mice (n=5/group) received an i.v. adoptive transfer of cells and immunisations as previously 
described (Figure 44). Six days after the final immunisation mice received an i.v. transfer of 
naive cells with and without SIINFEKL peptide coating and differentially stained with VPD450 
(4.5 x 106 of each). After 24 h spleen, draining lymph nodes and blood were harvested and 
cells stained to detect adoptively transferred cells (CD45.2+Vα2+) and analysed by flow 
cytometry. Site-specific frequency of donor cells is presented as mean and SEM (A). 
SIINFEKL coated-specific cellular lysis is presented in a min to max box and whiskers plot 
(B). Statistical significance was determined with (A) and without (B) log transformed data 
comparing successive ovalbumin doses within groups using one-way ANOVA with 
Bonferroni‟s post-hoc test p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****. 
Empty minicells were shown to significantly increase donor cell frequency in blood, 
DLNs and spleen following the final immunisation (Figure 45A) with 100 µg of 
ovalbumin (p<0.0001). However, when compared to ovalbumin alone, or ovalbumin 
with LPS, there were no significant differences. At a 100 µg ovalbumin dose, CT was 
significantly better at inducing increases in donor cell frequency than ovalbumin 
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alone or with empty minicells or LPS in each sample site (p<0.05 to p<0.0001), with 
the exception of ovalbumin with empty minicells in the blood. 
Specific cell lysis (Figure 45B) was very efficient when a 100 µg ovalbumin dose was 
administered with and without adjuvant, with no significant differences detected 
between these groups. Empty minicells with 10 µg ovalbumin doses were able to 
induce significant target cell lysis as compared to the PBS control in each sample 
site (p<0.0001), however, increases were not significant when compare to the 10 µg 
ovalbumin only group. This indicates that the response was due to the ovalbumin 
component and not due to the effect of minicells. CT was an effective adjuvant at 
100 µg and 10 µg ovalbumin doses (p<0.0001) and was the only group capable of 
significant lysis at the 0.1 µg ovalbumin dose, although this was only significant in 
the DLN samples (p<0.0001). 
Ovalbumin minicells and targeting 
OVA minicells alone or targeted to Clec9a failed to increase donor cell frequency in 
the blood during the course of immunisations (Figure 44) or in blood, DLNs or spleen 
after the final immunisation (Figure 45A). These immunisations were also ineffective 
at generating significant target-specific cell lysis (Figure 45B). 
Endogenous versus exogenous specific lysis 
To determine if the antigen-specific cell lysis was due endogenous or exogenous 
adoptively transferred T cells, one group of mice did not receive any OTI or OTII 
cells prior to immunisations. Groups with or without transferred cells were immunised 
with ovalbumin (100 µg/dose) with CT. Following three immunisations, the ability to 
lyse antigen-specific cell targets was evaluated (Figure 45B). Efficient target cell lysis 
was observed in the absence of adoptively transferred cells (no trans) in blood 
(82.7%), DLN (92.0%) and spleen (89.0%), however, lysis was lower than in those 
mice with transferred cells (98.9%, 98.8% and 98.7% respectively). Significance 
differences between these groups were detected in blood samples (p<0.05) but not 
DLN or spleen sites. These data suggest that it is not exogenous cells alone which 
are active in cell lysis, since target cell lysis could induced in mice without transferred 
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OTI CD8+ T cells. The data does not, however, quantify the proportion of cells lysed 
by endogenous and exogenous cells. 
5.3.3.2. Antibody responses 
Minicell induced ovalbumin-specific antibody responses were assessed by ELISA 
using ovalbumin as a capture antigen, and sera collected after the 3rd immunisation 
(Figure 46). Whilst 100 µg of ovalbumin alone was able to induce significant anti-
ovalbumin IgG responses (p<0.0001) as compared to the PBS control, significantly 
higher antibody titres were detected in mice where the same ovalbumin dose was 
co-administered with empty minicells (p<0.001), CT (p<0.0001) or LPS (p<0.0001). 
Ovalbumin alone or co-administered with empty minicells had a trend of decreased 
titres as the dose increased from 10 µg to 100 µg. This was reversed when CT was 
co-administered and significant increases were detected (p<0.0001). The highest 
antibody titres were recorded in mice which did not receive adoptively transferred T 
cells although this increase was not statistically significant relative to the comparative 
group which did receive OTI and OTII cells. Furthermore, antibody titres did not 
follow the same dose-related increases as observed in cellular responses. 
Figure 46: Ovalbumin-
specific IgG responses 
following immunisations. 
Mice (n=5/group) received 
an i.v. adoptive transfer of 
cells immunisations as 
previously described 
(Figure 44). Sera collected 
5 days after final 
immunisation was used to 
detect anti-ovalbumin IgG 
responses by ELISA with 
data presented as mean + 
SEM of the calculated titre 
where OD450 equalled 1.0. Statistical significance was determined with log transformed data 
comparing successive ovalbumin doses within groups using one-way ANOVA with 
Bonferroni‟s post-hoc test p<0.05 *, p<0.01 **, p<0.001 *** and p<0.0001 ****. (nd, nil 
detected) 
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All mice immunised with OVA minicells alone failed to reach an OD450 of 1.0, and 
when OVA minicells were targeted to Clec9, detected antibody titres were low. 
Whilst the OD450 value of 1.0 was arbitrarily picked as a reference point for this 
analysis, OVA minicell induced responses were near background in ELISA at a 
1:200 serum dilution and would not have reached a level of positivity even if the 
threshold was reduced to an OD450 of 0.5. This contrasts with earlier data (Figure 
43) where OVA minicells induced reasonable endpoint antibody titres. To compare 
antibody titres between experiments, the earlier data was used to calculate the titre 
at OD450 equal to 1.0 (Table 10). For each OVA minicell group, the ELISA was then 
repeated using the serum from both experiments simultaneously and confirmed both 
data sets. The reason for the discrepancy between the two experiments is not clear. 
The minicells used to immunise the mice had come from the same batch of purified 
minicells and no other logical explanation was apparent. In control groups which did 
not get ovalbumin, and groups immunised with 0.1 µg of ovalbumin (except with CT), 
an OD450 equal to 1.0 was not achievable and nil detected was recorded. 
Table 10: Comparative immunisation group mean results of calculated titre at OD450 
= 1.0 
Immunisations Experiment 1 
(3.4.3) 
Experiment 2 
(5.3.3) 
Ovalbumin (100 µg) 3300 3272 
CT + ovalbumin (100 µg) 177107 99001 
Empty + ovalbumin (100 µg) 132973 17061 
OVA minicells 8441  
OVA minicells + DEC205 2321 N/A 
OVA minicells + Clec9a N/A 1694  
OVA minicells + NS BsAb 4978  N/A 
 = each represents a single mouse where no value could be calculated 
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5.3.4. Evaluation of Plasmodium yoelii Apical Membrane Antigen-1 
packaged bacterial minicells 
The ovalbumin model allowed for assessment of the capacity of minicells to induce 
cell-mediated immune and antibody responses, but it did not elicit information about 
their protective capacity. Using the malaria model, and the PyAMA-1 protein as the 
antigen, experiments were designed to determine cellular activation and cytokine 
expression post-sporozoite challenge, parasite-specific antibody responses post-
immunisation and during infection, as well as protective capacity. An additional 
benefit of this model was that the PyAMA-1 protein antigen load was able to be 
increased to 1.0 µg/1010 minicells, a ten-fold increase to the antigen load in the OVA 
minicell studies. As noted above, the low ovalbumin antigen load could have been 
responsible for the lack of immune responses detected in those studies. 
5.3.4.1. Cell-mediated immune responses 
Cytokines 
To quantify cytokine levels in circulation, pooled serum from mice collected pre-
challenge (Day 0) and post-challenge (Days 2 to 10) was assayed using CBA for a 
range of Th1 and Th2 cytokines. A spike in IFN- was detected at days 7 and 8 in 
each group (Figure 47A). TNF and IL-6 responses rose during the course of 
infection, however, the profile of those cytokines were consistent between each 
immunisation group, so not antigen-specific. IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12p70 
and IL-13 were also assayed, however, cytokine levels remained close to the limit of 
detection for the assay.  
Based on the IFN- peaks at days 7 and 8 with the pooled samples, individual 
samples from these days were assayed for IFN-, as well as TNF and IL-6 cytokines 
(Figure 47B). The CBA data indicates that in some of the AMA1 minicell immunised 
mice with or without BsAbs, there was increased IFN- responses although these 
differences did not reach significance in comparison to other groups. Mice which 
were not infected (Figure 51B) had very low IFN- responses which were at or near 
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detection levels (Figure 47B). No significant group differences were detected for TNF 
or IL-6 cytokines. 
 
Figure 47: Circulating IFN-, TNF and IL-6 cytokine levels following immunisation and 
sporozoite challenge. Mice (n=5/group) received three s.c. immunisations at 3 week 
intervals with either AMA1 minicells (1010) with and without bi-specific antibodies to DEC205, 
Clec9a or a non-specific target, empty minicells (1010) with and without PyAMA-1 protein (1 
µg), or a homologous DNA prime with PyAMA-1 protein boost regimen. Ten days after the 
final immunisation mice were challenged by i.v. injection with live P. yoelii 17XNL 
sporozoites (103). Post-challenge sera was analysed using CBA for cytokine responses. (A) 
Pooled samples from pre-challenge to day 10 is shown for IFN-, and (B) individual samples 
on days 7 and 8 were used to quantify IFN-, TNF and IL-6 responses. Statistical 
comparisons between groups (B) using log transformed data using two-way ANOVA 
followed by Bonferroni‟s post-hoc test detected no significant variation. 
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White blood cell counts and activation markers 
To determine whether PyAMA-1 loaded minicells activated and/or increased cellular 
response during a Plasmodium infection, phenotypic activation markers were 
assessed using blood samples collected pre- and post- sporozoite challenge. During 
the first 10 days of infection, CD8+ and CD4+ T cells, B cells, monocytes and 
granulocytes were stained for various activation markers, specifically PD-L1, PD1, 
CD11a, CD49d, CD69, CD86 and GR-1 then analysed by flow cytometry.  
 
Figure 48: Monocyte PD-L1 expression following immunisation and sporozoite 
challenge. Mice (n=5/group) were immunised as previously described (Figure 47). Ten days 
after the final immunisation mice were challenged by i.v. injection with live P. yoelii 17XNL 
sporozoites (103). Blood collected pre- (day 0) and post-challenge (days 2 and 3) was 
analysed by flow cytometry with monocytes detected by FSC and SSC gating and Ly-6G 
(Gr-1) antibodies and programmed death-ligand 1 (PD-L1) expression levels detected by 
PD-L1 (CD274) antibodies. Data for days 0, 2 and 3 are shown as box and whiskers plots. 
Statistical comparisons to the PBS group used log transformed data using one-way ANOVA 
followed by Bonferroni‟s post-hoc test. p<0.05 *, p<0.01 **. 
Monocyte PD-L1 expression was up-regulated in pre-challenge samples in all groups 
which received minicells (Figure 48), with significant increases detected in PyAMA-1 
minicells alone (p<0.05) or targeted to DEC205 (p<0.05), or the non-specific 
antibody (p<0.05). This response did not appear to be antigen-specific since it was 
not restricted to PyAMA-1 minicells, with empty minicells with PyAMA-1 protein also 
having significant increased expression (p<0.01), and empty minicells alone had 
increased expression although it did not reach significance. Over the following 3 
days, monocyte PD-L1 expression was reduced to levels similar to that in PBS and 
164 
 
DNA/protein immunised groups with no significant intergroup after Day 0. This 
suggests that the PD-L1 expression was not a result of any Plasmodium-specific 
antigen stimulation, but was due to the bacterial components of the minicells. This 
PD-L1 response was restricted to monocytes with expression on other cell types not 
significantly different to the PBS control group. No effect of minicells on activation 
markers PD1, CD11a, CD49d, CD69, CD86 and GR-1 was detected.  
5.3.4.2.  Antibody responses 
Studies in the ovalbumin model showed that minicells could induce antigen-specific 
antibody responses even with a low antigen load (section 5.3.2.2). Furthermore, 
increases in ovalbumin from 0.1 µg to 10 µg increased titres so as to be detectible at 
OD450 = 1.0 (sections 5.3.3.2). The PyAMA-1 loaded minicells had an antigen load of 
1 µg per 1010 minicell dose, and as a consequence of the higher antigen content, it 
was anticipated that antigen-specific antibody titres would be higher than those 
induced by the ovalbumin minicells. To assess antibody responses, an ELISA was 
conducted using PyAMA-1 recombinant protein produced in the RTS cell free 
transcription/translation reaction (section 4.2.6) as the capture antigen (Figure 49).  
 
Figure 49: IgG antibodies against recombinant PyAMA-1 protein generated using RTS 
system and talon purification. Mice (n=5/group) were immunised as previously described 
(Figure 47). Sera collected nine days after final immunisation was diluted 1:200 then used in 
an ELISA against PyAMA-1 recombinant protein. Bars represent mean OD450 + SEM. 
Statistical comparisons to the PBS group used log transformed data using one-way ANOVA 
followed by Bonferroni‟s post-hoc test. p<0.05 *, p<0.01 ** and p<0.0001 ****. 
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All groups immunised with a minicell component had significant increases in 
antibody detected responses relative to the PBS control. There were no significant 
differences between empty minicells with or without PyAMA-1 protein, or any of the 
PyAMA-1 minicell immunised groups. Thus it is likely that the detected reactivity was 
not directed against the recombinant PyAMA-1, but instead a result of contamination 
of E. coli proteins from the RTS reaction kit, since significant responses (p<0.0001) 
from empty minicell immunisations alone were detected. Alternative sources for the 
PyAMA-1 protein were not available for further ELISA assessment. 
To examine whether the PyAMA-1 minicell induced antibodies were parasite-
specific, a flow-cytometry based IFAT was performed using P. yoelii blood-stage 
parasite extract (Figure 50). Pre-challenge sera in all minicell immunised groups had 
increased reactivity to the parasite extract as compared to the PBS and DNA/protein 
immunisation groups. The increased responses in these groups remained higher 
(non-significantly) than the PBS and DNA/protein immunisation groups until day 7, 
which coincided with the detection of parasitemia within the groups (section 5.3.4.3). 
To assess the antibody isotype responses IgG1, IgG2a, IgM, IgD and IgE were 
assayed using pre-challenge sera. Only IgG1 isotype responses detected. IgG1 data 
(Figure 50B) showed a similar response to the total IgG data at day 0 with positive 
responses in all minicell immunised groups. To compare IgG responses between 
groups over the first 22 days of infection, the AUC of IgG MFI (Figure 50C) was 
calculated. No significant differences between groups could be detected. Individual 
mouse data shows some mice with a low AUC but in each case these mice had no 
detectible parasitemia which accounts for the variation. 
The antibody results indicate the minicells have induced a non-specific antibody 
response with a cross-reaction between minicells and both PyAMA-1 recombinant 
proteins and the parasite extract. Additional studies would be required to 
conclusively determine if PyAMA-1 specific antibodies have been induced by 
PyAMA-1 minicells. It is possible that a cross-reactive antigen in the minicells and 
either PyAMA-1 or other P. yoelii blood-stage antigens exists which has caused 
these results, although this has not been previously reported. An ELISA with purified 
recombinant PyAMA-1 protein may clarify the detected results, however, this protein 
was not available for study within the timeframe of this thesis.  
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Figure 50: Serum antibodies against whole P. yoelii parasite extract. Mice (n=5/group) 
were immunised as previously described (Figure 47). Ten days after the final immunisation 
mice were challenged by i.v. injection with live P. yoelii 17XNL sporozoites (103). (A) Blood 
from individual mice diluted 1:300 was assessed for total IgG responses to P. yoelii blood-
stage extract and the median fluorescence intensity (MFI) is presented as the group mean. 
(B)The MFI data of pooled pre-challenge sera in a 2-fold titration for IgG1 responses is 
shown. (C) The area under the curve (AUC) of IgG MFI obtained from (A) is presented as 
individual mice data and mean + SEM. AUC statistical comparisons between groups used 
log transformed data then one-way ANOVA followed by Bonferroni‟s post-hoc test. No 
significant variation was detected. († dead mouse) 
5.3.4.3. Protection 
To assess the capacity of PyAMA-1 minicells to confer protection against sporozoite 
challenge, immunised mice were challenge with 1000 P. yoelii 17XNL sporozoites 
and parasitemia was measured during the course of infections using the FCAB 
assay. The mean parasitemia for each group (Figure 51A) shows a similar pattern 
for each group until day 18 post-challenge. However, four groups including AMA1 
minicells targeted to DEC205 or the non-specific antibody control, empty minicells 
and PBS all had a one to two day delay in the onset of parasitemia. Furthermore, the 
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peak parasitemia detected within these groups was lower, but non-significantly less 
than each other group. No significant differences could be detected between 
immunisation groups based on the parasitemia AUC (Figure 51B).  
The mean peak parasitemia in the non-immunised control (PBS) group was 13.0% 
which was lower than experimental challenges in other studies283 where mean peak 
parasitemia was within the 30 to 40% range. Nonetheless, the parasitemia profile 
and the time-course of the infection appeared normal despite the lower peak. 
 
Figure 51: Parasitemia following immunisation and sporozoite challenge. Mice 
(n=5/group) were immunised as previously described (Figure 47). Ten days after the final 
immunisation mice were challenged by i.v. injection with live P. yoelii 17XNL sporozoites 
(103). (A) Kinetics of parasitemia and (B) area under the curve were assessed using the 
FCAB assay. Data is presented as group means (A) and mean and SEM with individual data 
points (B). AUC statistical comparisons between groups used log transformed data then 
one-way ANOVA followed by Bonferroni‟s post-hoc test. No significant variation was 
detected. († dead mouse). 
168 
 
There were six mice where parasites were not detected post-challenge. Four of 
these mice were in groups which received PyAMA-1 minicells either alone (1/5) of 
targeted to Clec9a (2/5) or the non-specific antibody (1/5); and another putatively 
protected mouse from the positive control DNA/protein (1/5), however, one mouse in 
the empty minicell group also had no detectable parasites (1/5). Unfortunately the 
absence of parasites in one mouse in the empty minicell group confounds whether 
protection in the other groups was actually: a result of the immunisations; due to 
technical reasons; or maybe it was a result of a cross-reactive antigen consistent 
with antibody data described above (Figure 49 and Figure 50).  
5.4. Discussion 
5.4.1. Targeting minicells to dendritic cells 
The studies presented in this chapter were designed to evaluate the immunogenicity 
and protective capacity of antigen loaded minicells, and to see if responses could be 
enhanced by directly targeting DCs. We speculated, that by targeting DC surface 
receptors including DEC205 or Clec9a that receptor-mediated endocytosis would 
result in increased DC up-take of minicells, and subsequently a more robust 
immunological response. In order to test this, mice were immunised with minicells 
loaded with ovalbumin or PyAMA-1 proteins and plasmid DNA, with or without BsAbs 
to the DC targets. 
Previous studies using phagocytic cell lines RAW264, J774 and DC2.4 have shown 
that these cells are inefficient in the uptake of minicells with a transfection efficiency 
of between 0.002% and 0.2%236. However, even non-phagocytic cells can be 
induced to take up minicells with the inclusion of targeting molecules235 including 
BsAbs227,238. We were unable to assess the targeting strategy using RAW264, J774 
or DC2.4 because neither cell has the DEC205 or Clec9a receptors. Instead, 
assessment of minicell uptake, migration and presentation was done by injecting 
naive mice with ovalbumin loaded minicells ± BsAbs and then harvesting their DLNs 
to determine if mDCs were capable of inducing the proliferation of transgenic OTI 
CD8+ T cells or OTII CD4+ T cells in vitro. At 24 h post-injection there was an 
increase in CD11chigh MHCIIhigh mDC population within the DLNs (Figure 40) 
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including the presence of CD103+ dermal DCs (dDCs) (Table 8), which is consistent 
with previous studies368. These dDCs migrate from the skin regions to the DLNs and 
cross-present antigens making them a good target for vaccine delivery369,370. 
However, sorted mDCs with CD103+ or CD103- phenotypes, from mice immunised 
with ovalbumin minicells ± BsAbs, failed to induce proliferation of OTI or OTII cells. 
Proliferation was achieved using lymphocytes from mice injected with ovalbumin 
protein and CT, confirming that the minicell non-response was not a technical 
problem. To assess whether the result was not due to a delay in DCs migrating to 
DLNs, or to minicell uptake by cell without high CD11c and MHCII expression, a 
subsequent time-course assay was conducted with unsorted cells harvested from 
DLNs. The same outcomes were found. Data from these experiments are indicative 
only, as they were obtained from single mice experiments, and pooled lymphocytes 
which prevent any statistical comparison. The limitation of mouse numbers was as 
result of financial feasibility and a cost-benefit determination. 
To assess responses in vivo, the frequencies of adoptively transferred OTI or OT II 
cells were determined after three immunisations. There was no evidence of minicell 
induced proliferation of these cells when immunised with or without BsAbs. 
Furthermore, there was no detected cytolytic activity from minicell groups in the CTL 
assay, when OVA minicells were targeted to DEC205 or Clec9a. During this study, it 
was established that ovalbumin minicells were able to induce and antigen-specific 
IgG response, however, BsAb targeting did not significantly alter the titres. 
5.4.2.  Antigen dose requirements in minicells 
In a LCMV minicell experimental model reported by Giacalone et al.237, a dose 
titration of 1010, 109, 108 and 107 minicells with an antigen protein component of 1.2 
µg/dose down to 0.0012 µg/dose resulted in a protective efficacy with 89%, 40%, 
20% and 0% respectively. In the in vitro and initial in vivo studies reported herein, 
ovalbumin minicells had an antigen load of 0.1 µg whereas the ovalbumin ± CT or 
empty minicell doses consisted of 100 µg of protein. It was hypothesised that the 
experimental outcomes may be directly related to the low ovalbumin component in 
minicells. We tested this using an in vivo proliferation and CTL experiment using an 
ovalbumin dose titration and showed the requirement for an increased antigen load 
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for the efficient killing of SIINFEKL labelled cells. When the ovalbumin dose was 0.1 
µg, co-administration with empty minicells had no detectable effects. At this low 
ovalbumin dose, the only significant responses were with the co-administration of CT 
where antigen-specific target cell lysis was detected in the DLN (p<0.0001). Antibody 
responses were similarly dependant on a higher ovalbumin dose delivery. 
Experimental data suggests that whilst a higher 100 µg dose increased cellular 
responses, both cellular and antibody responses in the 10 µg per dose mice could be 
sufficiently efficacious for protection, with a frequency of antigen-specific CD8+ T 
cells exceeding 2%210. The actual frequency of CD8+ T cells would be higher than 
indicated in the presented data which represents only the exogenous CD8+ T cells, 
and does not include the endogenous population. The presence of an endogenous 
population, whilst not quantified, was evident by significant CTL responses 
(p<0.0001) in mice which did not receive adoptively transferred cells (Figure 45B).  
The ability to increase the antigen load in minicells is directly related to the ability of 
the bacteria to produce the protein. This was demonstrated in an earlier chapter 
(Chapter 4:). It may be possible to load exogenous proteins onto the minicells post-
purification in a manner similar to the uptake of chemotherapeutic drugs227,238, but 
this was not within the scope of this project. This type of loading would mean the 
inclusion of additional processing and related costs, however, it would render the 
platform usable for proteins which are unable to be produced in minicell producing 
strains. Minicells could be coated using a system of chemical linking in the same way 
that some VLP platforms have been developed128,156,162 or the proteins could be 
fused with sequences directing them to the outer membrane as has been achieved 
with bacterial ghosts274. As an indicator of the antigen load requirements for an 
effective vaccine using bacteria-like particles against Plasmodium, a BG with 
derivative proteins from PbCSP used 45 µg per dose371. 
5.4.3. Antigen loaded minicell induced immune responses 
Cell-mediated immune responses 
Whilst ovalbumin loaded minicells did not induced proliferation of OTI or OTII cells, 
nor induce cytolytic responses, empty minicells did act as an adjuvant when co-
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administered with ovalbumin. The ovalbumin titration experiment suggested the poor 
result was likely to have been a consequence of the low 0.1 µg ovalbumin load. In 
the subsequent PyAMA-1 minicell experiment a higher antigen load of approximately 
1 µg per dose was anticipated to be more immunogenic. In that experiment, cellular 
response data was limited to blood cytokine levels and WBC activation markers 
post-challenge. Minicells did not induce antigen-specific systemic cytokine 
responses in samples analysed during the challenge, with results similar to that of 
non-immunised controls. 
When lymphocyte activation markers were assessed, an up-regulation of monocyte 
PD-L1 receptors was induced by minicell immunisations (Figure 48). This response 
was not antigen or target related, but was an up-regulation induced by minicells 
themselves. The PD-L1 response was only evident in monocytes and returned to 
PBS control levels by day 3 and did not rise during the course of the infection. Whilst 
PD-L1 can be expressed on various APCs, it is only expressed on monocytes that 
have been stimulated with up-regulation induced by exposure to IFN-372 and 
macrophages can also be induced with LPS, and polyIC373,374. PD-L1 can have a 
stimulatory or inhibitory influence on T cells following interactions with PD-1 
receptors under different experimental conditions374. Given the high LPS component 
of minicells, the observed up-regulation is likely to be related to LPS, but may also 
be a result of IFN- production following a Th1 response by T cells or NK cells372.  
Antibody responses 
Initial ELISA results suggested that, despite the low antigen dose, OVA minicells 
were capable of inducing significant (p<0.0001) anti-ovalbumin IgG titres (Figure 43). 
The titre was similar to a 1000-fold higher protein only dose. However, in the 
subsequent dose titration experiment, ovalbumin loaded minicells did not induce any 
detectable IgG responses. This was not a minicell batch-related anomaly, as both 
experiments used minicells derived from the same purification. To investigate this 
discrepancy, a repeat ELISA was performed using sera from both experiments, 
which confirmed the different responses between experiments. Even at a serum 
dilution of 1:100, minicell induced IgG responses in the second experiment were 
close to background responses. This low antibody titre was consistent with the 0.1 
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µg ovalbumin immunised mice, where low but detectable IgG responses were only 
present in mice co-administered with CT. The low antibody responses are also 
consistent with previously reported studies of GFP minicells (7.6 µg/dose) and GFP+ 
GFP encoded plasmid DNA minicells (6.8 µg/dose) inducing IgG endpoint titres of 
1:102 and 1:105 respectively236. 
Studies were unable to conclusively establish if minicells induced a specific antibody 
response against PyAMA-1 due to a potential cross-reactivity between the minicells 
and both the RTS purified recombinant PyAMA-1 protein and the parasite extract. 
Reactivity against the protein is likely a result of bacterial contaminants from the E. 
coli lysate components of the RTS reactions. Pre-challenge IgG1 responses detected 
by a flow cytometry based IFAT showed that all minicell immunised mice had similar 
antibody responses against the parasite extract, regardless of the presence or 
absence of PyAMA-1. Other immunoglobulin subclasses including IgG2a, IgM, IgD 
and IgE were tested by the IFAT, however, only IgG1 responses were detected. 
There was no data to suggest that antigen loaded minicells had higher antibody 
responses. The IgG data obtained during the course of the infection was confounded 
by the potential effect of parasites in the challenge inducing antibody responses. 
Protection from P. yoelii sporozoite challenge 
The Plasmodium AMA-1 protein is expressed in both sporozoites and merozoites in 
liver and blood-stages of infection82,328,375, and as such presents itself as a target for 
both cell-mediated and antibody responses. PyAMA-1 minicell immunisations with or 
without BsAbs had no apparent influence on parasitemia; and although four of these 
mice did not develop detectable parasitemia, one mouse in the empty minicell 
control group also had no detectable parasitemia, thus confounding the interpretation 
of the data. 
5.5. Conclusion 
The ability of minicell producing bacteria to yield sufficient quantities of recombinant 
protein for incorporation into minicells for presentation to the host immune system, 
appears to be the major limitation of this platform. Data from the ovalbumin dose 
titration immunisation experiment suggests that a protein dose of 10 µg is sufficient 
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when combined with minicells to induce significant cellular and antibody titres. In 
order to increase the antigen load within minicells, future studies could assess 
alternative proteins from Plasmodium or other disease models, E. coli codon 
optimisation, or a modified protein construct371. In this study, data did not show any 
increase in immunogenicity or protective efficacy as a result of targeting minicells to 
DCs. However, this strategy may have been similarly limited by the antigen load. 
Additional studies with high protein yielding minicells would be required to 
conclusively establish the immunological benefit of DC targeting with this platform.
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Chapter 6: Discussion and conclusion 
The Plasmodium species has co-evolved with humans and has developed a variety 
of immune evasion and immunomodulation strategies which enable it to persist in 
the host376,377. People living in malaria endemic regions are able to develop clinical 
immunity in that they are protected from disease rather than infection, however, 
protection quickly wanes when they leave the endemic location378. In light of this, the 
development of a vaccine against Plasmodium must improve upon nature. 
Immunisations of mice379 and man380 with irradiated sporozoites have established 
the feasibility of developing a malaria vaccine. Recent work on whole-parasite 
vaccines includes radiation attenuated sporozoites36,40,41, infectious sporozoites 
under chemoprophylaxis42,43,381, genetically44,45,382 or chemically46 attenuated 
parasites. In a recent human trial, irradiated sporozoites induced sterile protection in 
6/6 adults, however, this required five i.v. doses of 1.35 x 105 sporozoites36. Whilst 
clearly efficacious, the ability to deliver cryopreserved sporozoites to geographical-
disperse communities in developing countries and to get subject compliance for the 
required five-dose regimen represents a serious hurdle.  
Sub-unit vaccines are rationally designed at the molecular level to induce cell-
mediated and/or antibody responses to specific pre-defined targets. Following the 
cloning of P. falciparum antigens in the 1980‟s, a study reported that immunisation 
with a recombinant protein incorporating the central repeat regions of the CSP 
induced high anti-CSP titres capable of inhibiting hepatoma cell invasion383. 
Subsequent sub-unit vaccine trials established that protective immunity could be 
conferred by immunisation with peptides representing defined epitopes from CSP, 
through the induction of cellular or antibody responses63,72,75. The most clinically 
advanced malaria vaccine candidate RTS,S/AS01, incorporating immunogenic 
regions of CSP into a VLP, has achieved only 30.1% vaccine efficacy in phase 3 
clinical trials37. Other vaccine candidate antigens have been evaluated, however, 
approximately half of vaccine trials have focused on either CSP, AMA-1 or the 
merozoite surface antigen (reviewed in 384,385). 
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A major hurdle for sub-unit vaccines is the fact that proteins and peptides are poorly 
immunogenic and require the co-administration of potent adjuvants386. There are 
only three adjuvants currently approved for human use- Alum, MF59 and 
monophosphoril lipid A387. Vaccines against intracellular pathogens such as 
Plasmodium require the induction of strong cell-mediated immunity and antibody 
responses which current vaccine platforms and adjuvant combinations are unable to 
achieve388. To address this issue, numerous novel adjuvants or adjuvant 
combinations are being evaluated and are in various stages of clinical development 
(reviewed in388).  
Various sub-unit vaccine platforms have been evaluated as potential platforms for a 
malaria vaccine. Plasmid DNA showed potential to elicit antibody and cell-mediated 
responses in animal models with plasmid encoded PyCSP inducing a CD8+ T cell 
dependant protection from sporozoite challenge76. Despite promising results in 
animal models, the efficacy of plasmid DNA as a homologous regimen in human 
clinical trials has been poor77 (and reviewed in389,390). Viral vectors, including 
poxvectors and adenoviral vectors use host mechanisms to express target antigen 
within infected cells, and are particularly good at inducing robust T cell responses 
and to a lesser extent antibody responses, and can simultaneously deliver multiple 
antigens124,390,391. However, pre-exposure to these vectors may limit their ability to 
induce T cell responses392 and antibody responses391. As a result of this limitation, 
and to enhance efficacy, vaccine regimens using multiple platforms have been 
investigated324. A recent clinical trial showed that a DNA prime with an adenovirus 
boost regimen incorporating both PfCSP and PfAMA-1 antigens, induced only low 
antibody titres, modest IFN- cellular responses and sterile protection in 27% of 
subjects393. It is likely that novel sub-unit vaccine platforms could overcome these 
limited immunological responses, and should to be investigated.  
In pursuit of the requirement to develop novel delivery platforms, I have developed 
and evaluated in this thesis: chimeric VLPs and capsomeres, and bacterial minicells 
targeting DC receptors DEC205 or Clec9a. The chimeric VLP and capsomeres 
comprised of a modified MuPyV VP1 structural protein expressed in bacteria and 
incorporated defined CD8+73,75 and CD4+71,72,74 T cell and B cell63 epitopes from 
PyCSP. These chimeric platforms have previously been evaluated for their ability to 
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induce robust epitope-specific antibody responses in other pathogen 
models170,173,188, however, cell-mediated immune responses have not been 
evaluated. The bacterial minicells were purified from E. coli DS410 and contained 
recombinant ovalbumin or PyAMA-1 protein and plasmid DNA for mammalian 
expression of the same antigen. Previously, this platform has been shown to induce 
antibody236 and cell-mediated responses, as well as a protective capacity in mice 
against an LCMV challenge237. However, in that study, APC uptake and expression 
of plasmid encoded antigens were low236, hence the minicell platform in my study 
targeted DC surface receptors in an attempt to enhance uptake and immunogenicity. 
The ability of each platform to induce immunological responses and provide 
protection from challenge was evaluated using a murine model. The well studied and 
leading candidate vaccine antigens CSP and AMA1 were used since each has been 
shown to be protective in other platforms37,97,390. 
6.1. Chimeric virus like particles 
The MuPyV VP1 structural protein chosen for study herein has been developed by 
the Middelberg laboratory to produce high yields of stable chimeric virus-like 
particles using a bacterial expression system187,189,288,289, and displays antigenic 
epitopes on exposed surface loops using flexible linker sequences (MuPyV VP1-S4-
G4S)173,188. The Middelberg laboratory has evaluated the ability of this platform to 
induce pathogen-specific antibodies, and to confer protection in mice in the influenza 
and group A streptococcus models170,173,188. The presented work is the first 
evaluation of the capacity of this platform to induce cellular immune responses as 
well as antibody responses and to confer protection against a complex pathogen 
using a murine malaria model.  
Six chimeric MuPyV VP1-S4-G4S constructs were made by genetically inserting P. 
yoelii 17XNL CSP CD8+ T cell epitopes280-288
75,58-67
73 or CD4+ T cell epitopes280-
295
72,57-70
74,59-79
71, or a B cell epitope63 individually into the S4 surface loop of the 
MuPyV VP1 protein with modified G4S flanking sequences173. Three of these 
constructs (CD8280-288, CD459-79 and B cell) were expressed by E. coli with high 
levels of soluble protein and were able to form stable VLPs following purification. The 
other three constructs (CD858-67 , CD4280-295 and 57-70) were predominantly insoluble, 
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and aggregated when the GST tag was removed. This protein instability is 
documented in other VLP studies156-158 and may be the result of a single amino acid 
within the insert158, moreover there are currently no ways to predict chimeric protein 
stability. The epitopes could have been inserted into different regions of the VP1 
protein which may have resolved the solubility and stability issues. The location of 
epitopes has been shown to impact on protein expression and VLP formation in 
HaPyV176 and BVP157 models. However, modifications to the insertion sites were not 
within the scope of this thesis.  
To confirm that VLPs had formed without aggregation and to determine the size of 
the particles, both TEM imagery and AF4-MALS analysis was performed. TEM 
images showed that chimeric VLPs had the same appearance as wild-type VLPs. 
AF4-MALS separates particles based on their size and then uses light scattering to 
determine their size. The chimeric VLP diameters ranged from 41.5 to 42.3 nm which 
were slightly larger than the 40.0 nm wild-type VLP as expected due to the insertion 
of additional amino acids increasing the molecular weight of each protein, and the 
protrusion of inserted epitopes from the S4 surface loops.  
A series of in vitro and in vivo experiments were conducted to assess the 
immunogenicity of each VLP construct. Initially, an in vitro assessment showed that 
the CD8280-288 VLP was able to induce proliferation of transgenic CS-TCR CD8
+ T 
cells which specifically recognise the PyCSP280-288 epitope. This confirmed that the 
chimeric CD8280-288 VLP was able to be processed and presented by APCs, for 
recognition by CD8+ T cells, as determined by the proliferation of the epitope-specific 
T cells.  
Subsequently the capacity of the chimeric VLP platform to induce immune responses 
and confer protection was evaluated using VLPs as individual or pooled constructs. 
This enabled the evaluation of single constructs, and to determine if any synergistic 
effects would result from pooling constructs. In addition to evaluating a homologous 
VLP regimen, a plasmid DNA prime/VLP boost regimen was also included. Whilst 
plasmid DNA induces both antibody and cell-mediated immune responses (reviewed 
in318), the prime/boost delivery using heterologous platforms has been shown to both 
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arms of the adaptive immune response and enhances protective efficacy against 
challenge93,318,394,395.  
Consistent with the in vitro experiment, data from the murine studies confirmed that 
VLPs induced CD8+ T cell responses in vivo. IFN- responses were detected when 
splenocytes were stimulated with either the CD8280-288 peptide or PyCSP transfected 
cells expressing that CD8280-288 epitope, indicative of a Th1 response. Notably the 
IFN- responses were consistently lower than the responses induced by plasmid 
DNA alone or the heterologous DNA prime/VLP boost regimen. Minimal differences 
were detected between the 10 µg and 30 µg per construct in pooled VLP doses, and 
the pooling VLPs offered no benefit.  
The VLP immunisations induced a very weak response against the PyCSP CD4+59-79 
T cell epitope. This was established by the limited cellular responses after 
restimulation with the CD459-79 peptide, which contrasted with the response of 
peptide-immunised mice which was consistently very high. Furthermore there was 
no apparent effect on antibody titres in mice immunised with B cell VLPs versus 
pooled VLPs containing both the B cell VLP and the CD459-79 VLP. Mice had been 
immunised with a dose of either 30 µg of peptide with polyIC or 10 µg to 30 µg of 
VLPs comparable to other HBV VLP studies with CD4+ T cell epitopes152,219. In those 
studies, in contrast to my findings, enhanced antibody and cellular immune 
responses were reported152,219. No in vivo studies using the MuPyV VLP with CD4+ T 
cell epitopes have been reported for a direct comparison, although the OVA CD4+ T 
cell chimeric VLP has been shown to induce proliferation of OTII cells in vitro
202. The 
comparative PyCSP59-79 epitope load in the 10 µg and 30 µg per construct in pooled 
VLP dose was only 0.52 µg and 1.56 µg respectively which may have contributed to 
the poor responses in my study.  
As anticipated from previous VLP induced antibody analysis170,173,188, the B cell 
chimeric VLP induced robust antibody responses. The antibody titres induced by a 
homologous VLP regimen were not significantly influenced by the dose of 10 µg or 
30 µg in pooled VLP immunisations, nor did the pooling of VLPs significantly differ 
from B cell VLPs administered alone. Whilst there was no enhancement of antibody 
titres achieved by pooling VLPs, there were also no adverse effects. The ELISA 
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results from pooled sera show that a single VLP dose induced very low antibody 
titres, and that at least two doses of VLPs were required to generate robust titres in 
the homologous regimen. Antibody titres were further enhancement by a third 
immunisation, however, the significance was not determined as only pooled sera 
was available for analysis. In contrast to a previous study173, there was a dominant 
IgG3 response induced by the B cell VLP immunisations. This appears to have been 
influenced by the inserted epitope, since both VLPs were produced using the same 
MuPyV VP1-S4-G4S construct, using the same purification protocols and the same 
immunisation routes. The dose does not appear to be relevant with the published 
study using 23 µg per immunisation173 whereas I used 10 µg in the pooled VLPs and 
30 µg in the B cell VLP immunisations. IgG3 antibodies against the same PyCSP B 
cell repeat has previously been protective in BALB/c mice63, and as such the 
presence of this isotype is perhaps advantageous. 
Importantly, the VLP induced antibodies were able to recognise conformational 
epitopes on recombinant protein, as well as on the surface of the sporozoite. 
Recognition of the CSP epitope on sporozoites is essential as antibodies to this 
target afford protection against challenge63.  
The prime/boost regimen, which only employed a single VLP boost with or without 
polyIC, induced significantly enhanced antibody responses when administered at 10 
µg/construct as compared to homologous DNA immunisations (p<0.0001). When the 
dose of pooled VLPs was increased to 30 µg/construct significance was no longer 
detected. It is likely that a prime/boost regimen including at least two VLP boosts 
would further enhance antibody titres, as was detected in the homologous VLP 
regimen. 
To assess whether the inclusion of an adjuvant would enhance the platforms 
performance, polyIC was co-administered with VLPs. PolyIC was selected as the 
adjuvant in this experiment because of its ability to enhance antibody as well as Th1 
cellular responses in other platforms294,295,297,312, in contrast to alum based adjuvants 
which are only efficient at inducing higher antibody titres307. In the literature there is 
contradictory evidence as to the requirement of adjuvants for VLPs161,215,216,316,317. 
VLPs with alum had a detrimental effect on CTL generation due to a prevention of 
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VLPs from entering into the MHC I processing pathway307. My results showed that 
whilst VLPs were self-adjuvanting in that they were able to induce cell-mediated and 
antibody responses without the requirement for adjuvants, the inclusion of polyIC 
resulted in an increased trend of both CD8+ T cell and antibody responses. 
6.2. Chimeric capsomeres 
Following the expression of the MuPyV VP1 protein, five VP1 proteins link together 
forming a pentameric capsomere168. The removal of the first 28 amino acids from the 
N-terminus and the least 63 amino acids from the C-terminal regions of the VP1 
protein prevents the formation of VLPs whilst maintaining the capsomere 
formation168,170. Genetic modifications to the MuPyV VP1 by Wibowo et al.170 from 
the Middelberg laboratory resulted in a stable capsomere platform into which four 
epitope insertion sites were installed per VP1 protein. The advantage of the 
capsomere platform above VLPs is that it reduces the production costs by 
eliminating the need for the induction of VLP formation, and increases the antigen to 
vector ratio which has been shown to increase antigen-specific immunogenicity174,175 
and reduce anti-carrier titres176. However, studies by the Middelberg laboratory on 
the capsomere platform had previously focused only on antibody responses170,173. 
The studies reported in this thesis were the first to investigate the capacity of this 
capsomere platform to induce cell-mediated responses. 
In contrast to VLPs, capsomeres need the inclusion of adjuvants for the induction of 
antibody responses131,170,173. This loss of self-adjuvant property is likely due to the 
loss of the highly repetitive array of VLPs which mimic the native virus136, and/or their 
ability to cross-link B cell receptors130. Some self-adjuvanting effects can be 
recovered when the capsomeres are able to assemble into larger particles, the 
formation of which is dependent on genomic modifications, as shown with HPV 
capsomeres178. However, capsomeres in that study were capable of inducing cell-
mediated responses without the particle size restrictions as seen with antibodies178. 
In another HPV study, capsomeres induced cell-mediated responses without 
adjuvant, however, responses were increased almost 10-fold with the inclusion of 
aluminium hydroxide, MPL and synthetic trehalose dicorynomycolate in squalene 
and Tween 80179.  
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Homologous capsomere immunisations induced significant cellular responses as 
shown in ELISpot and CBA analysis after restimulation of splenocytes with PyCSP 
transfected A20 cells, or with the PyCSP CD8280-288 peptide (p<0.0001). The ELISpot 
responses were robust in comparison to HPV capsomere responses with increases 
of approximately 5-fold in non-adjuvanted capsomeres178 and 2-fold in adjuvanted 
capsomeres179. Whilst the data are not directly comparable, they do give some 
indication as to the performance of capsomeres within this study. Capsomeres in 
polyIC had a trend of increased cellular responses when compared to non-
adjuvanted VLPs. This may be accounted for by the increased antigen load in 
capsomeres with three epitopes per protein resulting in triple the amount of epitopes, 
or by the location of the epitopes within the protein155. Capsomere induced cellular 
responses were very similar to VLPs co-administered with polyIC. Capsomeres 
preferentially induced responses against the PyCSP CD8280-288 peptide, however, 
they also induced significant responses to the PyCSP CD459-79 peptide (p<0.0001) as 
detected in the ELISpot data. 
Capsomeres induced significant IgG antibody responses against the B cell peptide 
(p<0.0001), and the antibodies recognised epitopes on recombinant protein and the 
surface of the sporozoites. The titres were however, significantly lower than those 
induced by VLPs regardless of whether capsomeres were administered with or 
without adjuvant (p<0.05). This may be related to highly repetitive structural array of 
VLPs167,168,396, the size of the particles178 or their ability to cross-link B cell 
receptors130. The dominant isotype induced by capsomeres was IgG1 which was the 
same as a previous study using the same capsomere construct but with incorporated 
GAS J8 epitopes173. Surprisingly, there was almost a complete absence in the IgG3 
isotype response in the capsomere immunised mice which was a dominant isotype 
induced by VLPs. The PyCSP B Cell repeat epitope which, as mentioned above, 
was suspected to have induced the IgG3 response, was the same epitope inserted 
into the capsomeres. This suggests that an alternative processing pathway has 
occurred between the two platforms397, or perhaps there was an inability of 
capsomeres to cross-link B cell receptors130. It would be interesting to further 
examine if there is a differential uptake of VLPs by APCs in vivo which may reveal 
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alternative processing pathways, however, this was not within the scope of this 
thesis.  
VLPs administered without adjuvant induced robust IgG1 and IgG3 antibody 
responses indicative of a Th2 response398,399 suggesting limited production of IFN- 
resulting from immunisations398. When VLPs were co-administered with polyIC, mice 
maintained similar IgG1 and IgG3 response, however, there was a more balanced 
Th1-Th2 response observed with the production of IgG2a and IgG2b isotypes (Figure 
26b). This balance response was not observed following capsomere immunisations 
which were only co-administered with polyIC. These results were surprising, as 
polyIC is reported to be an effective inducer of Th1 responses293, and further 
supports the suggestion of alternative processing pathways of VLPs and 
capsomeres. 
The heterologous DNA prime/capsomere boost regimen significantly increased the 
cellular responses as detected by ELISpot (p<0.01) compared to the capsomere only 
immunisations. Whilst the reported data established that both VLP and capsomere 
platforms were capable of inducing CD8+ T cell responses, both are considerable 
less efficient than plasmid DNA either alone or in a prime/boost regimen. These 
results are supported by other studies where using a dual platform including a 
plasmid DNA prime enhanced immune responses93,320-324, including when used with 
a VLP boost325. 
In each of the VLP and capsomere experiments, immunological data showing robust 
cellular and antibody responses supported the potential to protect immunised mice 
from sporozoite challenge63,299. However, in my studies, protection was not induced 
by capsomeres, nor VLPs as homologous constructs. There was a significant 
reduction in the liver parasite burden in the group of mice immunised with the 
DNA/VLP regimen using 30 µg of each construct (p<0.01), and two out of five mice 
immunised with 10 µg of each construct had no parasite RNA detected. The 
probable cause of this low protective efficacy is that the magnitude of the responses 
did not surpass the threshold required for protection63,73,210,301. For example the 
passive transfer of monoclonal antibodies to the PyCSP B cell epitope protected 
mice at doses of 500 µg (100%), 250 µg (83%), 125 µg (67%) but was completely 
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ineffective at 62.5 µg (0%)63. Similarly, the adoptive transfer of PyCSP CD8+ (280-289)T 
cell clones protected mice when each mouse received 20 x 106 (100%), and 10 x 106 
(50%) but not 3 x 106 (0%)
73. 
6.3. Bacterial minicells 
Previous studies with bacterial minicells examining bacterial and protein 
functions233,234, did not require the purification standards necessary for the 
immunisation of animals. Viable parental contamination of between one in 103 to 106 
minicells was sufficient for the purposes of studying protein responses222,335,336. A 
protocol effective at removing all viable bacteria, described by MacDiarmid et al.227 
utilised differential and density gradient centrifugation, combined with various 
filtration, elongation and antibiotic treatment steps. The procedure was further 
refined in my doctoral studies. By adding an additional density gradient centrifugation 
all filtration steps were avoided. This novel procedure also produced high minicell 
yields and no contamination by viable parent bacteria. Additionally the purification 
costs and labour components were reduced.  
Targeting minicells to non-phagocytic cells has previously been shown to enhance 
minicell uptake and minimise drug doses in cancer treatment171,227. This principle 
was the basis of my project where minicells loaded with recombinant protein and 
plasmid DNA were targeted to DCs using BsAbs directed against the DEC205 or 
Clec9a receptors. The rationale behind this strategy also came from reports 
indicating the DCs preferentially took up particles in the 40 to 50 nm diameter range 
whereas macrophages phagocytised larger particles196,400. It was hypothesised that 
targeting these receptors would overcome the poor minicell uptake as shown in 
previous studies235, by initiating receptor mediated endocytosis338,363,401.  
Low protein yields were encountered with each antigen including GFP, PyCSP, 
PyAMA-1, Tfr-ovalbumin and ovalbumin. Different expression vectors including 
pBAD/Myc-HisA, pTrcHis2A and pDual GC, various culture conditions and media 
types were investigated to optimise protein expression. The greatest variability in 
protein expression and minicell yields were achieved by changing the media. LB was 
preferential for protein expression, whereas high growth media TB was better for 
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minicell yields. The low level protein expression observed in dual transformants were 
suspected to be a result of plasmid incompatibility353. This incompatibility is caused 
by plasmids with the same origin of replication, competing for replication factors353 
and can result in fluctuations in plasmid copy numbers355. It was anticipated that 
changing to the dual expression plasmid pDualGC would resolve these issues, 
because only a single transformation was required and therefore plasmid 
incompatibility issues are removed. This was investigated in the OVA model and with 
the GFP reporter but the protein yield was also very low. It appears that the low 
protein yield with a maximum dose of OVA (0.1 µg) and PyAMA-1 (1.0 µg) per 1010 
minicells could limit the effectiveness of this platform. This is consistent with results 
in a dose related LCMV protection study where 1.2 µg, 0.12 µg and 0.012 antigen 
doses protected 8/9, 2/5, and 1/5 mice respectively237.  
The low antigen yield was suspected to be the cause of the lack of responsiveness 
of migrating DCs to stimulate the proliferation of transgenic OTI CD8+ or OTII CD4+ T 
cells in several in vitro experiments. To assess antigen requirements using this 
model, ovalbumin protein at 0.1, 10 and 100 µg was used to immunise mice with or 
without adjuvants. Although proteins were not encapsulated within minicells, this 
study did nonetheless give some indication of antigen requirements. Importantly it 
showed that a dose of 0.1 µg, which was the dose in the OVA minicell experiment, 
was insufficient to generate significant cellular or antibody responses. To get some 
perspective as to what a protein-only minicell platform may require to protect against 
a sporozoite challenge, bacterial ghosts required 45 µg of PbCSP per dose371. That 
antigen dose would be difficult to achieve in minicells, however, minicells in my 
platform deliver both antigenic proteins as well as plasmid DNA. This combination of 
modalities enhances immunogenicity236 and potentially reduces the protein load 
requirements. 
There was a significant minicell-induced antibody response detected in the original 
ovalbumin minicell experiment when mice were immunised with OVA minicells alone 
(1:1.9 x 105) or targeted to DEC205 (1:0.8 x 105) (p<0.0001). Those endpoint titres 
exceeded those reported in a GFP DNA/protein minicell experiment where a mean 
titre of less than 1:1250 was induced by three doses of 1010 minicells with an antigen 
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load of 6.8 ± 1.7 µg236. The inclusion of targeting BsAbs did not significantly alter the 
magnitude of the responses.  
Unexpectedly, the OVA minicell induced anti-ovalbumin antibody responses were 
not replicated in the subsequent experiment. Minicells used in both experiments 
were derived from the same batch of purified minicells, were given at the same 
administration route, dose and schedule of doses and sampling. To confirm that this 
was not a technical issue, the ELISA assay was repeated with minicell immunised 
sera analysed concurrently, with consistent results. Sera from the titration 
experiment were assayed at a dilution of 1:100 without detectable responses. 
In the PyAMA-1 minicells antibody analysis there was a cross-reactive response with 
sera from mice immunised with PyAMA-1 or empty minicells, with the RTS 
generated recombinant protein, as well as the parasite extract. It is possible that the 
RTS generated protein had some E. coli contamination following purification which 
has then reacted with antibodies induced by the minicells themselves. Alternatively, 
it is possible that a minicell antigen (other than PyAMA-1) was cross-reactive with 
PyAMA-1, which was present in both assays. However, there was no conclusive 
data to suggest that there was any specific response against the antigen, with no 
increased titres detected in the PyAMA-1 minicell groups above that induced by 
empty minicells.  
Experimental data did not present any evidence to suggest that either ovalbumin or 
PyAMA-1 loaded minicells were able to induce a cellular response. This contrasts 
with the one previous minicell study where approximately 5% of CD8+ T cells 
expressed IFN- upon restimulation of splenocytes237. Immunogenicity assays such 
as ELISpot, CBA and ICS, were not performed in my PyAMA-1 minicell experiment 
due to funding constraints and time limitations. Nonetheless, there was no direct 
evidence of immunisation induced parasite-specific activation of cellular responses. 
Likewise, there was no evidence to suggest that PyAMA-1 minicells induced 
protection from sporozoite challenge. This lack of protection is consistent with the 
poor immunogenicity of minicells as detected in the antibody and cellular assays. As 
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previously mentioned with the VLP and capsomere sections, there is a high level of 
immune responses required to protect against this complex pathogen63,73,210,301.  
6.4. Future directions 
Experimental studies represented within this thesis have established that chimeric 
VLPs and capsomeres incorporating defined CD8+ T cell epitopes are capable of 
inducing significant antigen-specific CD8+ T cell responses. Having established this 
capability, and showing robust antibody inducing capabilities consistent with previous 
studies, further investigations are warranted into how these responses could be 
enhanced: 
i. The location of the epitope within the chimeric MuPyV-VP1 protein is 
important for cross-linking B cell receptors in the VLP platform. For this 
reason epitopes were inserted into surface exposed regions of the VLP. This 
requirement is not essential for the insertion of epitopes specific for CD8+ and 
CD4+ T cell epitopes, and the immunogenicity may be enhanced by 
alternative epitope insertion sites. This may explain why capsomeres induced 
a moderate CD4+ T cell response whereas the same responses induced by 
VLPs were very weak. Future studies should address this issue by evaluating 
alternative epitope insertion sites. 
ii. All immunisations were administered s.c. at the base of the tail. This route of 
administration was utilised based on previous studies (REF) which indicated  
iii. The heterologous plasmid DNA prime followed by a VLP or capsomere boost 
induced significantly higher CD8+ T cell immune responses as compared to a 
homologous regimen. However, these responses were not significantly 
different to immunisations with plasmid DNA alone. The primary benefit of 
boosting with VLPs or capsomeres was in the induction of antibody 
responses, for which plasmid DNA alone was inefficient. The antibody titre 
subsequent to each dose of VLPs indicates that two or preferentially three 
VLP doses should be used to enhance antibody responses. Therefore, 
alternative dosing regimens should be investigated to optimise both cellular 
and antibody responses.  
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iv. It was apparent with the antibody titres and isotype responses, that VLP 
induced immunogenicity can be altered by the inclusion of adjuvants. PolyIC 
was included in this study due to its reported ability to induce a Th1 biased 
immune response295,296,312, and it was this type of cellular immune response 
which we were interested in evaluating. Further studies should now be done 
to evaluate alternative adjuvants in order to optimise responses.  
v. The different antibody isotype responses generated by immunisations with 
VLPs and capsomeres indicates that alternative processing pathways have 
been utilised. This may be the result of uptake of the particles by different 
antigen presenting cells, or by the ability of VLPs only to effectively cross-link 
B cell receptors and act in a T cell independent manner. The differential 
uptake could be investigated by evaluating the cells migrating to the DLNs 
following immunisation. This would be useful to better understand the 
mechanism of action of the platforms, which could result in a more rational 
approach to designing targeted immune responses.  
The evaluation of the bacterial minicell platform was primarily hampered by the low 
antigen yield produced by the minicell-producing E. coli strains used in this study. 
Issues arose with plasmid incompatibility following dual-transformation, which was 
anticipated to be resolved using the pDualGC vector with dual promoters. When 
ovalbumin cDNA was inserted into this vector however, the protein yield remained 
very low. In order to increase the protein antigen yield the following studies could be 
done: 
i. The Plasmodium CSP, and AMA-1 proteins were included in this study 
because they are leading antigens in vaccine candidate studies. They were 
however, difficult to express in minicell-producing E.coli strains. Other 
Plasmodium proteins, or alternatively proteins from different pathogens (such 
as LCMV236,237) should be evaluated firstly for antigen yield, and secondly for 
efficacy using the DC targeting minicell platform. 
ii. The proteins used in this study were not altered in any way to enhance 
protein yields. It may be that by removing regions which are difficult to 
translate, codon-optimisation of the proteins, or a combination of both 
strategies may result in an increased antigen yield.  
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6.5. Conclusion 
In my doctoral studies, I have evaluated chimeric VLPs and capsomeres as well as 
bacterial minicell sub-unit vaccine delivery platforms for their ability to induce cellular 
and antibody responses, and confer protection against sporozoite challenge. 
A major advantage with the VLP platform is that it can be quickly adapted to newly 
identified target antigens with relatively simple cloning, expression, purification and 
VLP formation protocols. My research has shown that chimeric VLPs induced robust 
antibody titres, and a moderate CD8+ T cell response, but only a very small CD4+ T 
cell response. Chimeric capsomeres similarly induced CD8+ T cell responses, and in 
contrast to VLPs induced moderate CD4+ T cell responses and reduced antibody 
responses. The data further suggest that a DNA prime/VLP boost regimen is more 
immunogenic with regards to T cell responses than a homologous regimen, but 
nonetheless responses were insufficient to protect mice from sporozoite challenge. 
Since DNA priming induced high cell-mediated responses, and antibody titres 
increased markedly after the second VLP immunisation, it would appear that a 
prime/boost regimen with at least two VLP immunisations should be evaluated in 
future studies.  
Minicells and other bacterial-derived platforms including outer-membrane vesicles 
and bacterial ghosts have the potential to be protective and licensed as shown with 
the recent approval of the meningococcal B OMV vaccine253. Furthermore, the ability 
to target minicells to professional APCs has the potential to increase uptake by 
receptor-mediated endocytosis, enhancing immune responses and reducing dose 
load requirements. During my studies, I investigated the potential of bacterial 
minicells as a vaccine platform, in both malaria parasite and ovalbumin models. In 
each model, minicells were packaged with antigens in the form of recombinant 
protein, and plasmid DNA for mammalian expression of the same protein. I 
developed a novel purification protocol which resulted in a high minicell yield and 
was efficient at removing all contaminating viable parent bacteria. This minicell 
package contains not only the antigen-specific material but surrounded by LPS it will 
activate DCs through TLR and pattern recognition receptors associated with 
bacterial PAMP recognition. The presented work establishes that the major limitation 
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of this platform is antigen load, which compromises the capacity of this platform to 
induce robust immune responses and confer protection. This may be overcome with 
high levels of protein expression by the bacteria perhaps using alternative proteins, 
or fragments of proteins which enable a high level of expression. Increasing the 
antigen load would be essential to conclusively determine if the strategy of targeting 
minicells to DCs would improve the efficacy of the platform. 
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Chapter 8: Appendices 
Appendix A: Buffers and media 
Buffer Composition 
Annealing buffer 10 mM Tris (pH 7.5-8.0) + 50 mM NaCl + 1 mM EDTA in 
milliQ water 
Antibody purification 
binding buffer 
5.8 mM Na2HPO4 + 4.2 mM NaH2PO4 + 150 mM NaCl + 10 
mM EDTA in MilliQ water 
Dulbecco‟s balanced salt 
solution 
Obtained from QIMR media store 
ELISA carbonate buffer 18 mM Na2CO3 + 45 mM NaHCO3 in deionised water 
adjusted to pH 9.6 
FCAB buffer PBS + 2 mM EDTA + 0.5% FCS 
FCAB fix/lyse buffer PBS + 4% w/v paraformaldehyde + 0.0067% w/v saponin 
GST column elution buffer 40 mM Tris-base + 200 mM NaCl + 1 mM EDTA + 5% (v/v) 
glycerol + 5 mM DTT + 10 mM reduced glutathione in milliQ 
water adjusted to pH 8.0 
Hybridoma culture media RPMI media (Life Technologies) supplemented with penicillin 
(60 mg/L) and streptomycin (100 mg/L), 1.5 mM L-glutamine, 
5 nM β-2-Mercaptoethanol and 5% FCS 
KD-MEM media Dulbecco's Modified Eagle's Medium (SAFC Global, St. 
Louis, USA) supplemented with 136 nM folic acid + 32 mM L-
asparagine + 67 mM L-arginine + 24 mM sodium bicarbonate 
+ 10 mM HEPES + 5 nM β-2-mercaptoethanol + 1.5 mM L-
glutamine + 100 units/L penicillin + 100 mg/L streptomycin  
Luria-Bertani broth (LB) 10 g/L peptone + 5 g/L yeast extract + 10 g/L NaCl in milliQ 
water 
Lysis buffer 40 mM Tris-base + 200 mM NaCl + 1 mM EDTA + 5% (v/v) 
glycerol + 5 mM DTT in milliQ water adjusted to pH 8.0 
MACS buffer PBS + 2 mM EDTA + 0.5% FCS 
Red blood cell lysis buffer 0.168 M NH4Cl in deionised water 
SDS-Page running 25mM Tris + 200 mM Glycine + 0.1% SDS in deionised 
water 
Super optimal broth with 
catabolite repression 
(SOC) 
20 g/L peptone + 5 g/L yeast extract + 0.5 g/L NaCl + 20 mM 
glucose in milliQ water 
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Talon wash buffer 20 mM sodium phosphate, 500 mM sodium chloride, and 10 
mM Imidazole in milliQ water adjusted to pH8.0 
Terrific broth (TB) 12 g/L peptone + 24 g/L yeast extract + 4 ml/L glycerol + 
2.31 g/L KH2PO4 + 12.54 g/L K2HPO4 in milliQ water 
Tris-borate buffer (TBE) 90 mM Tris + 90 mM boric acid + 2 mM EDTA in deionised 
water 
VLP Assembly buffer 500 mM (NH4)2SO4 + 20 mM Tris-base + 1 mM CaCl2 + 5% 
(v/v) glycerol in milliQ water adjusted to pH 7.4 
Western blot transfer 25mM Tris + 200 mM Glycine + 0.1% SDS in deionised 
water + 20 % methanol 
  
223 
 
Appendix B: Oligonucleotides used for chimeric VLP and capsomere 
constructs 
Oligonucleotide 
name 
Oligonucleotide sequence 5’ to 3’ TM 
(°C) 
CD8 Dom Forward AGCTATGTGCCGAGCGCGGAACAGATT 63 
CD8 Dom Reverse AATCTGTTCCGCGCTCGGCACATAGTC 63 
CD8 SubDom Forward ATTTATAACCGTAACATCGTGAACCGTCTG 59 
CD8 SubDom Reverse CAGACGGTTCACGATGTTACGGTTATAAAT 59 
CD4 Dom 1 Forward AGCTATGTGCCGAGCGCGGAACAGATTCTGGAATTTGTGAAACAGATC 70 
CD4 Dom 1 Reverse GATCTGTTTCACAAATTCCAGAATCTGTTCCGCGCTCGGCACATAGCT 70 
CD4 Dom 2 Forward AAAATTTATAACCGTAAAATCGTGAACCGTCTGCTGGGCGAT 66 
CD4 Dom 2 Reverse ATCGCCCAGCAGACGGTTCACGATGTTACGGTTATAAATTTT 66 
CD4 SubDom Forward 
TATAACCGTAACATCGTGAACCGTCTGCTGGGCGATGCGCTGAACGG
CAAACCGGAAGAAAAA 
75 
CD4 SubDom Reverse 
TTTTTCTTCCGGTTTGCCGTTCAGCGCATCGCCCAGCAGACGGTTCAC
GATGTTACGGTTATA 
75 
B Cell Forward CAGGGCCCGGGTGCGCCGCAAGGTCCAGGGGCCCCG 79 
B Cell Reverse CGGGGCCCCTGGACCTTGCGGCGCACCCGGGCCCTG 79 
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Appendix C: Flow cytometry antibodies 
Target Assay Fluorochrome Clone Isotype Supplier 
CD4 
ICS, OVA minicell CTL, 
AMA1 minicell 
BV510 RM4-5 R IgG2a Biolegend 
OVA minicell adoptive 
transfer 
PerCP/Cy5.5 GK 1.5 R IgG2a Biolegend 
CD8 
ICS PE-Cy7 53-6.7 R IgG2a Biolegend 
OVA and AMA1 minicell APC-Cy7 53-6.7 R IgG2a Biolegend 
CD11a AMA1 minicell AF647 M17/4 R IgG2a Biolegend 
CD11c 
OVA migrating DCs 
sorting 
PE N418 AH IgG Biolegend 
CD19 AMA1 minicell PE Cy5 6D5 R IgG2a Biolegend 
CD 45.1 OVA minicell FITC A20 M IgG2a Biolegend 
CD 45.2 OVA minicell PE 104 M IgG2a Biolegend 
CD 49d AMA1 minicell PE 9C10 R IgG2a Biolegend 
CD 69 AMA1 minicell FITC H1.2F3 AH IgG Biolegend 
CD 71 FCAB PE R172.7 R IgG2a Biolegend 
CD 86 AMA minicell AF700 P03 R IgG2b Biolegend 
CD90.1 
(Thy1.1) 
CS-TCR PE OX-7 M IgG1 BD 
CD103 
OVA migrating DCs 
sorting 
P.Blue 2E7 AH IgG Biolegend 
PD-L1 
(CD274) 
AMA1 minicell BV421 10F.9G2 R IgG2b Biolegend 
PD-1 
(CD279) 
AMA1 minicell BV605 29F.1A12 R IgG2a Biolegend 
Gr-1  (Ly-
6G/C) 
AMA1 minicell PE Cy7 RB6-8C5 R IgG2b BD 
Vα2 TCR 
OVA minicell APC B20.1 R IgG2a E.Bioscience 
OVA minicell PE B20.1 R IgG2a Biolegend 
MHC II 
OVA migrating DCs 
sorting 
FITC M5/114.15.2 R IgG2b Biolegend 
Goat α-
mouse Ig  
IFAT (flow) FITC Polyclonal G Ig BD 
IFN- ICS APC XMG 1.2 R IgG1 Biolegend 
IL-2 ICS PE JES6-5H4 R IgG2b Biolegend 
TNF ICS FITC MP6-XT22 R IgG1 E.Bioscience 
α-mouse 
IgG1 
AMA1 minicell-Isotype APC RMG1 R IgG Biolegend 
α-mouse 
IgG2a 
AMA1 minicell-Isotype FITC R19-15 R IgG1 BD 
α-mouse 
IgD 
AMA1 minicell-Isotype P.Blue 11-26c.2a R IgG2a Biolegend 
α-mouse 
IgM 
AMA1 minicell-Isotype PE Cy7 R6-60.2 R IgG2a BD 
α-mouse 
IgE 
AMA1 minicell-Isotype PE RME-1 R IgG1 Biolegend 
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Appendix D: Oligonucleotides for vector and plasmid DNA constructs used in 
the bacterial minicell studies 
Project Name Direc
tion 
RE site Oligonucleotide sequence 5’ to 3’ – (underlined 
sequences represent restriction enzyme sites) 
p
IA
S
O
 a
n
d
 p
V
R
V
5
 
c
o
n
s
tr
u
c
ti
o
n
 
RegionA F BglII ATATagatctGCTGTGCCTTCTAGTTG 
RegionA (+MfeI) R MfeI CGGGcaattgTCAGAATTGGTTAAT 
RegionB (+MfeI) F MfeI GAAAcaattgTTACGCCCCGCCCTGCCACTC 
RegionB (+ApaI) R ApaI CAAAgggcccATGGAGAAAAAAATCACTGGAT 
RegionC (+ApaI) F ApaI ATATgggcccAACACCCCTTGTATTACT 
RegionC R SpeI GGGGTAactagtCAATAATCAATGTCAACAT 
V5 F NotI GGCCGCaGGTAAGCCTATCCCTAACCCTCTCCTCGG
TCTCGATTCTACG  
V5 R BglII GATCTCGTAGAATCGAGACCGAGGAGAGGGTTAGG
GATAGGCTTACCtGC  
F
lu
o
re
s
c
e
n
t 
g
e
n
e
s
 
RFP-pVRV5 F BamHI GAGAggatccATGGTGAGCAAGGGCGAGGAGG 
RFP-pVRV5 R NotI ACCTgcggccgcCTTGTACAGCTCGTCCATGC 
GFP-pTrcHis2A F SacI ATCCgagctcAATGAGTAAAGGAGAAGAACTT 
GFP-pTrcHis2A R KpnI GATAggtaccTTTTTGTATAGTTCATCCATGC 
GFP-pDualGC F EarI CCctcttcAATGAGTAAAGGAGAAGAACTTTTC 
GFP-pDualGC R EarI CGctcttcCAAGTTTGTATAGTTCATCCATGC 
P
la
s
m
o
d
iu
m
 y
o
e
li
i 
g
e
n
e
s
 
PyAMA1-pVRV5 F BamHI CCGGGCggatccATGAAAGAAATATATTATATATTTATT
TT 
PyAMA1-pVRV5 R NotI TTAAgcggccgcATAATATGGTTTTTCCATCAAAACG 
PyAMA1-pTrcHis2A F SacI GCCCgagctcAATGAAAGAAATATATTATATATTTATTTT
ATGC 
PyAMA1-pTrcHis2A R KpnI TACAggtaccGTATAATATGGTTTTTCCATCAAAACG 
PyAMA1-pIVEX F NotI GAAGTTTgcggccgcATGAAAGAAATATATTATATATTTA
TTTT 
PyAMA1-pIVEX R SacI GTTTTTTgagctcCATAATATGGTTTTTCCATCAAAACG 
PyCSP-pVRV5 F BamHI TACCggatccATGAAGAAGTGTACCATTTTAGTTGTAG 
PyCSP-pVRV5 R NotI ACCTgcggccgcATTAAAGAATACTAATACTAATAATATT
AC 
PyCSP-pTrcHis2A F SacI ATTTgagctcAATGAAGAAGTGTACCATTTTAGTTGTA 
PyCSP-pTrcHis2A R KpnI GGGATggtaccTTATTAAAGAATACTAATACTAATAATA
TTAC 
PyCSP-pIVEX F NotI CTTAgcggccgcATGAAGAAGTGTACCATTTTAG 
PyCSP-pIVEX R SacI GGCCGCAgagctcCATTAAAGAATACTAATACTAATAAT
ATTACAAATCC 
O
v
a
lb
u
m
in
 
g
e
n
e
s
 Ova-pDualGC F EarI ATctcttcAATGGGCTCCATCGGCGCA 
TransOva-pDualGC F EarI CGctcttcAATGATGGATCAAGCTAGATCA 
Ova and TfrOva-
pDualGC 
R EarI CGctcttcAAAGAGGGGAAACACATCTGCCA 
S
e
q
u
e
n
c
in
g
 
pIASO F  GAGAGGGCTCTGCTGTGTGCTGC 
pIASO R  CCCCAGAATAGAATGACACC 
pBAD F  ATGCCATAGCATTTTTATCC 
pBAD R  CTGAATTAATCTGTATCAGG 
PyAMA1 (int500) F  GTCATTGTGTGCAAAACATACC 
PyCSP (int200) F  GCTCTCAACGGAAAACCAGAAG    
pTrcHis2 F  GCGAAGCGGCACTGCT 
pTrcHis2 R  TCTGAGTTCGGCATGGGGT 
pDUAL GC F  GCGAAGCGGCACTGC 
pDual GC SV40 R  CACTGCATTCTAGTTGTGG 
Ova and TfrOva (int)  R  TTGTCTGACTTTCTACCCAGGA 
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Appendix E: Amino acid sequences 
Plasmodium yoelii 17XNL circumsporozoite protein  
MKKCTILVVASLLLVDSLLPGYGQNKSVQAQRNLNELCYNEENDNKLYHVLNSKNGKIYNRNIVNRLL
GDALNGKPEEKKDDPPKDGNKDDLPKEEKKDDLPKEEKKDDPPKDPKKDDPPKEAQNKLNQPVVAD
ENVDQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPG
APQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQGPGAPQEPPQQ
PPQQPPQQPPQQPPQQPPQQPPQQPRPQPDGNNNNNNNNGNNNEDSYVPSAEQILEFVKQISSQL
TEEWSQCSVTCGSGVRVRKRKNVNKQPENLTLEDIDTEICKMDKCSSIFNIVSNSLGFVILLVLVFFN- 
 
Plasmodium yoelii 17XNL apical membrane antigen-1  
MKEIYYIFILCSIYLINLSYCSEGPNQVISEDGNINYESIPKENTERSIKLINPWDKYMEKYDIEKVHGSGI
RVDLGEDARVENRDYRIPSGKCPVIGKGITIQNSEVSFLKPVATGDKPVRSGGLAFPETDVHISPITITN
LKTMYKDHQDIVNLNDMSLCAKHTSLYVPGKDATSAYRHPVVYDKSNSTCYMLYVAAQENMGPRYC
SNDANNENQPFCFTPEKIENYKDLSYLTKNLRDDWETSCPNKSIKNAKFGIWVDGYCTDYQKHVVHD
SDSLLKCNQIIFNESASDQPKQYERHLEDATKIRQGIVERNGKLIGEALLPIGSYKSGQIKSHGKGYNW
GNYDSKNNKCYIFETKPTCLINDKNFIATTALSSTEEFEENFPCEIYKNKIAEEIKVLNLNQNTSNGNNSI
KFPRIFISTDKNSLNCPCDPTKLTESTCEFYVCSCVEQRQYIAENNDVIIKEEFIGDYENPKQKLLIIIVLI
GVGIIIVILLVAYYFKSGKKGENYDRMGQADDYGKSKSRKDEMLDPEVSFWGEDKRASHTTPVLMEK
PYY- 
 
MuPyV VP1-S4-G4S173 with flanking G4S sequence underlined 
GGMAPKRKSGVSKCETKCTKACPRPAPVPKLLIKGGMEVLDLVTGPDSVTEIEAFLNPRMGQPPTPE
SLTEGGQYYGWSRGINLATSDTEDSPGNNTLPTWSMAKLQLPMLNEDLTCDTLQMWEAVSVKTEVV
GSGSLLDVHGFNKPTDTVNTKGISTPVEGSQYHVFAVGGEPLDLQGLVTDARTKYKEEGVVTIKTITK
KDMVNKDQVLNPISKAKLDKDGMYPVEIWHPDPAKNENTRYFGNYTGGTTTPPVLQFTNTLTTVLLD
ENGVGPLCKGEGLYLSCVDIMGWRVTRGGGGSSAGGGGSYDVHHWRGLPRYFKITLRKRWVKNP
YPMASLISSLFNNMLPQVQGQPMEGENTQVEEVRVYDGTEPVPGDPDMTRYVDRFGKTKTVFPGN 
 
VP1ΔNΔC170 with epitope insertion sites underlined 
GSHVLIKGGMEVLDLVTGPDSVTEIEAFLNPRMGQPPTPESLTEGGQYYGWSRGINLATSAGTEDSP
GNNTLPTWSMAKLQLPMLNEDLTCDTLQMWEAVSVKTEVVGSGSLLDVHGFNKPTDTVNTKGISTP
VEGSQYHVFAVGGEPLDLQGLVTDARTKYKEEGVVTIKTITKKDMVNKDQVLNPISKAKLDKDGMYP
VEIWHPDPAKNENTRYFGNYTGGTTTPPVLQFTNTLTTVLLDENGVGPLCKGEGLYLSCVDIMGWRV
TRSAYDVHHWRGLPRYFKITLRKRWVKNPYV 
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Appendix F: VLP and capsomere estimated weights and Pi values  
 Construct Weight + 
GST (kDa) 
Pi + GST Weight – 
GST (kDa) 
Pi -GST 
VLP 
Wild 69.59 6.08 43.29 6.06 
CD8 Dom 70.56 5.98 44.27 5.87 
CD8 Sub-Dom 70.84 6.32 44.55 6.62 
CD4 Dom 1 71.42 5.98 45.13 5.88 
CD4 Dom 2 71.26 6.32 44.96 6.62 
CD4 Sub-Dom 71.98 6.20 45.69 6.30 
B Cell 70.60 6.08 44.31 6.06 
Capsomere 
Wild 58.99 5.91 32.85 5.73 
CD8 Dom 61.92 5.66 35.77 5.34 
CD8 Sub-Dom 62.77 6.66 36.62 7.83 
CD4 Dom 1 64.50 5.67 38.35 5.38 
CD4 Dom 2 64.01 6.66 37.86 7.82 
CD4 Sub-Dom 66.18 6.23 40.03 6.38 
B Cell 62.04 5.91 35.89 5.73 
 
